Interventions for preventing weight gain after smoking cessation by Farley, A.C. et al.
 
Interventions for preventing weight 
gain after smoking cessation 
Farley, A.C. , Hajek, P. , Lycett, D. and Aveyard, P. 
 
Published version deposited in CURVE June 2013 
 
Original citation & hyperlink:  
Farley, A.C. , Hajek, P. , Lycett, D. and Aveyard, P. (2012) Interventions for preventing weight 
gain after smoking cessation. The Cochrane Library, volume 1. 
http://dx.doi.org/10.1002/14651858.CD006219.pub3 
 
 
Copyright © and Moral Rights are retained by the author(s) and/ or other copyright 
owners. A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. This item cannot be reproduced or quoted extensively 
from without first obtaining permission in writing from the copyright holder(s). The 
content must not be changed in any way or sold commercially in any format or medium 
without the formal permission of the copyright holders.  
 
 
 
 
 
 
 
CURVE is the Institutional Repository for Coventry University 
http://curve.coventry.ac.uk/open  
Interventions for preventing weight gain after smoking
cessation (Review)
Farley AC, Hajek P, Lycett D, Aveyard P
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2012, Issue 1
http://www.thecochranelibrary.com
Interventions for preventing weight gain after smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
12DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
38CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
104DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Pharmacological interventions versus placebo for post cessation weight control: weight change,
Outcome 1 Mean weight change (kg) at end of treatment. . . . . . . . . . . . . . . . . . . 111
Analysis 1.2. Comparison 1 Pharmacological interventions versus placebo for post cessation weight control: weight change,
Outcome 2 Mean weight change (kg) at 6 months. . . . . . . . . . . . . . . . . . . . . . 112
Analysis 1.3. Comparison 1 Pharmacological interventions versus placebo for post cessation weight control: weight change,
Outcome 3 Mean weight change (kg) at 12 months. . . . . . . . . . . . . . . . . . . . . 113
Analysis 2.1. Comparison 2 Pharmacological interventions versus placebo for post cessation weight control: smoking
cessation, Outcome 1 Abstinence at 6 months. . . . . . . . . . . . . . . . . . . . . . . 114
Analysis 2.2. Comparison 2 Pharmacological interventions versus placebo for post cessation weight control: smoking
cessation, Outcome 2 Abstinence at 12 months. . . . . . . . . . . . . . . . . . . . . . . 115
Analysis 3.1. Comparison 3 Behavioural weight management interventions versus advice or no intervention: weight change,
Outcome 1 Mean weight change (kg) at end of treatment. . . . . . . . . . . . . . . . . . . 116
Analysis 3.2. Comparison 3 Behavioural weight management interventions versus advice or no intervention: weight change,
Outcome 2 Mean weight change (kg) at 6 months. . . . . . . . . . . . . . . . . . . . . . 117
Analysis 3.3. Comparison 3 Behavioural weight management interventions versus advice or no intervention: weight change,
Outcome 3 Mean weight change (kg) at 12 months. . . . . . . . . . . . . . . . . . . . . 118
Analysis 4.1. Comparison 4 Behavioural weight management interventions versus advice or no intervention: smoking
cessation, Outcome 1 Abstinence at 6 months. . . . . . . . . . . . . . . . . . . . . . . 119
Analysis 4.2. Comparison 4 Behavioural weight management interventions versus advice or no intervention: smoking
cessation, Outcome 2 Abstinence at 12 months. . . . . . . . . . . . . . . . . . . . . . . 120
Analysis 5.1. Comparison 5 CBT to accept moderate weight gain versus no behavioural weight advice: smoking cessation,
Outcome 1 Abstinence at 6 months. . . . . . . . . . . . . . . . . . . . . . . . . . . 121
Analysis 5.2. Comparison 5 CBT to accept moderate weight gain versus no behavioural weight advice: smoking cessation,
Outcome 2 Abstinence at 12 months. . . . . . . . . . . . . . . . . . . . . . . . . . 122
Analysis 6.1. Comparison 6 CBT to accept moderate weight gain versus no behavioural weight advice: weight change,
Outcome 1 Mean weight change (kg) at end of treatment. . . . . . . . . . . . . . . . . . . 123
Analysis 6.2. Comparison 6 CBT to accept moderate weight gain versus no behavioural weight advice: weight change,
Outcome 2 Mean weight change (kg) at 6 months. . . . . . . . . . . . . . . . . . . . . . 124
Analysis 6.3. Comparison 6 CBT to accept moderate weight gain versus no behavioural weight advice: weight change,
Outcome 3 Mean weight change (kg) at 12 months. . . . . . . . . . . . . . . . . . . . . 125
Analysis 7.1. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight change, Outcome 1
Mean weight change (kg) at end of treatment. . . . . . . . . . . . . . . . . . . . . . . . 126
Analysis 7.2. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight change, Outcome 2
Mean weight change (kg) at end of treatment: dose response. . . . . . . . . . . . . . . . . . 127
Analysis 7.3. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight change, Outcome 3
Mean weight change (kg) at 6 months. . . . . . . . . . . . . . . . . . . . . . . . . . 128
iInterventions for preventing weight gain after smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.4. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight change, Outcome 4
Mean weight change (kg) at 6 months: dose response. . . . . . . . . . . . . . . . . . . . . 129
Analysis 7.5. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight change, Outcome 5
Mean weight change (kg) at 12 months. . . . . . . . . . . . . . . . . . . . . . . . . . 130
Analysis 7.6. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight change, Outcome 6
Mean weight change (kg) at 12 months: dose response. . . . . . . . . . . . . . . . . . . . 131
Analysis 8.1. Comparison 8 Exercise interventions versus no exercise for smoking cessation: weight change, Outcome 1
Mean weight change (kg) at end of treatment. . . . . . . . . . . . . . . . . . . . . . . . 132
Analysis 8.2. Comparison 8 Exercise interventions versus no exercise for smoking cessation: weight change, Outcome 2
Mean weight change (kg) at 12 months. . . . . . . . . . . . . . . . . . . . . . . . . . 133
Analysis 9.1. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change, Outcome 1 Mean
weight change (kg) at end of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . 134
Analysis 9.2. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change, Outcome 2 Mean
weight change (kg) at end of treatment: patch v spray. . . . . . . . . . . . . . . . . . . . . 135
Analysis 9.3. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change, Outcome 3 Mean
weight change (Kg) at end of treatment: lozenge v gum. . . . . . . . . . . . . . . . . . . . 136
Analysis 9.4. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change, Outcome 4 Mean
weight change (kg) at end of treatment: dose response. . . . . . . . . . . . . . . . . . . . . 137
Analysis 9.5. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change, Outcome 5 Mean
weight change (kg) at 6 months. . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
Analysis 9.6. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change, Outcome 6 Mean
weight change (kg) at 6 months: patch v spray. . . . . . . . . . . . . . . . . . . . . . . 139
Analysis 9.7. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change, Outcome 7 Mean
weight change (kg) at 6 months: lozenge v gum. . . . . . . . . . . . . . . . . . . . . . . 140
Analysis 9.8. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change, Outcome 8 Mean
weight change (kg) at 12 months. . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
Analysis 9.9. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change, Outcome 9 Mean
weight change (kg) at 12 months: lozenge v gum. . . . . . . . . . . . . . . . . . . . . . 142
Analysis 9.10. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change, Outcome 10 Mean
weight change (kg) at 12 months: dose response. . . . . . . . . . . . . . . . . . . . . . . 143
Analysis 9.11. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change, Outcome 11 Mean
weight change (kg) at 12 months: longer course vs. shorter. . . . . . . . . . . . . . . . . . . 144
Analysis 10.1. Comparison 10 Varenicline versus placebo for smoking cessation: weight change, Outcome 1 Mean weight
change (kg) at end of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
Analysis 10.2. Comparison 10 Varenicline versus placebo for smoking cessation: weight change, Outcome 2 Mean weight
change (kg) at 6 months. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Analysis 10.3. Comparison 10 Varenicline versus placebo for smoking cessation: weight change, Outcome 3 Mean weight
change (kg) at 12 months. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Analysis 11.1. Comparison 11 Varenicline versus bupropion: weight change, Outcome 1 Mean weight change (kg) at end
of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
Analysis 12.1. Comparison 12 Varenicline versus NRT: weight change, Outcome 1 Mean weight change (kg) at end of
treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
147WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
148HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
148CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
148DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
148SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
149INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiInterventions for preventing weight gain after smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Interventions for preventing weight gain after smoking
cessation
Amanda C Farley1, Peter Hajek2, Deborah Lycett1, Paul Aveyard1
1Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK. 2Wolfson Institute of Preventive Medicine, Queen
Mary’s School of Medicine and Dentistry, London, UK
Contact address: Paul Aveyard, Primary Care Clinical Sciences, University of Birmingham, Edgbaston, Birmingham, West Midlands,
B15 2TT, UK. p.n.aveyard@bham.ac.uk.
Editorial group: Cochrane Tobacco Addiction Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 1, 2012.
Review content assessed as up-to-date: 7 October 2011.
Citation: Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database
of Systematic Reviews 2012, Issue 1. Art. No.: CD006219. DOI: 10.1002/14651858.CD006219.pub3.
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Most people who stop smoking gain weight. There are some interventions that have been designed to reduce weight gain when stopping
smoking. Some smoking cessation interventions may also limit weight gain although their effect on weight has not been reviewed.
Objectives
To systematically review the effect of: (1) Interventions targeting post-cessation weight gain on weight change and smoking cessation.
(2) Interventions designed to aid smoking cessation that may also plausibly affect weight on post-cessation weight change.
Search methods
Part 1 - We searched the Cochrane Tobacco Addiction Group’s Specialized Register and CENTRAL in September 2011.
Part 2 - In addition we searched the included studies in the following “parent” Cochrane reviews: nicotine replacement therapy (NRT),
antidepressants, nicotine receptor partial agonists, cannabinoid type 1 receptor antagonists and exercise interventions for smoking
cessation published in Issue 9, 2011 of the Cochrane Library.
Selection criteria
Part 1 - We included trials of interventions that were targeted at post-cessation weight gain and had measured weight at any follow up
point and/or smoking cessation six or more months after quit day.
Part 2 - We included trials that had been included in the selected parent Cochrane reviews if they had reported weight gain at any time
point.
Data collection and analysis
We extracted data on baseline characteristics of the study population, intervention, outcome and study quality. Change in weight was
expressed as difference in weight change from baseline to follow up between trial arms and was reported in abstinent smokers only.
Abstinence from smoking was expressed as a risk ratio (RR). We used the most rigorous definition of abstinence available in each
trial. Where appropriate, we performed meta-analysis using the inverse variance method for weight and Mantel-Haenszel method for
smoking using a fixed-effect model.
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Main results
Part 1: Some pharmacological interventions tested for limiting post cessation weight gain (PCWG) resulted in a significant reduction
in WG at the end of treatment (dexfenfluramine (Mean difference (MD) -2.50kg, 95% confidence interval (CI) -2.98 to -2.02, 1
study), phenylpropanolamine (MD -0.50kg, 95% CI-0.80 to -0.20, N=3), naltrexone (MD -0.78kg, 95% CI-1.52 to -0.05, N=2).
There was no evidence that treatment reduced weight at 6 or 12 months (m). No pharmacological intervention significantly affected
smoking cessation rates.
Weight management education only was associated with no reduction in PCWG at end of treatment (6 or 12m). However these inter-
ventions significantly reduced abstinence at 12m (Risk ratio (RR) 0.66, 95% CI 0.48 to 0.90, N=2). Personalised weight management
support reduced PCWG at 12m (MD -2.58kg, 95% CI -5.11 to-0.05, N=2) and was not associated with a significant reduction of
abstinence at 12m (RR 0.74, 95% CI 0.39 to 1.43, N=2). A very low calorie diet (VLCD) significantly reduced PCWG at end of
treatment (MD -3.70kg, 95% CI-4.82 to-2.58, N=1), but not significantly so at 12m (MD -1.30kg, 95% CI-3.49 to 0.89, N=1).
The VLCD increased chances of abstinence at 12m (RR 1.73, 95% CI 1.10 to 2.73, N=1). There was no evidence that cognitive
behavioural therapy to allay concern about weight gain (CBT) reduced PCWG, but there was some evidence of increased PCWG at
6m (MD 0.74, 95% CI 0.24 to 1.24). It was associated with improved abstinence at 6m (RR 1.83, 95% CI 1.07 to 3.13, N=2) but
not at 12m (RR 1.25, 95% CI 0.83 to 1.86, N=2). However, there was significant statistical heterogeneity.
Part 2: We found no evidence that exercise interventions significantly reduced PCWG at end of treatment (MD -0.25kg, 95% CI-0.78
to 0.29, N=4) however a significant reduction was found at 12m (MD -2.07kg, 95% CI-3.78 to-0.36, N=3).
Both bupropion and fluoxetine limited PCWGat the end of treatment (bupropionMD-1.12kg, 95%CI-1.47 to-0.77,N=7) (fluoxetine
MD -0.99kg, 95% CI-1.36 to-0.61, N=2). There was no evidence that the effect persisted at 6m (bupropion MD -0.58kg, 95% CI-
2.16 to 1.00, N=4), (fluoxetine MD -0.01kg, 95% CI-1.11 to 1.10, N=2) or 12m (bupropion MD -0.38kg, 95% CI-2.00 to 1.24,
N=4). There were no data on WG at 12m for fluoxetine.
Overall, treatment with NRT attenuated PCWG at the end of treatment (MD -0.69kg, 95% CI-0.88 to-0.51, N=19), with no strong
evidence that the effect differed for the different forms of NRT. There was evidence of significant statistical heterogeneity caused by
one study which reported a 4.3kg reduction in PCWG due to NRT. With this study removed, the difference in weight change at end
of treatment was -0.45kg (95% CI-0.66 to-0.27, N=18). There was no evidence of an effect on PCWG at 12m (MD -0.42kg, 95%
CI-0.92 to 0.08, N=15).
We found evidence that varenicline significantly reduced PCWG at end of treatment (MD -0.41kg, 95% CI-0.63 to-0.19, N=11),
but this effect was not maintained at 6 or 12m. Three studies compared the effect of bupropion to varenicline. Participants taking
bupropion gained significantly less weight at the end of treatment (-0.51kg (95%CI-0.93 to-0.09kg), N=3). Direct comparison showed
no significant difference in PCWG between varenicline and NRT.
Authors’ conclusions
Although some pharmacotherapies tested to limit PCWG show evidence of short-term success, other problems with them and the
lack of data on long-term efficacy limits their use. Weight management education only, is not effective and may reduce abstinence.
Personalised weight management support may be effective and not reduce abstinence, but there are too few data to be sure. One study
showed a VLCD increased abstinence but did not prevent WG in the longer term. CBT to accept WG did not limit PCWG and
may not promote abstinence in the long term. Exercise interventions significantly reduced weight in the long term, but not the short
term. More studies are needed to clarify whether this is an effect of treatment or a chance finding. Bupropion, fluoxetine, NRT and
varenicline reduce PCWG while using the medication. Although this effect was not maintained one year after stopping smoking, the
evidence is insufficient to exclude a modest long-term effect. The data are not sufficient to make strong clinical recommendations for
effective programmes to prevent weight gain after cessation.
P L A I N L A N G U A G E S U M M A R Y
Interventions for preventing weight gain after smoking cessation
When giving up smoking, most people put on weight. Many smokers are concerned about this and say it may put them off making an
attempt quit. Some studies show that weight gain also leads to people resuming smoking after an initially successful quit attempt. On
the other hand, there are good reasons to believe that trying to limit weight gain may reduce the chance of stopping smoking. Several
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drug and behavioural programmes to limit post cessation weight gain have been tested. Of the drug treatments, naltrexone showed the
most promise, but there were no data on its effects on weight once drug treatment stopped and there was not enough evidence to judge
its effects on long term quitting. Weight management education alone did not limit weight gain and may undermine cessation. Weight
management education with personalised support giving feedback on personal goals and a personal energy prescription limited weight
gain and there was no evidence that it undermined cessation. Intermittent use of a VLCD improved cessation success and weight gain
in the short term but not in the longer term.
Some smoking cessation treatments also limited weight gain. Bupropion, fluoxetine, NRT and varenicline all limited weight gain
during treatment, however the effects on weight gain reduction were smaller after the treatment had stopped and there was insufficient
evidence to be sure that these effects persisted in the long-term. There was some evidence to suggest that exercise reduced post cessation
weight gain but more studies are needed to clarify whether this was a chance finding. The effects of all interventions were modest in
relation to the average weight gain that follows stopping smoking.
B A C K G R O U N D
Although smoking cessation is associated with substantial health
benefits, it is usually accompanied by weight gain (Klesges 1997).
In the USA it is estimated that 80 percent of people who quit
smoking gain weight (USDHHS 1990). Studies have found that
on average women gain more weight than men. Among people
who sustained quitting for five years, O’Hara 1998 found that
women gained 5.2 kg in year one and a mean of 3.4 kg in years
one to five, while men gained a mean of 4.9 kg in year one and
a mean of 2.6 kg in years one to five. As well as gaining more
weight, a large cohort study showed that 13% of women com-
pared with 10% of men had a major weight gain greater than 13kg
(Williamson 1991).Weight gain in people who sustained quitting
for eight years has been shown to be 9kg (7kg above those who
continued to smoke during this time), with 42% of people gaining
over 10kg (Lycett 2011). This weight gain can have health conse-
quences, with the incidence of diabetes being higher in smokers
that quit smoking than continue with it, an effect that appeared
to be explained by weight gain (Davey Smith 2005; Yeh 2010).
Weight gain also reduces some of the benefits of quitting smoking
on lung function (Chinn 2005).
Among smokers there is a high prevalence of concerns about post-
cessation weight gain, and it has been cited as a primary rea-
son for putting off quit attempts, especially in women (Clark
2004;Klesges 1989;Klesges 1992).Weight consciousness has been
found to predict current smoking (Weekley 1992), and weight
gain experienced during or after smoking cessation has been as-
sociated with relapse (Klesges 1988; Klesges 1989; Klesges 1992).
However there is inconsistent evidence that fear of weight gain
or actual weight gain after quitting does in fact lead to relapse.
An equal number of studies show that it does (1 Copeland 2006;
Pomerleau 2001; Meyers 1997; Clark 2006) and does not (Killen
1996; Hutter 2006; Mizes 1998; Fidler 2009), and methodologi-
cal differences make it hard to draw a conclusion one way or the
other.
Some smoking cessation interventions have been developed to
promote smoking cessation and simultaneously control weight
gain in challenging populations, such as weight-concerned smok-
ers. They include behavioural interventions, such as exercise and
energy restriction or healthy eating advice. Dietary interventions
might serve to encourage reluctant quitters to try to stop smoking
if they can be reassured that weight gain might be limited (Filozof
2004). However, it is possible that such interventions might also
risk undermining the success of the quit attempt (1 Hall 1992).
There is evidence that hunger and cigarette cravings are related,
and that hunger can undermine quit efforts (1 Hall 1992) and
that hunger increases urges to smoke in current smokers (Cheskin
2005). Additionally, early weight gain has also been found to be as-
sociated with successful cessation (Gritz 1988; Hall 1986; Hughes
1991). This suggests interventions that limit dietary intake may
potentially reduce smoking cessation success and the adage that
smokers should stop smoking first and then diet and not do these
concurrently has become common in smoking cessation clinics.
There are a range of other treatments for smoking cessation that
have beendeveloped independently of concerns aboutweight gain,
with the sole aim of assisting smoking cessation. Some of these,
such as nicotine replacement therapy, antidepressants, varenicline
and exercise might plausibly influence weight gain as well as smok-
ing cessation. The effects of these interventions on smoking cessa-
tion are evaluated in the relevant Cochrane reviews, but the effects
on weight gain are summarised only in the exercise intervention
review (Ussher 2008). The effects of these medications on weight
gain will therefore be included in this review.
In this review, we examine the effect of interventions on weight
gain in abstinent smokers only, for several reasons. Firstly, if we
included those who were not abstinent mean weight gain would
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be reduced. This is because people who try to become abstinent
but fail after a few days do not gain weight, while those who re-
lapse to smoking seem to lose the weight they gained previously
(O’Hara 1998; Lycett 2011). Thus the average weight gain of a
mixed population of abstinent and non-abstinent smokers would
not reflect the weight gain of either. Secondly, this effect could
bias trial results. If an intervention increased abstinence rates, it is
very likely that it would appear to increase weight gain, regardless
of whether it actually suppressed weight gain or had no effect.
Thirdly, those who return to smoking tend not attend clinics for
follow up. Authors typically only report weight data in abstinent
smokers and imputing missing data on this weight is problem-
atic. We have so little data on the weight trajectory of people who
try and fail to achieve abstinence. It is likely that the weight will
depend on time since relapse and that simple practices as used
in weight loss trials, such as last observation forward or baseline
observation carried forward, are likely to be misleading. For these
reasons, we eschew the intention to treat approach which is typi-
cally used in the Tobacco Addiction Review Group’s reviews. This
issue has been discussed elsewhere (Parsons, 2009b; Spring 2011a;
Parsons 2011; Spring 2011b).
O B J E C T I V E S
To review the evidence from two kinds of trials:
Primary objectives
(i) Part 1 - The effects of interventions specifically designed to limit
weight gain on two outcomes: weight gain (at end of treatment, 6
and 12 months), and smoking cessation (at 6 and 12 months).
(ii) Part 2 - The effects of antidepressants, exercise, nicotine re-
placement therapy,varenicline and rimonabant on weight gain (at
end of treatment, 6 and 12 months).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials
Types of participants
Adult smokers attempting to quit smoking.
Types of interventions
Part 1 - Interventions that are designed specifically to limit post
cessation weight gain.
Part 2 - Smoking cessation interventions that are not designed pri-
marily to limit post cessation weight gain but which might plausi-
bly influence it, i.e. antidepressants, exercise, nicotine replacement
therapy (NRT), rimonabant and varenicline.
Types of outcome measures
There are two primary outcome measures:
(i) Smoking status six months or more after quitting
(ii) Mean (SD) change in body weight (kg) from baseline to follow
up in abstainers only.
Both outcomeswill be fully examined for studies that fit the criteria
for Part 1. For Part 2 studies, effects of these interventions on
smoking are reported in the parentCochrane reviews and therefore
we will only report the effects of interventions on weight change.
Search methods for identification of studies
Part 1 - We searched the Cochrane Tobacco Addiction Group’s
Specialized Register of trials in September 2011, using the fol-
lowing search terms in title, abstract or keywords: food, calorie
restrict*, intake, diet*, body mass index (BMI), Quetelet, waist-
hip ratio (WHR), weight, body-weight, weight-changes. At the
search date the specialized register included reports of trials in-
dexed in MEDLINE to update 20110826, EMBASE to 2011
week 33, PsycINFO to 20110822 and Web of Science, together
with hand searching of specialist journals, conference proceedings,
online registers of controlled trials and reference lists of previous
trials and overviews. In addition, we performed citation searches
of studies included in part 1 to exhaust possibilities of finding
published weight data.
Part 2 - We searched the following Cochrane reviews: Antidepres-
sants for smoking cessation (latest search, Jul 2009) Hughes 2007,
Exercise interventions for smoking cessation (latest search, July
2008) Ussher 2008, Nicotine replacement therapy for smoking
cessation (latest search, Oct 2007) Stead 2008, Cannabinoid type
1 receptor antagonists (rimonabant) for smoking cessation (lat-
est search, Jan 2011) Cahill 2011a and Nicotine receptor partial
agonists for smoking cessation (latest search, Oct 2010) Cahill
2011b published in Issue 9 2011 of the Cochrane library. The text
of references listed as included studies were searched except for
the nicotine receptor partial agonists for smoking cessation review
where we were only interested in trials of varenicline. In addition
we searched the Cochrane Central Register of Controlled Trials
(CENTRAL) Issue 4, 2011 to identify trials relevant to the Part 2
reviews published since the last update. Thie following strategies
were used:
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(smoking OR smoking cessation OR Tobacco) AND (nicotine
OR nicotine replacement therapy OR lozenge OR patch OR gum
OR inhaler OR microtab OR nasal spray)
(smoking OR smoking cessation OR Tobacco) AND (antidepres-
sant$ OR bupropion OR zyban)
(smoking OR smoking cessation OR Tobacco) AND (varenicline
OR nicotine partial agonist OR champix OR chantix)
Data collection and analysis
Two people independently identified studies that fulfilled the in-
clusion criteria and extracted data. Any discrepancies were dis-
cussed and resolved. Papers published in a foreign language were
translated into English.Where weight gain had beenmeasured but
not reported at all or in full we contacted authors or sponsors for
clarification. If we were unable to successfully contact an author
or sponsor, studies were excluded from the review.
For studies in Part 1, we extracted data on baseline characteris-
tics, the intervention, smoking, weight data relevant to study qual-
ity. Where possible we extracted smoking outcomes as continu-
ous biochemically confirmed abstinence, however we accepted less
strict definitions if confirmed continuous abstinence was not avail-
able. We checked that, for smoking abstinence estimates, partic-
ipants lost to follow up were coded as smokers and therefore all
randomised participants were included in the denominator and
if not we corrected abstinence rates for this. Abstinence rates and
their corresponding risk ratio (95% CI) were reported at 6 and 12
months of follow up. For studies in Part 2, we extracted data on
weight gain only.
The absolute mean (SD) difference in body weight (kg) from base-
line to follow up by trial arm was used as a summary statistic for
the treatment effect on weight.Mean weight change was estimated
in those abstinent from smoking only.
In some studies mean (SD) weight change by trial arm was not
reported in full. When the standard deviations for the changes in
body weight were not present, we used various different meth-
ods to calculate them using standard formulas depending on the
information available. This was mainly derived from confidence
intervals and standard errors. To calculate standard deviations of
the changes in weight from their associated confidence intervals
for studies with large sample size, we used the following formula:
SD = (
√
(n) x (upper limit - lower limit)) /standard error wide
For studies with 95% confidence intervals for difference in means
we divided by 3.92 standard errors wide. If sample size was less
than 60, the 3.92 standard error wide was replaced with numbers
specific to both the t-distribution and the group sample size minus
1.
To calculate standard deviation from standard error we used the
follow formula:
SD=SE x
√
(n)
When the absolute mean differences in body weight were not re-
ported explicitly, we calculated them by subtracting the baseline
mean weights from the post-intervention mean weights for the
intervention and control groups. SDs were calculated by using
an estimated correlation coefficient of 0.99, which describes how
similar the baseline and finishing weight were across participants.
This was estimated in abstinent smokers from raw data that we
have collected from a trial to prevent weight gain on smoking ces-
sation (Parsons 2009) and from any other included studies that
report standard deviations for mean weight at baseline, final mea-
surement, and changes in means. To estimate the correlation co-
efficient for the intervention and control groups from other stud-
ies reporting starting and finishing means with SDs, we used the
following formula:
r = (SD (B)2 + SD (F)2 - SD (C)2) / (2 X SD(B) X SD (F)).
[where r= correlation coefficient, SD= standard deviation for the
changes in means, B= baseline, F= final measurement, and C=
change in mean weight measurement.]
The imputed correlation coefficient was used to calculate themiss-
ing standard deviations for changes in means for the intervention
and control groups by using the following formula:
SD (C) =
√
((SD (B)2 + SD (F)2) - (2 X r X SD (B) X SD (F))
Part 2 - As data have already been extracted on the participants,
interventions and study quality in the Cochrane reviews included
in Part 2 we extracted only data about weight gain. Weight data
was extracted using the same approach as described in Part 1.
In some studies in Part 1 and 2, more than one trial arm had
been compared with a control arm. Where appropriate, to create
one comparison intervention arm we combined outcome data.
For smoking we added together the numerator and denominator
from each arm. Weight outcomes from more than one trial arm
were calculated using the following formulas:
Meanc = ((Mean1*n1)+(Mean2*n2))/(n1+n2)
Standard deviation=
√
varc√
varc= (sumsqc - (nc * (Meanc
2)))/(nc-1)
sumsqc= (((n1-1)*(var1 + ((n1/n1-1))*(mean1
2) + ((n2-1)*(var2
+ ((n2/n2-1))*(mean22))
Key: Meanc= Combined mean, sumsq=sum of squares
For studies in Part 1, we rated the potential for bias of included
trials on methods of randomisation, allocation concealment and
blinding followingmethods described in theCochrane Handbook
for Systematic Reviews of Interventions (Handbook 2005). This
had already been performed for studies in Part 2 in the parent
reviews.
Smoking cessation outcome data are given based on the number
of quitters in the treatment and control groups divided by the total
number of participants receiving treatment and reported as a risk
ratio with 95% confidence intervals. A risk ratio greater than 1.0
indicates that more people quit in the treatment group than in
the control group. Therefore, effective interventions appear to the
right of the axis on the meta-analysis graph. We used the Man-
tel-Haenszel fixed-effect method for smoking cessation outcomes
where appropriate. Weight change outcome data are given as the
difference in mean weight change between the intervention and
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control arms and estimates were combined using the inverse vari-
ance method where appropriate. The I² statistic was used to inves-
tigate statistical heterogeneity, given by the formula [(Q-df )/Q] x
100%, where Q is the chi-squared statistic and ’df ’ is its degrees
of freedom.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Interventions specifically designed to address post
cessation weight gain
We found 16 trials which matched our inclusion criteria for the
first part of the review. Two of these studies contributed data to
both Parts 1 and 2 of the review (1 Cooper 2005; 1 Spring 1995).
All studies recruited community volunteers who wanted to stop
smoking and avoid weight gain. Nine studies recruited women
only (1 Cooper 2005; 1 Copeland 2006; 1 Danielsson 1999;
1 Klesges 1990;1 Levine 2010 1 Perkins 2001; 1 Pirie 1992; 1
Spring 1995; 1 Spring 2004 ) and the remainder included smokers
of both sexes ( 1 Hall 1992;1 Hankey 2009; 1 Klesges 1995; 1
Norregaard 1996; 1O’Malley 2006; 1 Parsons 2009; 1 Toll 2010).
Participants averaged 20-25 cigarettes per day with the exception
of four studies where mean consumption was higher at between
26-32 (Hall 1992; 1 O’Malley 2006;1 Pirie 1992 and 1 Spring
1995). Mean baseline weight and/or body mass index (BMI) was
reported in all but three studies (1 Klesges 1990; 1 Klesges 1995;
1 Toll 2010) and ranged between 64-76 kg/BMI 23-29.
Seven studies compared the effects of pharmacological interven-
tions to placebo on smoking cessation and post cessation weight
change. Pharmacological interventions included: 8.33 mg Phenyl-
propanolamine gum 16 pieces/day for 8 weeks (1 Cooper 2005),
9 pieces/day for 2 weeks (1 Klesges 1990) and up to 10 pieces/
day for 4 weeks (1 Klesges 1995), 20 mg Ephedrine plus 200 mg
caffeine 3/day for 12 weeks (1 Norregaard 1996), 100, 50 and 25
mg/day Naltrexone for 6 weeks (1O’Malley 2006) and 30 mg/day
Dexfenfluramine for 12 weeks (1 Spring 1995). This study also
examined the efficacy of 40 mg/day of fluoxetine for preventing
weight gain (1 Spring 1995). As the other fluoxetine studies were
included in Part 2 of the reviews, this comparison is described in
Part 2.
Six studies assessed the effects of multi component behavioural
interventions to prevent weight gain added to usual smoking ces-
sation support. In three studies the intervention consisted of edu-
cation on weight management. This was education on healthy eat-
ing, increasing physical activity and behavioural change strategies
such as self monitoring (Hall 1992;1 Hankey 2009; 1 Pirie 1992).
Although, one study advised all participants to reduce energy in-
take by 100-300kcal/day depending on how much they smoked
and increase activity to one hour of walking three times a week,
this was general advice given to the group and no feedback was
given. (1 Pirie 1992). One of these studies (1 Hankey 2009) gave
advice appropriate to “stage of change”. These have been classified
as “weight management education” interventions. Three studies
additionally included feedback on personal goals and a personal
energy prescription (500kcal deficit of energy requirement calcu-
lated from age, gender, weight and activity level of individuals
(Hall 1992; 1 Perkins 2001) or a 150-300kcal deficit based on
individuals’ food diaries (food was prepared and provided to par-
ticipants in this study) (1 Spring 2004). These have been classified
as “personalised weight management support” interventions. We
considered the behavioural interventions to be compared to a “no
weight intervention” arm, if participants received no intervention
targeted at weight management (1 Pirie 1992) or if the control
arm included minimal weight intervention given to appease the
participants (1 Hall 1992, good nutrition and exercise informa-
tion pack not aimed at post cessation weight gain given to par-
ticipants, 1 Spring 2004, last session (Wk16) spent talking about
weight loss strategies, 75/107 randomised participants attended)
rather than a specifically designed to have an effect.
One study tested the efficacy of a very low calorie diet (VLCD).
In this study, participants in the intervention and control group
both received the weight management education as well as usual
smoking cessation support. Both groupswere also advised to follow
a 1600kcal diet, while the intervention group received two, two
week blocks of a VLCD provided free of charge. Treatment took
place in a specialist obesity treatment centre (1 Danielsson 1999).
Cognitive behavioral therapy (CBT) to address concern about
weight gain is aimed at ameliorating concern and promoting ab-
stinence, not at reducing weight gain as such, but we included
these studies. 1 Perkins 2001 tested the effect of CBT to promote
acceptance of modest weight gain added to standard smoking ces-
sation counselling compared to usual smoking cessation support
only. 1 Levine 2010 tested the effect of CBT and bupropion sep-
arately and in combination added to standard smoking cessation
counselling.
1 Spring 2004 tested whether it was better to quit first then ad-
dress weight gain or whether the two could occur concurrently.
In this study participants, all participants received 16 weeks of
smoking cessation support (target quit day,week 5) and in addi-
tion were randomised to a concurrent personalised weight man-
agement support programme (weeks 1-8) or personalised weight
management support programme sequential to quitting (weeks 9-
16). In the third arm participants did not receive a personalised
weight management support programme but the final session fo-
cused on weight management education. 75/107 participants en-
rolled in the control arm were present for the final session.
Finally, one study compared the effect of group to individual
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relapse prevention follow up sessions on smoking cessation and
weight change after a 2 week smoking cessation programme (1
Copeland 2006). As therewas no control groupwithout theweight
advice, the study is not included in the meta analyses below.
Smoking cessation therapy was provided for all participants in all
studies of pharmacological and behavioural interventions. The du-
ration, number and format of sessions of the behavioural therapy
varied from brief individual advice for two weeks to hour-long
group sessions conducted over 16 weeks, but the content was sim-
ilar including the following components: cognitive behavioural
skills such as anticipating and planning for high risk situations,
coping skills, relapse prevention and benefits of quitting smoking.
In four studies all participants were also supplied with NRT (1
Copeland 2006; 1 Danielsson 1999;1 Hankey 2009;1 O’Malley
2006) and in 1 Pirie 1992 two of the four comparison arms re-
ceived NRT.
Nine studies (1 Cooper 2005; 1 Copeland 2006; 1 Danielsson
1999; Hall 1992;1 Hankey 2009; 1 Norregaard 1996; 1 Perkins
2001; 1 Pirie 1992; 1 Spring 2004) reported smoking as an out-
come at six and/or 12 months. Smoking was either recorded as
point prevalence (1 Cooper 2005, 1 Hall 1992) or prolonged or
continuous abstinence (all others). Continuous abstinence was de-
fined as ’not a single puff since quit date’. Definitions of prolonged
abstinence varied, but mainly allowed for a grace period for the
two first weeks after quit day or for small lapses that did not lead to
full relapse. All studies apart from one (1O’Malley 2006) reported
biochemically confirmed rates. All 15 studies reported weight gain
as an outcome at end of treatment, and some reported weight at
six and/or 12 months.
Interventions not specifically designed to address
post cessation weight gain
We found 53 individual trials from the lists of included studies
in the parent reviews which matched our inclusion criteria for the
second part of the review and had extractable data. Two of these
studies also contributed data to the first part of the review (2 NRT
Cooper 2005;2 NRT Pirie 1992 ). We included 4/11 exercise
studies, 12/67 antidepressant studies (2 ADGonzales 2006; 2 AD
Jorenby 2006; 2 AD Nides 2006 also appear in varenicline list),
28/133 nicotine replacement therapy studies, and 12/15 vareni-
cline studies. We were unable to obtain published or unpublished
data from the authors of any studies in the cannabinoid recep-
tor antagonists parent review. One additional study was identified
through the update search (2 NRT Pack 2008). Participants were
adult smokers who were typically volunteers from the community
(although some studies recruited participants from a primary care
setting and one study recruited hospitalised patients). All weremo-
tivated to quit smoking and smoked an average of 20-30 cigarettes
per day. Twenty three studies reported baseline weight/BMI which
was within healthy weight to slightly overweight (with mean BMI
of 24-25 or mean weight no greater than 85 kg) the remaining
33 studies did not report baseline weight or BMI. As these were
populations intent on smoking cessation only, they are likely to be
smokers of typical body weight. One study, recruited participants
based on cigarette consumption, smoking an average of 17-18
(2 NRT Shiffman 2002A) and 25-26 (2 NRT Shiffman 2002B)
cigarettes per day.
Twelve studies from the antidepressant parent review were in-
cluded in this review, three of which compared bupropion to
varenicline as well as placebo and therefore also appear in the list
of included studies for varenicline (2 VA Gonzales 2006; 2 VA
Jorenby 2006; 2 VA Nides 2006). Overall, ten studies compared
weight change in participants treatedwith bupropion to placebo (2
AD Gonzales 2006; 2 AD Hurt 1997; 2 AD Jorenby 2006; 2 AD
Nides 2006;2 AD Piper 2007; 2 AD Rigotti 2006; 2 AD Simon
2004;2 AD Simon 2009; 2 ADUyar 2007; 2 ADZellweger 2005)
and two studies compare fluoxetine to placebo (2 ADNiaura 2002;
2 AD Saules 2004). 2 AD Saules 2004 tested fluoxetine versus
placebo, but both intervention and control arms used NRT, but
we included it in the analyses with other fluoxetine versus placebo
studies. One other study examined the efficacy of fluoxetine ver-
sus placebo (1 Spring 1995). It was not included in the parent
Cochrane review because smoking cessation at 6 months was not
reported, but was identified and included here.
All bupropion studies administered 300 mg/day and 2 AD Hurt
1997 also included a 100 mg/day and 150 mg/day arm. For the
main comparison, the 300 mg/day arm is used for the Hurt study
and the lower dose arms are used to compare to the standard
300 mg/day treatment to the lower dose arms . Two fluoxetine
studies compared two dosing levels (30 mg & 60 mg/day (2 AD
Niaura 2002) and 20mg&40mg/day (2 ADSaules 2004)) which
were combined for the main comparison and the lower doses and
higher doses were compared in a separate comparison to examine
for a dose dependent effect. One other study examined 40 mg
fluoxetine versus placebo (1 Spring 1995). The treatment period
for all antidepressant studies ranged from seven weeks to 14 weeks
with a run in to quit day of one to four weeks.
Four studies provided data from the exercise interventions par-
ent review. In all four studies, participants in the treatment arm
received an exercise component in parallel with cognitive be-
havioural treatment for smoking cessation, which was supple-
mented with nicotine replacement therapy in 2 EX Ussher 2003
and 2 EX Bize 2010. The exercise component included super-
vised exercise in three studies. 2 EX Marcus 1999 tested three su-
pervised exercise sessions/week for 12 weeks, 30-40 mins resting
heart rate plus 60-85% heart reserve, 2 EX Marcus 2005 tested
one supervised, four unsupervised exercise sessions/week for eight
weeks, at least 30 minutes at resting heart rate plus 45-59% heart
reserve and 2 EX Bize 2010 tested moderate-intensity (40-60% of
maximal aerobic power) group-based cardiovascular (CV) activity
under the supervision of a trained monitor for 45 minutes weekly
for nine weeks. In contrast, 2 EXUssher 2003 compared the effect
of seven weeks of exercise counselling to participants receiving a
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smoking cessation intervention with brief health education.
Eleven studies provided data onweight change whilst using a patch
compared with placebo (2 NRT Abelin 1989; 2 NRT CEASE
1999; 2 NRT Ehrsam 1991; 2 NRT Fiore 1994A; 2 NRT Fiore
1994B; 2 NRT Gourlay 1995, 2 NRT Richmond 1994, 2 NRT
Sachs 1993; 2 NRT Stapleton 1995; 2 NRT Tonnesen 1991; 2
NRT TNSG 1991) and one study provided data comparing three
different dosing regimes (11 mg, 22 mg and 44 mg) (2 NRTDale
1995) which has been included in a separate comparison. Dosing
regimes in the nine placebo controlled studies varied although
usually contained a mixture of participants treated with either a
lower dose patch (e.g. 14 or 15 mg) and/or a higher dose patch
(e.g. 21/22 or 25 mg) for those who were more addicted or opted
for higher doses.
Five studies provided data on weight change whilst using NRT
gum, in two cases compared to placebo (2 NRT Garvey 2000 2
NRT Hjalmarson 1984), and in three cases compared to no gum
(1Cooper 2005, 2NRTGross 1995, 1 Pirie 1992). In two studies,
participants used 2mgwith ad libitumdosing instructions (2 NRT
Hjalmarson 1984, 1 Pirie 1992). One study asked participants
to chew 10-12 pieces daily (1 Cooper 2005). In 2 NRT Gross
1995, participants were given 2 mg gum but then randomised to
instruction to chew seven, 15, or 30 pieces daily. 2 NRT Garvey
2000 randomised smokers to placebo, 9-15 pieces of 2 mg gum,
or 9-15 pieces of 4 mg gum. Treatment length varied from eight
weeks to one year, with a median of 12 weeks.
There were two placebo controlled studies of nicotine nasal spray
up to 40 mg/day (2 NRT Hjalmarson 1994; 2 NRT Sutherland
1992). There were two placebo controlled study of up to 6
months usage of nicotine inhaler (2 NRT Hjalmarson 1997; 2
NRT Tonnesen 1993), two placebo controlled studies of nicotine
lozenge 2 mg for smokers of a lower daily consumption (2 NRT
Shiffman 2002A) and 4 mg for smokers of higher daily consump-
tion (2 NRT Shiffman 2002B), one placebo controlled study of
2 mg nicotine sublingual tablet (2 NRT Wallstrom 2000), one
placebo controlled study of nicotine inhaler added to 15 mg nico-
tine patch (2 NRT Blondal 1999), one placebo controlled study
of 16hr/15 mg nicotine patch added to nicotine inhaler (2 NRT
Bohadana 2000) versus inhaler alone (and this was therefore in-
cluded in the patch versus placebo comparison), one placebo con-
trolled study of nicotine patch added to nicotine gum (2 NRT
Puska 1995) versus gum alone and this was included in the patch
versus placebo condition. The median length of treatment for all
NRT studies was 12 weeks (range 4-52). Fifteen studies included
a period after treatment for reducing the dose (2 NRT Abelin
1989; 2 NRT Blondal 1999; 2 NRT Ehrsam 1991; 2 NRT Fiore
1994B; 2 NRTGarvey 2000; 2 NRTGross 1995; 2 NRT Lerman
2004; 2 NRT Hjalmarson 1997; 2 NRT Puska 1995; 2 NRT
Sachs 1993; 2 NRT Shiffman 2002A; 2 NRT Shiffman 2002B; 2
NRT Stapleton 1995; 2 NRT Tonnesen 1991; 2 NRTWallstrom
2000).
One study directly compared the effectiveness of nicotine lozenge
with nicotine gum (2 NRT Pack 2008) and one study directly
compared nicotine patch to nicotine spray (2NRTLerman 2004).
Three studies allowed direct comparisons between different NRT
doses (2 NRT CEASE 1999; 2 NRT Dale 1995; 2 NRT Gross
1995).
Twelve studies in the nicotine receptor antagonist parent review
reported weight change when using varenicline. Eleven studies
were placebo controlled and included a 2 mg/daily arm, 2 VA
Nakamura 2007, 2 VA Nides 2006 and 2 VA Oncken 2006 also
randomised participants to 0.3 mg and/or 1 mg/daily with or
without titration. We compared these lower doses to higher doses
in a comparison of dose response.
One study compared 2 mg/daily varenicline to a 21 mg patch
tapering to 7 mg (2 VA Aubin 2008). As mentioned above, 2
VA Gonzales 2006; 2 VA Jorenby 2006; 2 VA Nides 2006 also
compared varenicline with bupropion. Two of the twelve studies
were phase II trials (2 VA Nides 2006; 2 VA Oncken 2006). The
treatment phase lasted for 12 weeks in six studies (2 VA Aubin
2008; 2 VA Gonzales 2006; 2 VA Jorenby 2006; 2 VA Nakamura
2007; 2 VA Oncken 2006; 2 VA Tonstad 2006; 2 VA Tsai 2008)
and six weeks in one study ( 2 VA Nides 2006). In Tonstad 2006,
all participants received a 12 week course of open-label treatment
with varenicline, and successful quitters were randomised to an
additional 12 weeks of varenicline or placebo and the effect of an
extra 12 weeks of treatment is explored in a separate comparison.
This was combined with the other studies where the 12 weeks of
varenicline/placebo was given in the first 12 weeks of abstinence,
not the second. All studies used a one week medication run in
period before the target quit day.
Weight change from baseline in all of the studies included in the
second part of the review was measured in abstainers only. Defi-
nition of abstinence varied between studies as in the first part of
the review and is noted in the table of characteristics of included
studies. In most studies, all participants received some form of
smoking cessation behavioural support in addition to the phar-
macotherapy/exercise therapy and details are outlined in the table
of characteristics of included studies. Some of the end of treat-
ment data and longer term follow-up data were received through
personal communication with authors and this is also noted in
characteristics of included studies.
Risk of bias in included studies
We extracted information about randomisation, allocation con-
cealment, blinding and measurement of abstinence and assessed
the potential for bias in each domain (Figure 1). No studies were
found to have used biased methods of randomisation or allocation
concealment however a large proportion of studies didn’t report
the method of generating the random allocation sequence (31/72
studies) or allocation concealment (44/72 studies) in enough detail
for likelihood of bias to be assessed. As the majority of these stud-
ies were published before the CONSORT statement guidelines
8Interventions for preventing weight gain after smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
were issued, it is likely that this is due to lack of reporting rather
than bias. Given the nature of the behavioural interventions and
exercise interventions, blinding was not possible for these stud-
ies and therefore there was some potential for bias. However, in
1 Perkins 2001 participants were blinded to their allocation un-
til after they had completed baseline information. The degree to
which unblinding occurred was reported in a further two studies.
1 Norregaard 1996 found that 68% of the treatment group and
63% of the placebo group had correctly guessed their allocation
to active or placebo NRT and 2 NRT Tonnesen 1993 46% on
active treatment and 58% on placebo treatment guessed correctly,
indicating guessing was no better than chance. A more serious po-
tential for bias concerns the weight management interventions in
the group of ’behavioural treatment’ studies. Six out of the seven
studies recruited women concerned about post-cessation weight
gain. It is feasible that in these ’open label’ studies women allo-
cated to ’no weight help’ interventions were more likely to drop
out. Six studies out of all included in the review measured weight
change in abstinent participants measured using point prevalence
criteria. This was defined as being abstinent at the time of fol-
low up in one study (1 Cooper 2005/2 NRT Cooper 2005) and
abstinent for seven days previous to follow up in the remaining
five studies (1 Hall 1992; 2 AD Piper 2007; 2 AD Rigotti 2006;
2 NRT Fiore 1994A; 2 NRT Fiore 1994B). Whether abstinence
was biochemically validated or unvalidated, this was deemed as
demonstrating a high risk of bias as smoking prior to the seven
day period would reduce potential weight gain. Six studies were
rated as being unclear in terms of bias introduced by abstinence
measurement. This was because in three studies abstinence was
measured as prolonged or continuous (i.e. participants need to be
completely abstinent from two weeks after their quit day or from
their quit day, respectively) but was not biochemically validated
(1 O’Malley 2006; 2 AD Nides 2006/2 VA Nides 2006; 2 NRT
Lerman 2004), in two study the definition of abstinence was not
reported (1 Hankey 2009; 2 NRTEhrsam 1991) and in one study
although participants were only counted as abstinent if their ex-
haled CO levels were below 11 ppm at follow up, they were able
to smoke up to three cigarettes per week (2 NRT Abelin 1989).
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Effects of interventions
Effect of pharmacological interventions to prevent
post cessation weight gain on weight and smoking
cessation
There was evidence that dexfenfluramine (mean difference (MD)
-2.50 to 95% confidence interval (CI) -2.98 to -2.02), one study),
phenylpropanolamine (PPA) (MD -0.50 kg, 95% CI -0.80 to -
0.20, three studies) and naltrexone (MD -0.78 kg, 95% CI -1.52
to -0.05, two studies) reduced weight gain at the end of treatment
(Analysis 1.1) but no evidence that ephedrine and caffeine (MD
-1.30 kg, 95% CI -2.87 to 0.27 kg, one study) or chromium
(MD -0.81 kg, 95% CI -3.05 to 1.43, one study) did so. No
pharmacological intervention significantly reduced weight gain at
six or 12 months, but this was examined only for chromium,
ephedrine and caffeine, and PPA. (Analysis 1.2 and Analysis 1.3).
There was no evidence that these pharmacological interventions
either increased or decreased quit rates at six or 12 months, but
the wide confidence intervals mean the estimates were imprecise
(Analysis 2.1; Analysis 2.2).
Effect of behavioural interventions to prevent post
cessation weight gain on weight and smoking
cessation
There was no evidence at any follow up that weight management
education alone reduced weight gain (At EOTMD -0.04 kg, 95%
CI -0.57 to 0.50, two studies; at 6 months MD 0.89 kg, 95%
CI -0.78 to 2.55, two studies; and 12 months MD -0.21 kg,
95% CI -2.28 to 1.86, two studies (Analysis 3.1; Analysis 3.2;
Analysis 3.3)). Interventions providing weight management edu-
cation only compared with no intervention showed no difference
in quit rate at six months (RR 1.02, 95% CI 0.80 to 1.31, three
studies, Analysis 4.1). At 12 months, however, the intervention
significantly reduced success in quitting (RR 0.66, 95% CI 0.48
to 0.90, two studies, Analysis 4.2).
Personalised weight management support programmes signifi-
cantly reduced weight gain at end of treatment (MD -1.11 kg,
95% CI -1.93 to -0.29, 3 studies, Analysis 3.1) and this effect
was strengthened at 12 months (MD -2.58 kg, 95% CI -5.11 to
-0.05), two studies, Analysis 3.3). However, one study (1 Spring
2004) provided data at six months and showed no difference in
weight change between a personalised weight management sup-
port programme and no intervention (MD0.40 kg, 95%CI -2.54
to 3.34, Analysis 3.2). The within study comparison from 1 Hall
1992 suggested that personalised weight management support is
more effective than weight management education only at end of
treatment (-MD1.12 kg, 95%CI -2.17 to -0.07, Analysis 3.1) and
at 12 months (MD -2.49 kg, 95% CI -5.51 to 0.53, Analysis 3.3).
Personalised weight management support had no effect on quit
rate at six months (RR 0.88, 95% CI 0.54 to 1.43, two studies,
Analysis 4.1) or at 12months (RR 0.79, 95%CI 0.47 to 1.33, two
studies, Analysis 4.2) although confidence intervals were wide..
The single study (1 Danielsson 1999) that incorporated an inter-
mittent very low calorie diet into a weight management education
intervention showed a significant reduced weight gain at end of
treatment (MD -3.70 kg, 95% CI -4.82 to -2.58, Analysis 3.1).
At 12 months the effect was smaller and not significant (MD -
1.30 kg, 95% CI -3.49 to 0.89, Analysis 3.3). This intervention
was associated with a significant improvement in abstinence at 12
months (RR 1.73, 95% CI 1.10 to 2.73, Analysis 4.2).
Effect of CBT to accept post cessation weight gain on
weight and smoking cessation
There was mixed evidence for the effect of CBT to reduce weight
gain concerns showing no reduction in weight gain at end of treat-
ment (MD -0.18 kg, 95% CI -0.56 to 0.20, two studies, I² 92%,
Analysis 6.1) or at 12 months (MD 0.13 kg, 95% CI -0.72, 0.98,
two studies, I² 71%, Analysis 6.3). However, there was evidence
of significantly increased weight in the CBT group at 6 months
(MD 0.74 kg, 95% CI 0.24 to 1.24, 2 studies, I² 82%, Analysis
6.2). CBT significantly increased the quit rate at 6 months (RR
1.70, 95% CI 1.13 to 2.56, 2 studies, I² 57%, Analysis 5.1) but
not at 12 months (RR 1.25, 95% CI 0.83 to 1.86, 2 studies,
I² 26%, Analysis 5.2). One study (1 Levine 2010) tested CBT
added to treatment with bupropion (300 mg/day), and found no
evidence of reduced weight gain or increased abstinence in those
who received CBT and bupropion treatment compared to those
who received bupropion treatment with no additional CBT for
weight concerns. (Analysis 4.1; Analysis 4.2; Analysis 3.1; Analysis
3.2; Analysis 3.3). However, there was evidence of significantly
increased weight gain at six months (MD 0.86 kg, 95% CI 0.30
to 1.42 kg, 1 study). There was significant statistical heterogeneity
when combining studies as the effects seen in each study differed
markedly, with 1 Perkins 2001 finding a significant effect of CBT
on weight reduction at end of treatment, six and 12 months and
increased quit rates at six months and 1 Levine 2010 finding no
such effects at any time point, but finding significant weight gain
in the CBT arm at six months.
Effect of antidepressants on post cessation weight
gain
Bupropion (300 mg/day) limited post cessation weight gain com-
pared with placebo at the end of treatment (MD -1.12 kg, 95%CI
-1.47 to -0.77, seven studies, Analysis 7.1). At six and 12 months
the reduction in weight was lower than at end of treatment and
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it was not significant (MD -0.87 kg, 95% CI -2.21 to 0.47, four
studies, Analysis 7.3 and MD -0.38 kg, 95% CI -2.00 to 1.24,
four studies, Analysis 7.5). There was no evidence of a dose depen-
dent response for bupropion at end of treatment, six or 12 months
(Analysis 7.2, Analysis 7.4, Analysis 7.6).
Fluoxetine reduced weight gain at end of treatment (MD -0.99 kg,
95% CI -1.36 to -0.61, two studies, Analysis 7.1). At six months,
the effect was smaller and not significant (MD -0.19 kg, 95% CI -
1.10 to 0.71, two studies, Analysis 7.3), Two studies of fluoxetine
randomised participants to higher and lower doses as well as to
placebo (2 ADNiaura 2002 to 60 mg and 30 mg and 2 AD Saules
2004 to 40 mg or 20 mg). There was no evidence that higher doses
were more effective at six months and in fact people randomised
to 60 mg had significantly greater weight gain at six months than
people randomised to 30 mg, an effect not seen in the 40 mg
versus 20 mg comparison (Analysis 7.4).
Effect of exercise interventions on post cessation
weight gain
Neither individual nor pooled data for the three trials of exercise
programmes showed any reduction in weight gain at the end of
the programme (Analysis 8.1), with a summary estimated mean
difference of -0.25 kg (95% CI -0.78 to 0.29). However, three
studies provided data at 12 months follow up which when pooled
showed a significant reduction in weight gain favouring treatment
(Analysis 8.2), with a summary estimate of -2.07 kg (95% CI -
3.78 to -0.36).
Effect of nicotine replacement therapy (NRT) on post
cessation weight gain
Participants taking any type of NRT gained less weight than
placebo referents at the end of treatment (MD -0.69 kg, 95% CI
-0.88 to -0.51, 19 studies, I²=82%). Statistical heterogeneity was
due to one study 2 NRT Abelin 1989 which showed a 4.3 kg
difference between weight gain in the treatment and control arm.
When this study was removed, statistical heterogeneity reduced to
0% and the overall estimate decreased but remained statistically
significant (MD -0.46 kg, 95% CI -0.66 to -0.27, Analysis 9.1).
Estimates of difference in weight gain for different types of NRT
were similar: gum MD -0.58 kg (95% CI -1.02 to -0.13.4 stud-
ies), patch (without Abelin 1989) MD -0.45 kg (95% CI -0.70 to
-0.20, 10 studies), inhaler MD -0.37 kg (95% CI -1.19 to 0.45,
two studies), sublingual tablet MD -0.48 kg (95% CI -0.99 to
0.03, 2 studies), intranasal spray (+ patch) MD 0.90 kg (95% CI
-1.54 to 3.34, one study). There was some evidence that there was
less weight gain at the end of treatment in participants using the
lozenge compared to those using patch (MD -2.45 [-4.43, -0.47],
1 study), although this difference didn’t remain in the long term.
Overall, weight gain was less for those taking NRT at six and 12
months although not significantly (MD -0.37 kg, 95% CI -0.88
to 0.14, 9 studies Analysis 9.5 and MD -0.42 kg, 95% CI -0.92
to 0.08, 15 studies, Analysis 9.8). 2 NRT Lerman 2004 compared
patch to spray and found no significant difference in weight gain
at end of treatment or six months (Analysis 9.2; Analysis 9.5).
Longer courses of NRT with 15 mg or 25 mg patches were not
associated with reduced weight gain at 12 months Analysis 9.11.
Four trials compared the effects of different doses of NRT. 2 NRT
Garvey 2000 compared 4 mg and 2 mg NRT gum to placebo,
2 NRT Dale 1995 compared 44 mg, 22 mg and 11 mg patches
to placebo, 2 NRT CEASE 1999 compared 25 mg and 15 mg
patches to placebo, and 2 NRT Gross 1995 compared different
numbers of 2 mg NRT gum per day. There was no significant
dose dependent difference in weight gain at the end of treatment
(Analysis 9.4) or at 12 months (Analysis 9.10).
Effect of rimonabant on post cessation weight gain
We were unable to obtain mean weight change data with confi-
dence intervals for rimonabant on post cessation weight gain. All
weight related findings that have been reported have been sum-
marised by the parent Cochrane review (Cahill 2011a) which in-
dicates that rimonabant may reduce weight gain during treatment
by a small amount. However, the FDA did not authorise the use
of rimonabant and the European Medicines Agency and Food
and Drug Administration have withdrawn marketing authorisa-
tion because they concluded the benefits of rimonabant did not
outweigh the risks.
Effect of varenicline on post cessation weight gain
There was no evidence that 1 mg of varenicline reduced weight
gainmore thanplacebo (MD-0.12kg, 95%CI -0.68 to 0.43, three
studies) but there was evidence that 2 mg daily did reduce weight
gain (MD -0.41 kg, 95% CI -0.63 to -0.19, 11 studies) (Analysis
10.1). Only one study provided data at six months, showing no
evidence of effect (MD 0.41 kg, 95% CI -0.79 to 1.61, Analysis
10.2) and two studies at 12 months, also showing no evidence of
an effect (MD 1.11 kg, 95% CI -0.75 to 2.98, Analysis 10.3).
Three studies compared treatment with bupropion to varenicline.
Participants taking varenicline gained significantly more weight at
the end of treatment (MD 0.51 kg, 95% CI 0.09 to 0.93, Analysis
11.1). There was no evidence that weight gain differed in the one
trial of varenicline versus NRT (2 VA Aubin 2008, Analysis 12.1).
D I S C U S S I O N
Since the first version of this review was published in 2009, we
have found five additional trials and received data from the authors
of a further trial fitting criteria for part 1, and there are now 16
trials of interventions specifically designed to limit post cessation
weight gain. Although a range of pharmacological interventions
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were tested, none showed evidence that weight gain was prevented
in the longer term. Behavioural interventions were more promis-
ing. Personalised weight management support, which included
weight management education with both feedback on personal
goals and a personal energy prescription, showed reduced weight
gain at one year, but the estimate of effect was very imprecise cov-
ering both substantial benefit and a clinically irrelevant benefit.
There was no evidence that detailed weight management educa-
tion without personalised assessment, planning and feedback re-
duced weight gain and at least some evidence that this may have
reduced smoking cessation rates. The earlier version of this review
suggested that CBT to accept moderate weight gain increased ab-
stinence, and limited long term post cessation weight gain how-
ever, a subsequently published trial was not as promising. When
the two trials were combined, although smoking cessation rates
were still significantly increased at six months, there was a signifi-
cant increase in weight gain at six months, and no effects on either
weight or quitting at 12 months. However, statistical heterogene-
ity was high. Eight new trials were identified during the update
that fitted the criteria for Part 2 of this review (three bupropion
studies, four varenicline studies and an NRT study that compare
lozenge to gum preparations). In total, we examined evidence for
five different interventions used to support smoking cessation that
might incidentally reduce weight gain on cessation. There was
strong evidence that four of these, NRT, bupropion, fluoxetine,
and varenicline all reduced weight gain by about 0.5 kg (NRT
and varenicline) and about 1 kg (fluoxetine and bupropion) by
the end of the usual treatment period. A few of the trials recorded
weight at later follow ups, and there was no evidence that these
pharmacotherapies attenuated weight gain when assessed then but
there is insufficient evidence to exclude an effect. There was some
evidence that nicotine nasal spray did so at one year and it is
perhaps notable that spray was available for the whole year for
participants in these trials. One behavioural intervention, exercise
to assist smoking cessation, showed no evidence that it reduced
weight gain during the exercise programme but, perhaps surpris-
ingly given this finding, there was evidence of reduced weight gain
at one year.
Pharmacotherapy to limit weight gain
To date, six pharmacological interventions (phenylpropanolamine
(PPA), ephedrine + caffeine, naltrexone, dexfenfluramine, fluoxe-
tine and chromium) have been combined with standard smoking
cessation treatment to test their effect on post cessationweight gain
compared with smoking cessation treatment alone. None have
shown evidence of a long-term effect on weight gain and therefore
none can be recommended for use in clinical practice. There was
however promising evidence that PPA, dexfenfluramine, and nal-
trexone prevent weight gain in the short term. Dexfenfluramine
has been withdrawn from use because it causes serious problems
and the dose of PPA allowed for use is lower than the dose tested
in these trials. Naltrexone, which is used in treatment of other
substance use dependence, is promising, although the effect on
weight gain is modest.
Behavioural programmes to limit weight gain
English smoking cessation guidelines fromNICEmake no specific
recommendations about preventing post cessation weight gain,
while US guidance recommends either bupropion, NRT, or ex-
ercise as interventions. A common perception is that concurrent
behavioural treatment for smoking and weight undermines smok-
ing cessation and advice is to establish smoking cessation before
tackling weight (McEwan 2006). Some of the reason for this is the
evidence from laboratory studies which show increased urges to
smoke during periods of food restriction (Cheskin 2005, Leeman
2010). With one possible exception, our review revealed no evi-
dence to reinforce this fear.
US guidelines do not discuss the role of dietary interventions,
which are the mainstay of weight control interventions in other
contexts. Our review suggested that weight management pro-
grammes did not generally undermine smoking cessation. At six
months no interventions showed strong evidence that cessation
was reduced and at 12 months, only one intervention did. This
was weight management education without personalised support.
Given there was no evidence that cessation was undermined at six
months, these data are hard to interpret. Nevertheless there was no
evidence that this kind of non personalised weight management
education reduced weight gain and such general advice cannot be
recommended. The other similar but more intensive personalised
weight management support programmes look the most promis-
ing of all interventions we reviewed, but the effect estimate is im-
precise and requires confirmation. These interventions differed
but all included personal goal setting, monitoring and feedback
on progress. Other elements that may have contributed to success
were degree of personalised energy restriction, or providing food
to help with adherence. Although it would be possible to manip-
ulate one element at a time, the commonalities of these data with
those in the weight loss field suggest that all elements are likely
to be important ingredients in the success of the intervention. It
is also worth noting that the point estimates for abstinence both
suggested that cessation was less likely in those receiving this in-
tervention, though not significantly so. Further trials of this ap-
proach are required for confirmation. The other dietary approach
that showed distinct promise was the VLCD. There was evidence
that use early on in cessation increased abstinence in the long-term
and clear evidence of a short-term reduction in weight gain and
non-significant evidence of a reduction in weight at one year. In
this study, the control arm was advised to adhere to a 1600kcal/
day diet, which creates an energy deficit, therefore this may have
masked the full effect of the VLCD in the intervention arm. How-
ever, this was one trial that advertised for participants and whether
this kind of demanding intervention would be popular with many
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people trying to stop smoking remains to be seen.
Physical activity or exercise programmes were included in Part 2 of
our review because they were aimed at increasing cessation. There
is strong evidence that exercise reduces cravings to smoke. (Taylor
2007). In most trials of interventions in weight management, the
difference between intervention and control is most marked at
end of treatment and declines over follow up. In this context, it is
puzzling that there was no evidence of effectiveness of exercise on
weight at end of programme, but there was at 12 month follow
up. This might either represent a chance finding or reflect the
fact that the programme encouraged people to go on exercising
after it had finished. Further evidence is required before we can be
confident that physical activity programmes provide an effective
intervention.
There is a caveat regarding the open label design of the above be-
havioural intervention studies. With the exception of 1Hall 1992,
they all enrolled women who had problems with weight gain on
cessation and were therefore looking to be enrolled in weight con-
trol programmes. Such participants may have been more likely to
default from the control programme than when allocated the ac-
tive intervention that they presumably wanted, especially in stud-
ies such as 1 Danielsson 1999 and 1 Spring 2004 where this in-
cluded free meals. The open label design is unavoidable in this
field, but it is important to note that it could bias the smoking
abstinence results in favour of the intervention. Another possible
explanation of the positive result of the very low calorie diet is that
it induced ketosis, which may have suppressed hunger (Johnstone
2008) and nicotine withdrawal.
Reducing fears about weight gain through CBT
CBT to address weight gain concerns increased weight and im-
proved quit rates at six months, but there was no evidence of any
effect at 12 months. The results of the two studies that have tested
this approach varied significantly. Thus, further trials of this in-
tervention are required before it can be recommended as a treat-
ment programme for weight concerned smokers wanting to stop
smoking.
Pharmacotherapy for smoking cessation
We found evidence that antidepressants, nicotine replacement
therapy, and varenicline attenuate weight gain during the treat-
ment phase, however there was insufficient evidence that the effect
persisted in the longer term. The evidence suggested that for an-
tidepressants, fluoxetine and bupropion, and for varenicline, the
weight of those allocated to active intervention was the same as
that for placebo in the longer term. The picture was more com-
plicated for long term effects of NRT. The strongest effect at 12
months was seen in trials of nasal spray and inhaler, however in
these trials participants were allowed to use the NRT preparation
for up to a year. Taking these data together, they seem to indicate
that the effect of pharmacotherapies is seen during treatment and
that those who use pharmacotherapy catch up with accelerated
weight gain once treatment is withdrawn. Data from within tri-
als, 2 NRT Sutherland 1992, and an observational study (Hajek
1988) strengthens the conclusion that the possible long-term effect
of NRT depends upon long-term use. The difference in weight
between long-term users and non-users was several kilograms in
these studies, but little is known regarding possible adverse effects
of long term use of NRT. Although we found no dose response
effects in trials where participants were randomised to a higher or
lower dose of NRT, there is preliminary data from records of NRT
actually consumed that weight gain is associated with the dose of
NRT used (Ferguson 2011).
Methodological considerations
Several features of our review merit comment. First, we encoun-
tered studies of fluoxetine in Part 1 and Part 2 of the review.
The study of fluoxetine in Part 1 was excluded from the parent
Cochrane reviewbecause it did not incorporate at least a six-month
follow up. It was included in the Part 1 search because the aim was
to reduce weight gain. Thismeans that it is possible that we did not
include some other studies of fluoxetine that were not specifically
aimed at reducing weight gain and did not incorporate a six- or
12-month follow up. There is no reason to imagine that excluding
them would create a bias, however. Second, in this update but not
in the original version of our review, we added 2 VA Tonstad 2006
to our main analysis of the effect of varenicline on weight gain.
In this trial, participants had taken 12 weeks of varenicline before
the abstinent participants were randomised to a further 12 weeks
or placebo. Thus this study examines weight gain in months three
to six of a quit attempt, not months zero to three as in the other
studies. We could see no strong reason to imagine that this would
bias the analysis. Weight gain is less rapid in months three to six
(O’Hara 1998) so, if anything, it is likely that taking varenicline
would prevent less weight gain during this later period than dur-
ing the former. However, the statistical significance of the result
is sensitive to whether the Tonstad study is included or excluded
from the meta-analysis.
We split the behavioural interventions for weight control in part
one of the review into two categories: those that provided weight
management education only, and those that provided personalised
weightmanagement support. This split was chosen based onmeta-
analysis evidence that healthy eating and physical activity inter-
ventions combining self-monitoring with at least one other tech-
nique derived from control theory, (such as specific goal setting,
feedback on progress or review of goals set) are significantly more
effective than those that do not (Michie 2009).
As noted in the introduction, the data here relate to weight gain
in abstinent smokers only. It is practically difficult to follow up
non-abstinent smokers as they have no motive to attend smoking
cessation clinics and thus authors do not usually provide data
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on continuing smokers. However, most people gain weight on
cessation and most people make repeated attempts to quit. It is
possible that this leads to incremental weight gain and it would be
useful if data could be collected on this.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• Weight management education may reduce abstinence and
is not effective at controlling weight and should not be used.
• Personalised weight management support programmes,
incorporating both feedback on personal goals and a personal
energy prescription may reduce weight gain and there is no
strong evidence they reduce abstinence. Further research is
required to examine whether these effects can be replicated, and
if the effect can be generalised to all smokers, not just those
specifically concerned about gaining weight. Until then they
should be used cautiously, ideally in research.
• Very low calorie diets may increase abstinence and prevent
weight gain in the short-term at least, but these conclusions are
based on a single trial only.
• The evidence showed that CBT to allay concerns about
weight gain does not reduce weight gain or increase abstinence in
the long term. There was significant heterogeneity between the
findings of two studies of this approach.
• There is mixed evidence that exercise limits post cessation
weight gain but further research is required to show conclusively
that it is beneficial.
• Nicotine replacement therapy, bupropion, fluoxetine and
varenicline all reduce weight gain in the short term, but patients
need to be told that it is unclear whether they reduce weight gain
in the long term.
• The long-term effect of all combined smoking cessation
and weight control interventions on weight gain is small at best,
less than 1 kg, compared with the weight gain at one year (about
5 kg) and is of borderline clinical relevance. The only possible
exceptions are personalised dietary and exercise interventions
which may reduce this weight gain by half.
Implications for research
• It is important to know whether the effects of personalised
weight management support programmes and very low calorie
diets can be replicated and if the effect is confirmed, whether it
can be generalised to all smokers trying to stop or whether the
effect is specific to smokers concerned about weight gain.
• Further studies of CBT to reduce weight concerns are
required to clarify its effect on weight gain and smoking
cessation, as the two studies carried out to date vary significantly
in their estimation of effect and there was some evidence of
increased weight gain at six months.
• Further studies of exercise interventions are needed. The
finding that an intervention aimed at increasing exercise levels
had no effect initially but somehow affected weight on year later
seems counterintuitive as adherence to exercise regimes usually
decline rather than increase with time.
• Future trials of interventions for limiting post cessation
weight gain should report mean weight change, standard
deviation for the weight change and the number contributing to
the mean in biochemically confirmed continuous or prolonged
abstinent participants only rather than in those abstinent for
only one week. Weight change in those who continue to smoke
should be reported separately.
• Trials of current and future pharmacotherapies for smoking
cessation should measure weight change, reporting mean weight
change, standard deviation of the change and numbers
contributing to the mean, separating abstinent from smoking
participants as described above.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
1 Cooper 2005
Methods Country: USA
Recruitment: community volunteers
Participants 439 weight concerned female smokers (>= 10 CPD) Av.age 38, av.cpd 23, av baseline
weight 64-66kg
Interventions 1. Phenylpropanolamine (PPA) gum 8.33mg 16 pieces/d 8w, weaning last 3 wks
2. Nicotine gum (2mg), 10-12 pieces/day recommended, for 8 wks, weaning last 3 wks.
3. Placebo gum
All participants received x13 1hr weekly cognitive behavioural group sessions focused
on smoking and weight. Ppts cut down weeks 1-4 by 25% and quit week 5
Outcomes 1. PP abstinence at 12m (Validation: CO<10ppm)
2. Mean (SD) weight change (kg) in abstainers at 6m and 12m
Notes PP abstinence defined as validated self report of no smoking at the time of the assessment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methods not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk All group facilitators and participants were
blind to treatment conditions
Definition of abstinence High risk Weightmeasured in self report point preva-
lent abstainers
1 Copeland 2006
Methods Country: USA
Recruitment: Community volunteers
Participants 79 women smokers motivated to quit and weight concerned (at least 10 CPD for 1yr)
av CPD 20.1, av FTND score 4, av BMI 24
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1 Copeland 2006 (Continued)
Interventions All participants completed a smoking cessation programme (6 sessions over 2w) involving
smoking cessation and relapse prevention advise and given an 8w supply of NRT.
Randomised to follow up in either individual or group format:
Six follow up relapse prevention sessions including psychological, dietary, and exercise
components over 38 weeks
Outcomes 1. Continuous abstinence at 6 months (Validation: CO<=10ppm)
2. Mean (SD) weight change (kg) in continuous abstainers at 6m
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk “Statisticians generated the random assign-
ment sequence for follow up condition”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Therapists were blind to participant fol-
low-up treatment condition assignment
until the last meeting of the cessation pro-
gram.”
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
1 Danielsson 1999
Methods Country: Sweden
Recruitment: community volunteers
Participants 287 weight concerned female smokers age range 30-60 >=10cpd, av CPD 20, av BMI
26
Interventions 1. Nicotine gum (2 or 4 mg) with moderate behavioural advice: 11 sessions (45 min) in
16 weeks in combination with behavioural weight control programme and intermittent
very low energy diet as total food replacement ((Nutrilett 1.76MJ/day), twoweek periods
(weeks 1 and 2, 7 and 8, 13 and 14). All participants were recommended a standardised
balanced diet of about 6.7 MJ/day.
2. Control group received the same as intervention but without the very low energy diet
Outcomes 1. Prolonged abstinence 12m (Validated: CO<10ppm)
2. Mean (SD) weight change (kg) in prolonged abstainers at 6m
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1 Danielsson 1999 (Continued)
Notes Prolonged abstinence defined as “completely and continuously stopped from week 2
onwards”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Open consecutive randomisation (in the
order their questionnaires were received at
the clinic)
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
1 Hall 1992
Methods Country: USA
Recruitment: community volunteers
Participants 180 smokers, 27% F, av age 39-42, av CPD 26-32, av baseline weight 67-73kg
Interventions Participants received treatments in groups. All groups completed 2 week behavioural
smoking cessation programme. Participants were randomly assigned to follow up group
for weight management:
1. Innovative intervention - individualised multifactorial intervention including exercise,
daily weight monitoring, individual energy prescription to result in 2lb/week weight loss
if weight was gained(based on weight, age, gender, activity level), healthy eating advice
and behavioural advice to manage triggers for uncontrolled eating (4w)
2. Standard treatment condition - given an information pack on good nutrition and
exercise not targeted for SC induced weight gain at end of 2w SC programme
Outcomes 1. Point prevalence abstinence at 6 and 12m (Validation: CO < 10.5 at 6,12 and 26w,
Cotinine blood levels below 50 ng/ml at 12 m)
2. Mean (SD) weight change (kg) in abstainers at end of treatment and 12 months
Notes Non individualised weight programme arm also in this study that has not been used I
thought we did use this to compare individual with general (nutritional, exercise and
behavioural eduction delivered in group sessions)
Risk of bias
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1 Hall 1992 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study
Definition of abstinence High risk Weight measured in biochemically vali-
dated point prevalent abstainers
1 Hankey 2009
Methods Country: Scotland
Recruitment: Smokers at a smoking cessation clinic
Participants 138 smokers, 75.4% female, av baseline weight 76.2 (18.1) kg, av age 50yrs, av BMI
28.2 (5.5), av CPD, 25.2 (12.6)
Interventions (1) 24wk dietary stage of change based interventions focusing advice and self monitoring
of physical activity (ppts given pedometers), portion control, fruit and vegetable intake
and fat intake for 4 weeks post quit. Also included bolster session at weeks 8, 12, 16 and
20 post quit. No individual targets set
(2) No dietary intervention
Both conditions were embedded within a smoking cessation clinic that followed the
Maudsley model
Outcomes 1. Abstience at 6m (validation: CO monitoring). Definition of abstinence or CO level
not given
2. Mean (SD) weight change (KG) in abstainers at end of treatment and 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk computer generated
Allocation concealment (selection bias) Low risk Randomisation carried out via an interac-
tive voice response system
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1 Hankey 2009 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk Not possible
Definition of abstinence Unclear risk Definitions of abstinence and biochemical
verification not given
1 Klesges 1990
Methods Country: USA
Recruitment: Community volunteers
Participants 57 adult female smokers who had previously experienced post cessation weight gain, av
age 27, av 22.4 CPD, mean CO 49.8ppm
Interventions 1. PPA gum 8.33mg 9/day 2w
2. Placebo gum
All participants received a “brief but intensive stop-smoking intervention” and were
offered a cash reward and opportunity to win prizes if they were successful at quitting
for 2 weeks
Outcomes 1. Mean (SD) weight change (kg) in continuous abstinent smokers at end of treatment
(Validation: CO <=7ppm)
Notes Intervention only 2 weeks long. No 6 month follow up.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
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1 Klesges 1995
Methods Country: USA
Recruitment: community volunteers
Participants 107 male and female smokers, age between 18-60, CPD 20+, CO>15ppm
Interventions 1. PPA gum 8.33mg up to 10 pieces/day 4w
2. Placebo gum same regime
All participants received one 30 min session on smoking cessation and relapse prevention
Outcomes 1.Mean (SD)weight change (kg) in continuous abstainers at endof treatment (validation:
CO<8ppm)
Notes No 6 months follow up data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent randomisation
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Neither the investigators nor the subjects
knew which gum contained the active in-
gredients”
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
1 Levine 2010
Methods Country: USA
Recruitment: community volunteers
Participants 349 weight concerned women smokers, aged between 18-65yrs,motivated to quit smok-
ing, av 20.7cpd, av age 42
Interventions 1. weight concerns CBT + bupropion 300mg/day2. weight concerns CBT + placebo3.
Standard cessation counselling + bupropion 300mg/day
4. Standard cessation counselling + placebo
CBT was delivered weekly for Buproprion/placebo was taken for 26 wks
Outcomes 1. Prolonged abstinence at end of treatment and 6m (Validatio: CO</= 8ppm, or urinary
cotinine <15µg/L)
2. Mean (SD) weight change (kg) at 12w, 6m and 12m
Notes
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1 Levine 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation sequence
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
1 Norregaard 1996
Methods Country: Denmark
Recruitment: Community volunteers
Participants 225 smokers who wanted to quit without gaining weight, 65% F, av BMI 23-24, av age
38-39, av 20 CPD
Interventions 1. 20mg Ephedrine plus 200mg caffeine combination 3/day 12w then decreased until
39w. TQD -first session. Eight visits were scheduled for the 52-week study period (at
the beginning of the study and after weeks 1, 3, 6, 12, 26, 39, and 52).
2. Placebo
All participants given advice on how to quit smoking and prevent weight gain (inc
booklet about low fat food)
Outcomes 1. Prolonged abstinence at 6 and 12m (validation: CO<10ppm)
2. Mean (SD) weight change (kg) in prolonged abstainers at end of treatment, 6 and
12m
Notes Prolonged abstinence defined as no smoking after week 1 post quit
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Minimisation
Allocation concealment (selection bias) Unclear risk Not described
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1 Norregaard 1996 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Blinding was incomplete because 68% in
the ephedrine plus caffeine-treated group
and 63% in the placebo group correctly
guessed their treatment at trial termination
(p < 0.001)”
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
1 O’Malley 2006
Methods Country: USA
Recruitment: Community volunteers
Participants 400 smokers, 46% F, av BMI 27-28, av 26-29 CPD, av age 45-47
Interventions 1. Naltrexone 25mg 6w
2. Naltrexone 50mg 6w
3. Naltrexone 100mg 6w
4. Placebo
All participants also given 6w supply of 21mg patches and 6 sessions of behavioral
support (1x45mins, 5x15mins)
Outcomes 1.Mean (SD)weight change (kg) in continuous abstainers at endof treatment (validation:
exhaled CO<10ppm)
Notes Arms 1-3 combined for the main comparison
No 6 month follow up data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation, stratified by sex after
the first 150 participants
Allocation concealment (selection bias) Low risk Random sequence was provided to the
pharmacist, who assigned participants
Blinding (performance bias and detection
bias)
All outcomes
Low risk All were blinded to the treatment assign-
ment
Definition of abstinence Unclear risk Weightmeasured in continuous abstainers,
validation unclear
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1 Parsons 2009
Methods Country: UK
Recruitment: community volunteers
Participants 143 smokers, 63% female, av age 45.5 (12.4) years, av baseline weight 75.1 (17.8) kg,
av 20(8) CPD
Interventions 1. St John’s Wort ((Jarsin preparation (LI 160, Lichtwer Pharma, Berlin, Germany),
standard hypericin content 0.12% - 0.28%)) 900mg daily and chromium polynicotinate
400micrograms daily for 14w
2. SJW active, Chromium placebo
3. SJW placebo, Chromium active
4. SJW placebo, Chromium placebo
All participants received 7w of behavioural counselling with TQD coinciding with the
3rd visit
Outcomes 1. Prolonged abstinence at end of treatment (validated: CO<10ppm) and 6m (self report)
2. Mean (SD) weight change (kg) in prolonged abstainers at end of treatment and 6m
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk independent statistician prepared an excel
spreadsheet using Stata to generate two lists
of randomly sequenced blocks of 2, 4, or 6,
which were passed to the medication pack-
ing company
Allocation concealment (selection bias) Low risk Lists were used to package together medi-
cation
of SJW or placebo and CR or placebo,
which were allocated in sequence to
participants in clinic.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, therapists, and outcome asses-
sors were blind to
the treatment allocation.
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
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1 Perkins 2001
Methods Country: USA
Recruitment: community volunteers
Participants 219 weight concerned women av age 44, av body weight 69kg, mean 21 CPD
Interventions 1. Weight control - Programme to attenuate weight gain, with a 500kcal deficit of the
energy required tomaintain baseline weight. behavioural support (stimulus control tech-
niques), self monitoring and constructive feedback. 10x 90min sessions over 7 weeks2.
Standard - No additional support given for weight, session time used to talk about smok-
ing cessation
3. CBT - therapy to promote the acceptance of modest weight gain, reduce concerns
and encourage healthy eating.
All participants received standard CB SC counselling at each session
Outcomes 1. Continuous abstinence 6 and 12m (validation: CO </=8ppm)
2. Mean (SD) weight change (kg) for continuous abstainers 6 and 12m
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk After a sufficient number of participants to
form a group recruited, group assigned to
a treatment condition
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Participants did not learn of their treat-
ment condition assignment until the first
treatment session, after all baseline infor-
mation had been received”
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
1 Pirie 1992
Methods Country: USA
Recruitment: community volunteers
Participants 417 women smokers, av CPD 25-27, av age 42-44, av BMI 23-24, 30-40% expressed
great weight concern
Interventions 1. Group SC therapy plus weight control programme (general calorie restriction 100-
300kcal based on cigarette consumption, increased exercise to 1hour daily walking,
encouraged to self monitor, acceptance of weight gain)
2. Group SC therapy only
48Interventions for preventing weight gain after smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1 Pirie 1992 (Continued)
Outcomes 1. Continuous abstinence at 6 and 12m (Validation: expired CO </=10ppm)
2. Mean (SD) weight change (kg) in continuous abstainers at 6 and 12m
Notes 2 additional arms in the study that haven’t been used in this review- SC therapy + 2mg
nicotine gum ad lib and SC therapy + weight control programme + 2mg NRT ad lib
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Not possible due to nature of the interven-
tions
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
1 Spring 1995
Methods Country: USA
Recruitment: community volunteers
Participants 144 female weight concerned smokers, av age 41, av CPD 27, av BMI 23-25
Interventions 1. Dexfenfluramine 30mg/day 12w
2. Fluoxetine 40mg/day 12w
3. Placebo
All participants received weekly group behavioural support for first 4w and fortnightly
support for remaining 8w
Outcomes 1.Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (validation:
CO <10ppm)
Notes No 6 months follow up data
Prolonged abstinence defined as validated continuous abstinence after a 2 week grace
period
Fluoxetine arm used in first part of review as taken specifically to prevent post cessation
weight gain and this study is not included in the parent antidepressant review
Risk of bias
Bias Authors’ judgement Support for judgement
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1 Spring 1995 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “All subjects received identical packets of
three pills”
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
1 Spring 2004
Methods Country: USA
Recruitment: community volunteers
Participants 315 mildly weight concerned women, av age 42.7 (10.3) yrs, av 20.3 (9.5) CPD, av
BMI 27.4 (7.6)
Interventions 1. Early diet group. Diet during 1-8w of treatment programme (Pre-packaged Nutri/
system foods: high-carbohydrate, low-fat, balanced diet based on baseline precessation
energy intake from food diaries minus 150 kcal per day). Ppts led on a 30 minute walk
after the treatment programme session
2. Late diet group. Diet during 9-16w of treatment programme
3. Control. Final smoking cessation group session focused on weight loss strategies
All participants received 16 weekly cognitive behavioural smoking cessation group sup-
port sessions
Outcomes 1. Mean (SD) weight change (kg) at end of treatment and 6m in continuous abstainers
(validation: CO</=10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk not applicable
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1 Spring 2004 (Continued)
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
1 Toll 2010
Methods Country: USA
Recruitment: community volunteers
Participants 127 weight concerned smokers, 28.5% males, mean BMI 28.4±6.16, mean 25.5±10.76
expired CO,
Interventions (1) 25-mg naltrexone daily beginning the week before quitting continuing until 26w
(2) placebo
All ppts received 21mg patches 6wks and then 14mg 2wks, starting on quit day. All
received CBT for weight concerns weekly for 4 wks, bimonthly twice and then monthly
Outcomes 1. Point prevalence abstinence at end of treatment (26w)
2. Mean (SD) weight change (kg) at end of treatment (26w) in continuous abstainers
(validation: CO <10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block stratified for gender, sequence pro-
vided by author and given to pharmacist
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 AD Gonzales 2006
Methods Country: USA
Recruitment: community volunteers
Participants 1025 smokers 55% female (Placebo), 48% female (Bup); av age 45, av CPD not specified
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2 AD Gonzales 2006 (Continued)
Interventions 1. Varenicline 1mg x2/day for 12w
2. Bupropion 300 mg/day for 12w
3. Placebo
All participants received brief individual counselling at visits w1-7, 9, 12, + telephone
counselling at 4 and 5m
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (validation:
CO <10ppm)
Notes Prolonged abstinence defined as complete abstinence from weeks 9-12
Arm 2 compared with 3 (same study as 4 VA Gonzales)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization: computer generated se-
quence 1:1:1
Allocation concealment (selection bias) Low risk Participants were randomised according to
a predefined central computer sequence
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 AD Hurt 1997
Methods Country: USA, multi-centre
Recruitment: community volunteers
Participants 615 smokers, 55% F, av age 44, av CPD 27
Interventions 1. Bupropion 100 mg/day for 7w, begun 1w before TQD
2. Bupropion 150 mg/day
3. Bupropion 300 mg/day
4. Placebo
All participants received physician advice, S-Hmaterials, and brief individual counselling
by study assistant at each visit
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (email com-
munication), 6 (email communication) and 12 m (email communication) (Validation:
CO < 11ppm)
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2 AD Hurt 1997 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified by site, method not specified
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 AD Jorenby 2006
Methods Country: USA, multi centre
Recruitment: community volunteers
Participants 1027 smokers, 41% F, av age 42, av CPD 22
Interventions 1. Bupropion 300mg for 12 w + placebo varenicline
2. Varenicline 2mg for 12 w + placebo bupropion
3. Placebo bupropion + placebo varenicline
All participants received brief (< 10min) individual counselling at eachweekly assessment
for 12w & 5 follow-up visits. One telephone call 3 days after quit day
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (validation:
CO < 10ppm)
Notes Prolonged abstinence defined as validated self reported abstinence w 8-12
Arm 1 and 3 in main comparison (same study as VA Jorenby 2006)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised, computer-generated
Allocation concealment (selection bias) Low risk “SItes used an electronic system to assign
participants to treatment”
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2 AD Jorenby 2006 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 AD Niaura 2002
Methods Country: USA, multi-centre, 16 sites
Recruitment: Community volunteers
Participants 989 smokers, 61% F, av age 42 av CPD 28
Interventions 1. Fluoxetine 30 mg for 10w, starting 2w before TQD
2. Fluoxetine 60 mg for 10w, starting 2w before TQD
3. Placebo
All arms: 9 sessions (60-90mins) individualCBT. Included coping skills, stimulus control
techniques and relapse prevention
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (Validation:
CO less than 8ppm and salivary cotinine less than 20ng/ml)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Low risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
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2 AD Nides 2006
Methods Country: USA, multi-centre, 7 sites
Recruitment: Volunteers (phase II study)
Participants 638 smokers, 51% F, av age 41, av CPD 20, av BMI 25-27
Interventions 1. Varenicline 0.3mg 1/d for 6w, + 1wk placebo
2. Varenicline 1.0mg 1/d for 6w, + 1wk placebo
3. varenicline 1.0mg 2/d for 6w, + 1wk placebo
4. Bupropion 150mg 2/d (titrated in wk 1) for 7 wks
5. Placebo tablets 2/d for 7 wks
All participants received up to 10 mins counselling at 7 weekly clinic visits, 12 & 24w
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (validation:
CO</= 10ppm) (email communication)
Notes Continuous abstinence defined as self reported quit from target quit daywith biochemical
validation. Arms 1-3 and 5 in main comparison (same study as 3 VA Nides 2006)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Low risk “Investigators assigned medication to sub-
jects in numerical order of acceptance into
the study” from computer generated list
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Unclear risk Weight measured in self report prolonged
abstainers
2 AD Piper 2007
Methods Setting: USA
Recruitment: volunteers
Participants 608 smokers of 10 CPD; 58% F, av. age 42, av CPD 22, no details of depression
history
Interventions 1. Nicotine gum (4 mg) and bupropion (300 mg)
2. Placebo gum and bupropion
3. Double placebo
All arms: 3x 10 min counselling over 3 weeks
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2 AD Piper 2007 (Continued)
Outcomes 1. Mean (SD) weight change (kg) in point prevalent abstainers at end of treatment (data
from email communication)
(validation: CO<10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Unclear risk methods not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence High risk Weight measured in biochemically validated
point prevalent abstainers
2 AD Rigotti 2006
Methods Country: USA
Recruitment: hospital patients with cardiovascular disease
Participants 248 smokers, 31% F, av age 56, av CPD 21-23.
Interventions 1. Bupropion 300 mg for 12w
2. Placebo
All participants received multi component CBT cessation & relapse prevention pro-
gramme 30-45 mins and 5 X10 min post-discharge contacts (2 days,1,3,8, 12w)
Outcomes Mean (SD) weight change (kg) in point prevalence abstainers at end of treatment (email
communication) and 12m (email communication) (Validation: <=20ng/ml cotinine)
Notes Point prevalence abstinence defined as validated self report of no smoking in previous 7
days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated stratified
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2 AD Rigotti 2006 (Continued)
Allocation concealment (selection bias) Unclear risk “The study pharmacist used the computer
generated sequence, concealed from enrol-
ment staff, to assign participants to study
arm.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence High risk Weight measured in biochemically vali-
dated point prevalent abstainers
2 AD Saules 2004
Methods Country: USA
Recruitment: community volunteers
Participants 150 smokers, 20% history of MDD 55% F, av age 40
Interventions 1. Fluoxetine 40 mg for 14w, nicotine patch for 10w
2. Fluoxetine 20 mg for 14w, nicotine patch for 10w
3. Placebo & nicotine patch
All participants received CBT 6 sessions.
Outcomes Mean (SD) weight change (kg) in continuous abstainers at 6 months (email communi-
cation) (Validation: CO<10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
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2 AD Simon 2004
Methods Country: USA
Recruitment: outpatients
Participants 244 smokers, 79% veterans, 15% F, Av age 50, Av CPD 24, av BMI 26-28
Interventions 1. Bupropion 300 mg for 7w, nicotine patch for 2m
2. Placebo bupropion, nicotine patch for 2m
All participants received 3m of CBT counselling, S-H materials and telephone follow-
up counselling
Outcomes Mean (SD) weight change (kg) in continuous abstainers at 12m (email communication)
(Validation: salivary cotinine of less than 15ng/ml)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Participants allocated according to com-
puter generated list
Blinding (performance bias and detection
bias)
All outcomes
Low risk “All study personnel engaged in providing
interventions to participants were blinded
to treatment assignment”
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 AD Simon 2009
Methods Setting: San Francisco Veterans Affairs Medical Center, USA
Recruitment: hospitalised volunteers
Participants 85 inpatient smokers, 3.5% female, av age 56 yrs, av BMI 27.5, av CPD 16
Interventions 1. Bupropion 300 mg for 7w
2. Placebo
All ppts received Individual cognitive behavioural 30-60 min during hospital stay + 5
phone
calls at w1, w3, w5, w8, w12, recycling encouraged.
Outcomes Mean (SD) weight change (kg) in continuous abstainers at 6m (data from email com-
munication)
Validation: saliva cotinine <15 ng/ml
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2 AD Simon 2009 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk used a computer algorithm to generate a
random
list of treatment assignments
Allocation concealment (selection bias) Low risk All study
personnel engaged in providing interven-
tions to participants
were blinded to treatment assignment.
Blinding (performance bias and detection
bias)
All outcomes
Low risk All study
personnel engaged in providing interven-
tions to participants
were blinded to treatment assignment.
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 AD Uyar 2007
Methods Setting: cessation clinic, Turkey
Recruitment: cessation clinic patients
Participants 131 smokers; 81% M, av. age 36, av baseline weight 70-75kg, av ftnd score 3.9-4.8
Interventions 1. Bupropion 300mg for 7 weeks (150 mg daily for the first 3 days, then 150
mg twice daily for 6 weeks)
2. Nicotine patch 21mg for 6 weeks incl tapering
3. Advice and follow up only
All arms: Brief counselling and booklet on consequences of smoking with follow up for
24 weeks
Outcomes Mean (SD) weight change (kg) in continuous abstainers at 24 weeks (data from email
communication)
Validation: CO levels <10 ppm
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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2 AD Uyar 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 AD Zellweger 2005
Methods Country: 12 European countries, 26 centres
Recruitment: volunteers, healthcare professionals (qualified practising physician or
nurse)
Participants 667 smokers (>= 10 CPD) (excludes 1 centre enrolling 20 people, and 3 people who
took no medication) 64% female, av CPD 23
Interventions 1. Bupropion SR 300 mg/day for 7w
2. Placebo
All participants received brief (10-15 min) motivational support at weekly clinic visits
and telephone support one day before TQD, 3 days after TQD, monthly during follow
up
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (email com-
munication), 6m (email communication) and 12m (email communication) (Validation:
CO <= 10 ppm)
Notes Prolonged abstinence defined as continuous abstinence from week 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 3:1 ratio
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
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2 AD Zellweger 2005 (Continued)
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 EX Bize 2010
Methods Country: Switzerland
Recruitment: Community volunteers
Participants 481, av age 42, av CPD 27, sedentary: < 150 mins moderate intensity physical activity
per week and <60 mins vigorous intensity activity, av BMI 24-25
Interventions 1. Intervention:moderate-intensity group-basedCV activity, 45mins, weekly for 9weeks
+ 15 mins cessation counselling for 9 weeks (including NRT prescription)
2. Control: 9 weeks of 15 mins per week cessation counselling (including NRT prescrip-
tion) + Health Education for equal time as exercise intervention (not exercise)
Exercise started 5 weeks before quit date
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment and 12m
(Validation: CO <10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Remotely and randomly generated by a
computer.
Allocation concealment (selection bias) Low risk Secured by means of sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Not possible
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 EX Marcus 1999
Methods Country: USA
Recruitment: not described
Participants 20 women, av age 39, av CPD 28, av BMI 24-27.
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2 EX Marcus 1999 (Continued)
Interventions 1. CV equipment: group, facility 30-45 min, 60-85% HR max, 3 times/week for 12
weeks + cessation programme (twice a week for 4 weeks)
2. Cessation programme only (twice a week for 4 weeks)
Outcomes Mean weight change (kg) in continuous abstainers at end of treatment (8w) and at 60w
(validation: CO <8ppm and cotinine level less than 57 nmol/L [10ng/ml])
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Allocation concealment (selection bias) Low risk “randomisation code for group assignment
was generated by a computer code”
Blinding (performance bias and detection
bias)
All outcomes
High risk Not possible
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 EX Marcus 2005
Methods Country: USA
Recruitment: community volunteers
Participants 217 women, mean age 43, mean CPD 21 exercise <= 90 mins /wk.
Interventions 1. 1x 1hr facility (group) session + 4x 30min session home (individual) or facility (group)
, 45-59% HR reserve or 50%-69% maximum HR, goal: 165 min/week for 8w plus 8w
of cognitive behavioural smoking cessation therapy
2. Smoking cessation therapy as 1. once/week for 8 weeks + health education once/week
for 8 weeks
Exercise began before quit date, time in therapy matched for two groups
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment
(Validation: saliva cotinine < 10ng/ml, CO < 8ppm)
Notes Published paper of Marcus 2003a conference abstract (included study in exercise inter-
ventions parent review)
Risk of bias
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2 EX Marcus 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk “Group assignment was based on a ran-
domisation code generated by a computer
software program”
Blinding (performance bias and detection
bias)
All outcomes
High risk Not possible
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 EX Ussher 2003
Methods Country: UK
Recruitment: community volunteers
Participants 309 sedentary smokers, 60% Female, av age 43, av CPD 22, av BMI 25-26
Interventions 1. Exercise counselling (once a week for 7 weeks) + cessation programme (once a week
for 7 weeks).
2. Cessation programme as 1. once/week for 7 weeks + brief health education once/week
for 7 weeks
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Allocation concealment (selection bias) Low risk Allocated in order of attendance
Blinding (performance bias and detection
bias)
All outcomes
High risk Not possible
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
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2 NRT Abelin 1989
Methods Country: Switzerland
Recruitment: 21 Primary care clinics
Participants 199 primary care patients 40% female, av.age 41, av.cpd 27
Interventions 1. Nicotine patch, 24hr, 12 wk with weaning; 21mg smokers of >20 CPD, 14 mg for
<20 CPD
2. Placebo patch
Participants did not receive any psychological support
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (Validation:
CO content 0-11ppm)
Notes Abstainence defined as participants who smoked 0-3 cigarettes per week with validation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Unclear risk Participants were allowed to smoke up to 3
cigarettes per week
2 NRT Blondal 1999
Methods Country: Iceland
Recruitment: community volunteers
Participants 237 smokers 67% F, av.age 41-43, av. tobacco use 25g/day
Interventions 1. Nicotine nasal spray (NNS) (0.5mg/dose) + 15mg nicotine patches for 3m, weaning
over further 2m. NNS could be continued for 1 yr
2. Placebo nasal spray + 15 mg nicotine patches on same schedule
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (email
communication) and 12m (email communication) (Validation: CO<11ppm)
Notes
Risk of bias
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2 NRT Blondal 1999 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated code at pharmacy
Allocation concealment (selection bias) Low risk “participants allocated their treatment by
generated randomisation code at a local
pharmacy”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 NRT Bohadana 2000
Methods Country: France
Recruitment: community volunteers
Participants 400 smokers, 18-70 yrs, 51% F, Av CPD: Group 1 26.1, Group 2 23.5; FTND>6
Interventions 1: Nicotine inhaler, 26wks, combined with nicotine patch (15 mg/16hr) for first 6wks,
placebo patch for next 6wks
2: Nicotine inhaler, 26wks, placebo patch for first 12wks
All received brief counselling and support from investigator at each visit
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (email com-
munication) and 12 m (email communication) (Validation: CO<10ppm)
Notes Prolonged abstinence defined as validated self report from two weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated code
Allocation concealment (selection bias) Low risk “sealed randomisation envelopes were pro-
vided for each subject and were held by the
hospital pharmacy, which was responsible
for dispensing medication”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
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2 NRT Bohadana 2000 (Continued)
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 NRT CEASE 1999
Methods Country: Multicentre - 36 clinic centres in 17 European countries
Recruitment: community volunteers
Participants 3575 smokers 48% female, av age 41, av CPD 27, av weight 71-73 kg
Interventions Factorial design compared 2 patch doses and 2 treatment durations. Dose 15mg or 25mg
(16hr), duration of active treatment 28 wks (incl 4 wk fading) or 12 wks (incl 4 wk
fading)
1. 25mg patch for 28 wks (L-25)
2. 25mg patch for 12 wks (S-25)
3. 15mg patch for 28 wks (L-15)
4. 15mg patch for 12 wks (S-15)
5. Placebo
All participants received brief advice & self help brochure
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (email com-
munication) and 12m (email communication) (validation: CO <10ppm)
Notes Prolonged abstinence defined as validated self report from 2w
Doses and durations collapsed in main analyses.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified only by centre
Allocation concealment (selection bias) Low risk “A computer-generated allocation list was
prepared centrally and allocated subjects to
treatment numbers”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
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2 NRT Cooper 2005
Methods Country: USA
Recruitment: community volunteers
Participants 439 weight concerned female smokers (>= 10 CPD) Av.age 38, av.cpd 23, av baseline
weight 64-66kg
Interventions 1. Phenylpropanolamine (PPA) gum 8.33mg 16 pieces/d 8w, weaning last 3 wks
2. Nicotine gum (2mg), 10-12 pieces/day recommended, for 8 wks, weaning last 3 wks
3. Placebo gum
All participants received x13 1hr weekly cognitive behavioural group sessions focused
on smoking and weight. Ppts cut down weeks 1-4 by 25% and quit week 5
Outcomes 1. PP abstinence at 12m (Validation: CO<10ppm)
2. Mean (SD) weight change (kg) in abstainers at 6m and 12m
Notes PP abstinence defined as validated self report of no smoking at the time of the assessment
Although these treatments are specifically tested for their effect on smoking and on
weight gain the NRT arm is included in the second part of the review as it is included
in the parent Cochrane review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk All group facilitators and participants were
blind to treatment conditions
Definition of abstinence High risk Weight measured in biochemically vali-
dated point prevalent abstainers
2 NRT Dale 1995
Methods Country: USA
Recruitment: community volunteers and smoking clinic attenders
Participants 71 smokers stratified according to light, moderate and heavy smoking rates. 56% female,
av.age 48, av.cpd 26, av weight 79.4kg
Interventions 1. 11mg/24hr nicotine patch
2. 22mg/24hr nicotine patch
3. 44mg/24hr nicotine patch
4. Placebo patch for 1 wk followed by 11 or 22mg patch for 7 wks
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2 NRT Dale 1995 (Continued)
Duration of patch use 8 wks. High level of support including 6 day inpatient stay
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (email
communication) and 12m (email communication) (Validation: Blood cotinine)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 NRT Ehrsam 1991
Methods Country: Switzerland
Recruitment: university (primary care)
Participants 112 smokers Av.age 26, av.cpd 23
Interventions 1. Nicotine patch (21 or 14mg/24hr, 9 wks, tapered)
2. Placebo patch
Outcomes Mean (SD) weight change (kg) in abstainers at the end of treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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2 NRT Ehrsam 1991 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Definition of abstinence Unclear risk Not described
2 NRT Fiore 1994A
Methods Country: USA
Recruitment: community volunteers
Participants 88 smokers, av CPD 28-31, av age 42-44yrs, av weight 79-81kg
Interventions 1. Nicotine patch (22mg/24hr, 8 wks, no weaning)
2. Placebo patch
All participants received intensive group counselling.
Outcomes Mean (SD) weight change (Kg) in point prevalence abstainers at end of treatment (email
communication) (Validation: CO <10ppm)
Notes Point prevalence abstinence was defined as validated self report abstinence for 7 days
prior to measurement.
Different participants to Fiore 1994B added in separately in the main comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Pregenerated computer sequence
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence High risk Weight measured in biochemically vali-
dated point prevalent abstainers
2 NRT Fiore 1994B
Methods Country: USA
Recruitment: community volunteers
Participants 112 smokers, av age 43-45yrs, av weight 72-73kg
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2 NRT Fiore 1994B (Continued)
Interventions 1. Nicotine patch (22mg/24hr, 6 wks incl weaning)
2. Placebo patch
All participants received x8 weekly 10-20 min individual counselling
Outcomes Mean (SD) weight change (kg) in point prevalence abstainers at end of treatment (email
communication) (Validation: CO <10ppm)
Notes Point prevalence abstinence was defined as validated self report abstinence for 7 days
prior to measurement.
Different participants to Fiore 1994A added in separately in the main comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Pregenerated computer sequence
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence High risk Weight measured in biochemically vali-
dated point prevalent abstainers
2 NRT Garvey 2000
Methods Country: USA
Recruitment: community volunteers
Participants 608 smokers, aged>20 51% female, av.cpd 23, av weight (males) 80-81kg, av weight
(female) 64-69
Interventions 1. 4mg nicotine gum (recommended 9-15 pieces), weaning from 2m + weaning
2. 2mg nicotine gum, use as 1.
3. Placebo gum
All received brief counselling (5-10 mins) at each study visit (1, 7, 14, 30 days, 2, 3, 6,
9, 12m)
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (email com-
munication) (Validation: CO<= 8ppm)
Notes Prolonged abstinence defined as participants who had not returned to smoking for 7 or
more consecutive days or episodes
4 + 2mg doses combined in main comparison.
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2 NRT Garvey 2000 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated, stratified by high- and
low-dependence
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 NRT Gourlay 1995
Methods Country: Australia
Recruitment: community volunteers
Participants 629 smokers (>15 CPD) who had relapsed after transdermal nicotine and behavioural
counselling in an earlier phase of the study.
Minimal additional support
Interventions 1. Nicotine patch 30cm2 (21mg/24 hr) for 4 wks, 20cm2 (14mg/24 hr) for 4 wks,
10cm2 (7mg/24 hrs) for 4 wks.
2. Placebo patch
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (Validation:
expired CO<9ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatments were randomly allocated to
study numbers by using a 1:1 ratio within
blocks of 10
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
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2 NRT Gourlay 1995 (Continued)
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 NRT Gross 1995
Methods Country: USA
Recruitment: community volunteers
Participants 177 smokers, 51% female, av. age 42, av.cpd 33, av. FTND score 7.8
Interventions 1. Nicotine gum (2mg), tapered from wk 12. Active gum groups further randomised to
chew 7, 15 or 30 pieces of gum per day.
2. No gum
All participants received 1 pre-quit group counselling session, 14 clinic visits in 10 wks
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (Validation:
CO<=10ppm)
Notes Prolonged abstinence defined as validated self reported abstinence (allowed up to 3 cigs)
Long-term abstinence rates not affected by amount of gum chewed, so these groups
collapsed for comparison with no gum condition
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Not possible
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 NRT Hjalmarson 1984
Methods Country: Sweden
Recruitment: smoking cessation clinic
Participants 206 smokers, 56% female, av.age 42, av. CPD 24
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2 NRT Hjalmarson 1984 (Continued)
Interventions 1. Nicotine gum (2mg) (no restrictions on amount or duration of use)
2. Placebo gum
All participants received 6 group sessions of SC behavioural support in 6 wks
Outcomes Mean (SD)weight gain (kg) in continuous abstainers at 6months (email communication)
(Validation: CO<10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized by therapy group.
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Unclear if enroller blind, but therapists
blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 NRT Hjalmarson 1994
Methods Country: Sweden
Recruitment: smoking cessation clinic
Participants 248 smokers, 57% female, av.age 45, av. CPD 22, av weight (male) 77-83kg, av weight
(female) 64-66kg
Interventions 1. Nicotine nasal spray (0.5 mg/spray) used as required up to 40 mg/day for up to 1 yr
2. Placebo spray
All participants received x845-60min group sessions over 6wkswith clinical psychologist
Outcomes Mean (SD) weight change (kg) in continuous abstainers at 12m (Validation:
CO<10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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2 NRT Hjalmarson 1994 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Treatment allocater not blinded if more
than 1 participant from the same house-
hold so that they could be given samemed-
ication
Blinding (performance bias and detection
bias)
All outcomes
Low risk Therapists and participants
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 NRT Hjalmarson 1997
Methods Country: Sweden
Recruitment: smoking cessation clinic
Participants 247 smokers, 64% female, av.age 48, av.cpd 21
Interventions 1. Nicotine Inhaler (recommended minimum 4/day, tapering after 3m, use permitted
to 6m)
2. Placebo inhaler
All participants attended 8 group meetings over 6 wks
Outcomes Mean (SD) weight change (kg) in prolonged abstainers end of treatment and 12 months
(Validation: CO<10ppm)
Notes Prolonged abstainers defined as validated self reported abstinence from week 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants assigned a number on attend-
ing first group session. Numbers on a list
randomising to medication. Participants
from the same household randomised to
same treatment
Allocation concealment (selection bias) Unclear risk Treatment allocater not blinded if more
than 1 participant from the same house-
hold so that they could be given samemed-
ication
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2 NRT Hjalmarson 1997 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participant and therapist blinded
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 NRT Lerman 2004
Methods Country: USA
Recruitment: community volunteers and referrals
Participants 350 smokers (includes 51 who withdrew before treatment)
54% F, av.age 46, av. CPD 21
Interventions 1. Nicotine patch (21 mg/24hr) for 8 wks incl tapering
2. Nicotine nasal spray (8-40 doses/day, max 5/hr) for 8 wks, tapering over final 4 wks
All participants received 7x90 min behavioural group counselling sessions. TQD in wk
3
Outcomes Mean (SD) weight change (kg) in unvalidated continuous abstainers
Notes For prolonged abstinence, relapse was defined as 7
consecutive days of smoking at any point during follow-up period
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, operated by data
manager.
Allocation concealment (selection bias) Low risk After allocation only outcome assessors
blind
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Definition of abstinence Unclear risk Weight measured in self report continuous
abstainers
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2 NRT Pack 2008
Methods Country: USA
Recruitment: community volunteers
2x2 factorial design
Participants 408 smokers, 56%F, ave age 40-44yrs, ave CPD 22-24
Interventions 1. Nicotine lozenge + 4 calls from Wisconsin Tobacco Quit Line
2. Nicotine gum + 4 calls from Wisconsin Tobacco Quit Line
3. Nicotine lozenge + Self help brochure
4. Nicotine gum + Self help brochure
Participants were treated with 8w of NRT. F/U at 8wks, 6m and 12m
Outcomes Mean (SD) weight change (kg) in 7-day point prevalence abstainers at end of treatment,
6m, 12m
Notes Weight data from arms 1&2 and 3&4 were combined for the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Definition of abstinence High risk Weight measured in CO validated point
prevalent abstainers
2 NRT Pirie 1992
Methods Country: USA
Recruitment: community volunteers
Participants 417 women smokers. Av CPD 25-27. av BMI 23-25
Interventions 1. Group therapy 8w
2. Group therapy plus weight control programme 8w
3. Group therapy plus nicotine gum 8w
4. Group therapy plus weight control programme and nicotine gum 8w
Gum type: 2mg ad lib 8 week treatment period + 3 months supply
Outcomes Mean (SD) weight change (kg) in continuous abstainers end of treatment, 6 and 12m
(Validation: expired CO <=10ppm)
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2 NRT Pirie 1992 (Continued)
Notes Group 3 compared with group 1. Group 1, 3 and 4 compared in first part of review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 NRT Puska 1995
Methods Country: Finland
Recruitment: community volunteers
Participants 300 volunteers aged 20-65, smoking >10 CPD for >3 yrs, no serious illness
Interventions 1. Nicotine patch (15mg/16hrs, 12 wks+ 6 wks taper) plus nicotine gum (2mg at least
4 daily)
2. Placebo patch plus nicotine gum (same regimen)
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (email com-
munication) and 12m (email communication) (Validation: CO<10ppm)
Notes Prolonged abstinence defined as verified continuously lapse free abstinence after week 1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
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2 NRT Puska 1995 (Continued)
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 NRT Richmond 1994
Methods Country: Australia
Recruitment: community volunteers
Participants 315 smokers, av. CPD 29.
Interventions 1. Nicotine patch (24 hr, 22mg/24 hr, 10 wks incl tapering)
2. Placebo patch
All participants received group smoking cessation behavioural support
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (email com-
munication), 6 months (email communication) and 12 months (email communication)
(Validation: CO</=10ppm)
Notes Prolonged abstainers were defined as continuous abstinence for a sustained period pre-
ceding the assessment point at 12 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 NRT Sachs 1993
Methods Country: USA
Recruitment: community volunteers
Participants 220 adult smokers. Av. CPD 28-9, av weight 72-76kg
Interventions 1. Nicotine patch (15mg/16hr, 12 wks + 6 wks tapering)
2. Placebo patch
All participants received physician advice at 8 visits during treatment period
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2 NRT Sachs 1993 (Continued)
Outcomes Mean (SD)weight change (kg) in continuous abstainers at 6m (Validation: CO<10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 NRT Shiffman 2002A
Methods Country: USA & UK (15 sites)
Recruitment: community volunteers, low dependence (time to first cigarette >30mins)
Participants 917 smokers, 58% Female, Av age 41, av CPD 17-18, av weight 74-76kg
Interventions 1. Nicotine lozenge, 2mg. Recommended dose 1 every 1-2 hrs, min 9, max 20/day for
6 wks, decreasing 7-12 wks, available as needed 13-24 wks
2. Placebo lozenge, same schedule
All participants received brief advice at 4 visits.
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (email com-
munication), 6 (email communication) and 12 months (email communication) (Vali-
dation: CO<=10ppm)
Notes Prolonged abstinence defined as sustained from 2 wks, no slips allowed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Not described
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2 NRT Shiffman 2002A (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 NRT Shiffman 2002B
Methods Country: USA & UK (15 sites)
Recruitment: community volunteers, high dependence (time to first cigarette <30mins)
Participants 901 smokers, 55% Female, av age 43-44, av CPD 25-26
Interventions 1. Nicotine lozenge, 4mg. Recommended dose 1 every 1-2 hrs, min 9, max 20/day for
6 wks, decreasing 7-12 wks, available as needed 13-24 wks
2. Placebo lozenge, same schedule
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (email com-
munication), 6 (email communication) and 12 months (email communication) (Vali-
dation: CO<=10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 NRT Stapleton 1995
Methods Country: UK
Recruitment: General practice patients
Participants 1200 smokers Av. CPD 23-4, av weight 71-72kg
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2 NRT Stapleton 1995 (Continued)
Interventions 1. Nicotine patch standard dose (15mg/16 hr for 18 wks)
2. Nicotine patch with dose increase to 25mg at 1 wk if required
3. Placebo patch group
The nicotine patch groups were further randomised to gradual tapering or abrupt with-
drawal from wk 12
All participants received physician advice & brief support at 1, 3, 6, 12 wks
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (email com-
munication) and 12m (email communication) (Validation: CO <10ppm)
Notes Prolonged abstinence defined as validated self reported abstinence from week 2. The
dose increase after 1 wk did not affect cessation, 1+2 vs 3 in main comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Computer-generated list
Allocation concealment (selection bias) Low risk “Study subjects were assigned a treatment
according to a computer generated list
compiled in blocks of six”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 NRT Sutherland 1992
Methods Country: UK
Recruitment: Smoking cessation clinic patients
Participants 227 male and female smokers. Av. CPD 25-27, av age 38-41yrs, av weight women 62-
64kg, av weight men 75-77kg
Interventions 1. Nicotine nasal spray, maximum 40 mg/day
2. Placebo spray
All participants received 4 wks of group support
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at 12 months (Validation: CO
<10ppm)
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2 NRT Sutherland 1992 (Continued)
Notes Prolonged abstinence defined as validated self reported no smoking from the start of the
last week of group treatment to the 12 months follow up
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Drew card with A or P for active or placebo
allocation
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Subjects and therapist were blind to spray
assignment”
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 NRT TNSG 1991
Methods Country: USA (9 sites)
Recruitment: community volunteers (treated at smoking cessation clinics)
Participants 808 smokers 60% female, av.age 43, av. CPD 31, av weight 72.4 kg
Interventions 1. Nicotine patch (21mg /24 hr, 6 wks+)
2. Nicotine patch 14mg
3. Placebo patch
All participants received group smoking cessation behavioural support
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (6w) (Vali-
dation: CO <9ppm)
Notes 2 trials pooled and data relating to a 7mg patch group used in only 1 trial omitted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Not described
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2 NRT TNSG 1991 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 NRT Tonnesen 1991
Methods Country: Denmark
Recruitment: community volunteers
Participants 289 smokers 70% F, av.age 45, av. CPD 22
Interventions 1. Nicotine patch (15mg/16 hr for 12 wks with tapering)
2. Placebo patch
All participants receive brief behaviour support at clinic visits
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (email com-
munication) and 12m (email communication) (validation: CO <=10ppm)
Notes Prolonged abstinence was defined as validated self report abstinence after 1 week of
quitting
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk According to a computer generated ran-
domisation code
Allocation concealment (selection bias) Unclear risk “packages labelled with consecutive num-
bers from computer-generated random
code”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
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2 NRT Tonnesen 1993
Methods Country: Denmark
Recruitment: community volunteers
Participants 286 smokers, av CPD 20 60% F, av.age 39
Interventions 1. Nicotine inhaler (2-10/day) up to 6m
2. Placebo inhaler
All participants received brief advice at 8 clinic visits, 0, 1, 2, 3, 6,12, 24, 52 wks)
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (email
communication) and 12m (email communication) (Validation: expired CO<10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation code
Allocation concealment (selection bias) Unclear risk “participants were randomly assigned ac-
cording to code generated by a computer”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 NRT Wallstrom 2000
Methods Country: Sweden
Recruitment: community volunteers
Participants 247 smokers (>= 10 CPD) 59% female, av.age 45, av. CPD 18-20, av weight (male) 80-
81kg, av weight (female) 66-67kg
Interventions 1. Nicotine sublingual tablet 2mg. Recommended dosage 1 tab/hr for smokers with
FTND < 7, 2 tabs/hr for scores >= 7. After 3m treatment, tapering period of 3m if
necessary
2. Placebo tablet
All participants received brief 5 mins counselling at study visits
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at 12 months (Validation:
CO<10ppm)
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2 NRT Wallstrom 2000 (Continued)
Notes Prolonged abstinence defined as complete abstinence from wk 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer assignment
Allocation concealment (selection bias) Low risk “Subjects were randomised to receive either
active or placebo treatment using a com-
puter program”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 VA Aubin 2008
Methods Country: Belgium, France, Netherlands, UK, USA
Recruitment: smoking cessation clinics or community volunteers
Participants Healthy adults, Mean age 42.9yr, 50.8% female, Mean CPD 22.7
Interventions 1. Varenicline 1mg x2/day for 12 wks, titrated 1st wk.
2. Nicotine patch (21mg wks 2-6, 14mg wks 7-9, 7mg wks 10-11).
No placebo control group.
All participants received Clearing the Air S-H booklet at baseline, and brief counselling
(=<10 mins) at each clinic visit or by phone
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (email com-
munication) (Validation: CO<=10ppm)
Notes Prolonged abstainers defined as completely quit from week 9.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Central computer-generated sequence.
Allocation concealment (selection bias) Low risk Central allocation
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2 VA Aubin 2008 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label design
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 VA Gonzales 2006
Methods Country: USA
Recruitment: community volunteers
Participants 1025 smokers 55% F (Placebo), 48% F (Bup); av age 45, av CPD not specified
Interventions 1. Varenicline 1mg x2/day for 12w
2. Bupropion 300 mg/day for 12w
3. Placebo
All participants received brief individual counselling at visits w1-7, 9, 12, + telephone
counselling at 4 and 5m
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (validation:
CO <10ppm)
Notes Prolonged abstinence defined as complete abstinence from weeks 9-12
Arm 1 compared with 3 (same study as 3 AD Gonzales)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated sequence 1:1:1
Allocation concealment (selection bias) Low risk Participants were randomised according to
a predefined central computer sequence
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
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2 VA Jorenby 2006
Methods Country: USA, multicentre
Recruitment: community volunteers
Participants 1027 smokers, 41% F, av age 42, av CPD 22
Interventions 1. Bupropion 300mg for 12 w + placebo varenicline
2. Varenicline 2mg for 12 w + placebo bupropion
3. Placebo bupropion + placebo varenicline
All participants received brief (< 10min) individual counselling at eachweekly assessment
for 12w & 5 follow-up visits. One telephone call 3 days after quit day
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (validation:
CO < 10ppm)
Notes Prolonged abstinence defined as validated abstinence w 9-12. Arm 1 and 3 in main
comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised, computer-generated
Allocation concealment (selection bias) Low risk “SItes used an electronic system to assign
participants to treatment”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 VA Nakamura 2007
Methods Country: Japan
Recruitment:community volunteers
Participants 619 healthy smokers, aged 20-75, smoking >=10cpd. 1 ppt excluded from ITT denom-
inator as withdrew prior to treatment. Demographic data only supplied for nicotine-de-
pendent group (515/618): 75% male, mean age 39.8, mean CPD 24, mean Fagerstrom
score 5.6
Interventions 1. Varenicline 0.25mg x 2/day 12w
2. Varenicline 0.50mg x 2/day 12w
3. Varenicline 1.00mg x 2/day 12w
4. Placebo tablet x 2/day 12w
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2 VA Nakamura 2007 (Continued)
All participants received S-H booklet Clearing the Air at baseline, + brief counselling (=
<10 mins) at each clinic visit
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (validation:
CO <=10ppm)
Notes Prolonged abstinence defined as continuous abstinence during weeks 9-12
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number lists
Allocation concealment (selection bias) Low risk ’randomised to 1 of the 4 treatment groups
in a 1:1:1:1 ratio using a central procedure’
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’double-blinding of subjects and investiga-
tors was maintained throughout the study’
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 VA Niaura 2008
Methods Country: USA
Setting: 5 research centres
Participants 320 healthy adult volunteers, aged 18-65, smoking >=10cpd. 52%M, 91% white, mean
age 42, mean CPD 22, mean Fagerström score 5.4
Interventions (1) Varenicline tartrate 12w (Week 1: titrated from 0.5 to 1.0 mg/day) followed by a
self-regulated flexible schedule (Weeks 2-12: 0.5-2.0 mg/day).
(2) Placebo
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (12w).
(Validation: CO</=10ppm)
Notes Continuous abstinence defined as self report abstinence weeks 4-12 with biochemical
validation
Risk of bias
Bias Authors’ judgement Support for judgement
88Interventions for preventing weight gain after smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2 VA Niaura 2008 (Continued)
Random sequence generation (selection
bias)
Low risk randomly permuted blocks and a pseudo-
random number generator
Allocation concealment (selection bias) Low risk participants were assigned in a 1:1 ratio to
varenicline treatment or placebo in the nu-
merical order that theywere accepted to the
study
Blinding (performance bias and detection
bias)
All outcomes
Low risk double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 VA Nides 2006
Methods Country: USA, multi-centre, 7 sites
Recruitment: Volunteers (phase II study)
Participants 638 smokers, 51% F, av age 41, av CPD 20, av BMI 25-27
Interventions 1. Varenicline 0.3mg 1/d for 6w, + 1wk placebo
2. Varenicline 1.0mg 1/d for 6w, + 1wk placebo
3. Varenicline 1.0mg 2/d for 6w, + 1wk placebo
4. Bupropion 150mg 2/d (titrated in wk 1) for 7 wks
5. Placebo tablets 2/d for 7 wks
All participants received up to 10 mins counselling at 7 weekly clinic visits, 12 & 24w
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (validation:
CO</= 10ppm) (email communication)
Notes Continuous abstinence defined as self reported quit from target quit daywith biochemical
validation. Arms 1-3 and 5 in main comparison (same study as 3 AD Nides 2006)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Low risk ”Investigators assigned medication to sub-
jects in numerical order of acceptance into
the study“ from computer generated list”
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2 VA Nides 2006 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
2 VA Oncken 2006
Methods Country: USA
Recruitment: community volunteers
Participants 647 smokers, 50.5% female, av CPD 21, av age 42-44yrs, av BMI 26-28
Interventions 1. Varenicline 0.5mg nontitrated (2/d for 12 wks)
2. Varenicline 0.5mg titrated (wk1 1/d, wks 2-12 2/d)
3. Varenicline 1.0mg nontitrated (2/d for 12 wks)
4. Varenicline 1.0mg titrated (0.5mg 1/d for 3 days, 0.5mg 2/d for 4 days, 1.0mg 2/d
wks 2-12)
5. placebo tablets 2/d 12 wks
All participants received S-H booklet at baseline, + brief (<=10mins) counselling at
weekly clinic visits throughout treatment phase
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (validation:
CO <= 10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Subjects and investigators were blinded to
the study drug treatment assignment”
Definition of abstinence Low risk Weight measured in biochemically vali-
dated continuous abstainers
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2 VA Rigotti 2010
Methods Country: 15 countries in Europe, Asia, Americas
Setting: 39 research centres
Participants 714 adult smokers, aged 35-75, smoking at least 10cpd, with stable CVD andmotivated
to quit. 79% male, 80% white, mean CPD 22, mean Fagerström 5.6
Interventions 1. Varenicline 1.0 mg 2/d for 12 wks, preceded by 1wk titrated dose.
2. Placebo tablets as above.
Both groups received brief (10mins) counselling at weekly clinic visits throughout treat-
ment phase, and phone call 3d post-TQD
Outcomes Mean (SD) weight change (kg) in week 9-12 continuous abstainers at end of treatment
(12w) and 12 months (12m)
(Validation: expired CO</=10 ppm).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study sponsor conducted the random-
ization centrally using a computer gener-
ated list that prespecified the order of treat-
ment allocation
Allocation concealment (selection bias) Low risk see above
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind (participants and study im-
plementation). Cardiovascular outcomes
“were reviewed separately and adjudicated
under blinded conditions by an indepen-
dent event committee made up of 3 board-
certified cardiologists”
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers from 9 weeks
2 VA Tashkin 2011
Methods Country: USA (17 centres), Spain (3 centres), France (4 centres), Italy (3 centres)
Setting: 27 research centres.
Participants 504 adult smokers with mild-to-moderate COPD, aged 35+, smoking 10+ CPD, mo-
tivated
to quit; allocated to varenicline (250), or placebo (254). 62% male, mean age 57,
CPD 24-25, Fagerström score 5.9-6.2., av BMI 26.6 (SD5.5)
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2 VA Tashkin 2011 (Continued)
Interventions 1. Varenicline 1.0 mg 2/d for 12 wks, preceded by 1wk titrated dose.
2. Placebo tablets as above.
Both groups received SC educational booklet, + brief (10mins) counselling at weekly
clinic visits throughout treatment phase, and phone call 3d post-TQD
Outcomes Mean (SD) weight change at in continuous abstainers end of treatment (12w) and 12m
(Validation: CO</=10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methods not described
Allocation concealment (selection bias) Unclear risk Methods not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers from week 9
2 VA Tonstad 2006
Methods Country:USA (6 centres) and ’international’ (18 centres, acrossCanada,CzechRepublic,
Denmark, Norway, Sweden, UK)
Recruitment: smoking cessation clinics
Participants 1210 successful quitters (62.8% of initial cohort) following a 12-wk open-label course
of varenicline for smoking cessation. 51% female, av age 45, av CPD 21
Interventions 1. Varenicline 1mg x2/day for 11 wks after 1wk titrated dosage
2. Placebo tablets, same regime
Participants had already received 12w of varenicline. All participants received brief coun-
selling (<=10 mins) at each clinic visit throughout treatment phase (wks 13-24). Treat-
ment phase clinic visits were at wks 13, 14, 16, 20 and 24
Outcomes Mean (SD) weight change (kg) in continuous abstainers at 6 months (validation: CO
<=10ppm)
Notes Continuous abstinence was defined as validated complete abstinence during week 13-
24
92Interventions for preventing weight gain after smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2 VA Tonstad 2006 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated lists stratified by cen-
tre, x4 random block design
Allocation concealment (selection bias) Low risk computer generated sequence used for al-
location of participants
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers from week 13
2 VA Tsai 2008
Methods Country: Taiwan and Korea
Recruitment: community volunteers
Participants 250 healthy adult volunteers, motivated to quit, aged 18 to 75; allocated to varenicline
(126), or placebo (124). 11% female, av age 40.3, BMI >15 or <38 or weight >45.5 kg,
av CPD 24
Interventions 1. Varenicline 1.0mg x 2/day 12w 1st w titrated
2. Placebo tablet x 2/day 12w
All participants received a smoking cessation booklet Clearing the Air at baseline + brief
counselling (=<10 mins) at each clinic visit
Outcomes Mean (SD) weight change (kg) in prolonged abstainers at end of treatment (validated:
CO <=10ppm)
Notes Prolonged abstinence is defined as validated complete abstinence during weeks 9-12
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permutated blocks (block=4)
Allocation concealment (selection bias) Low risk web- and telephone-based assignment
Blinding (performance bias and detection
bias)
Low risk Subjects, investigators, study staff and
sponsor personnel blind to treatment
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2 VA Tsai 2008 (Continued)
All outcomes
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers
2 VA Wang 2009
Methods Setting: Not described
Country: China (10 sites), Singapore (3 sites), Thailand (2 sites)
Participants 333 healthy adult volunteers, aged 18 to 75;97% male, mean age 39, BMI >15 and <38
or weight >45.5 kg, mean CPD 20, mean Fagerström score 5.4
Interventions 1. Varenicline 1.0mg x 2/day
2. Placebo tablet x 2/day
Treatment period 12 wks, 1st wk titrated dosage. All participants received a smoking
cessation booklet at baseline, + brief counselling (10 mins) at each clinic visit, except
for wks 5 and 7, when counselling was conducted by phone.
Outcomes Mean (SD) weight change (kg) in continuous abstainers at end of treatment (12w) and
6 months
(Validation: CO</=10ppm)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk eligible subjects were randomised in a 1:1
ratio
Allocation concealment (selection bias) Unclear risk not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk double blind
Definition of abstinence Low risk Weight measured in biochemically vali-
dated prolonged abstainers from week 9
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
1 Ames 2007 Not an intervention designed specifically to tackle post cessation weight gain
1 Chaney 2008 Exercise intervention excluded by parent cochrane review
1 Hughes 1997 Effect of NRT on post cessation weight gain, not identified in NRT parent review
1 Jeffery 1990 Study testing effect on intervention on weight control in general rather than on post cessation
control
1 Killen 1990 Effect of minimal contact smoking relapse prevention trial with NRT, not included in parent
review
1 King 2006 Weight only measured at end of 1 month (2 month intervention)
1 Lagrue 1994 Intervention on overweight patients only
1 Leischow 1992 Unable to obtain full data
1 Love 2011 Patients not randomised
1 Patterson 2006 Not an intervention designed to address weight gain
1 Pomerleau 1991 Excluded from antidepressant parent review.
1 Rohsenow 2007 No weight data
1 Spring 1991 Unable to obtain data
1 Toll 2008 Participants not randomised to experimental or control conditions
1 Wilcox 2010 Uncontrolled trial
2 AD Ahluwalia 2002 Unable to obtain full data
2 AD Aubin 2004 Unable to obtain full data
2 AD Berlin 1995 No weight data
2 AD Blondal 1999 No weight data
2 AD Brown 2006 No weight data
2 AD Cinciripini 05 No weight data
2 AD Collins 2004 No weight data
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(Continued)
2 AD Covey 2002 No weight data
2 AD Covey 2007 All participants received 8 weeks of open label bupropion and NRT
2 AD Da Costa 2002 No weight data
2 AD Dalsgareth 2004 Unable to obtain full data
2 AD Evins 2001 Unable to obtain full data
2 AD Evins 2005 No weight data
2 AD Evins 2006 No weight data
2 AD Evins 2008 less than 6 months follow up
2 AD Ferry 1992 No weight data
2 AD Ferry 1994 No weight data
2 AD George 2002 No weight data
2 AD GlaxoSmithK SMK20001 No weight data
2 AD Gonzales 2001 No weight data
2 AD Haggsträm 2006 No weight data
2 AD Hall 1998 No weight data
2 AD Hall 2002 No weight data
2 AD Hall 2004 No weight data
2 AD Hatsukami 2004 No weight data
2 AD Hays 2001 Unable to obtain full data
2 AD Hertzberg 2001 No weight data
2 AD Holt 2005 No weight data
2 AD Hurt 2003 No weight data
2 AD Killen 2000 No weight data
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(Continued)
2 AD Killen 2004 No weight data
2 AD Killen 2006 No weight data
2 AD Myles 2004 No weight data
2 AD Piper 2004 No weight data
2 AD Piper 2009 No weight data
2 AD Prochazka 1998 No weight data
2 AD Prochazka 2004 No weight data
2 AD Rovina 2009 No weight data
2 AD Selby 2003 No weight data
2 AD Swan 2003 No weight data
2 AD Tashkin 2001 No weight data
2 AD Tonnesen 2003 Unable to obtain full data
2 AD Tonstad 2003 Unable to obtain full data
2 AD Uyar 2005 Unable to obtain full data
2 AD Wagena 2005 No weight data
2 EX Hill 1985 No weight data
2 EX Hill 1993 No weight data
2 EX Kinnunen 2008 Unable to get data
2 EX Marcus 1991 No weight data
2 EX Marcus 1995 No weight data
2 EX Martin 1997 No weight data
2 EX Prapavessis 2007 Unable to get data
2 EX Russell 1988 No weight data
2 EX Taylor No weight data
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(Continued)
2 NRT Ahluwalia 1998 No weight data
2 NRT Ahluwalia 2006 No weight data
2 NRT Areechon 1988 No weight data
2 NRT Blondal 1989 No weight data
2 NRT Blondal 1997 Unable to obtain full data
2 NRT Bolin 1999 No weight data
2 NRT Br Thor Soc 83 No weight data
2 NRT Buchkremer 88 No weight data
2 NRT Bullen 2010 Participants took medication before quit day
2 NRT Campbell 1987 No weight data
2 NRT Campbell 1991 No weight data
2 NRT Campbell 1996 No weight data
2 NRT Cinciripini 96 No weight data
2 NRT Clavel 1985 No weight data
2 NRT Clavel-Cha ’92 No weight data
2 NRT Croghan 2003 No weight data
2 NRT Croghan 2007 No weight data
2 NRT Daughton 1991 No weight data
2 NRT Daughton 1998 No weight data
2 NRT Dautzenberg 01 No weight data
2 NRT Davidson 1998 No weight data
2 NRT Etter 2009 Participants took medication before the quit date
2 NRT Fagerstrom 82 No weight data
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(Continued)
2 NRT Fagerstrom 84 No weight data
2 NRT Fee 1982 No weight data
2 NRT Fortmann 1995 No weight data
2 NRT Garcia 1989 No weight data
2 NRT Gilbert 1989 No weight data
2 NRT Glavas 2003a No weight data
2 NRT Glavas 2003b No weight data
2 NRT Glover 2002 Unable to obtain full data
2 NRT Goldstein 1989 No weight data
2 NRT Hall 1985 No weight data
2 NRT Hall 1987 No weight data
2 NRT Hall 1996 No weight data
2 NRT Hand 2002 No weight data
2 NRT Harackiewicz 1988 No weight data
2 NRT Hatsukami 2007 Less than 6 months follow up
2 NRT Hays 1999 No weight data
2 NRT Herrera 1995 No weight data
2 NRT Hilleman 1994 No weight data
2 NRT Huber 1988 No weight data
2 NRT Hughes 1989 No weight data
2 NRT Hughes 1990 No weight data
2 NRT Hughes 1991 No weight data
2 NRT Hughes 1999 No weight data
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(Continued)
2 NRT Hughes 2003 No weight data
2 NRT Hurt 1990 No weight data
2 NRT Hurt 1994 No weight data
2 NRT ICRF 2007 No weight data
2 NRT Jamrozik 1984 No weight data
2 NRT Jarvis 1982 No weight data
2 NRT Jensen 1991 No weight data
2 NRT Jorenby 1995 No weight data
2 NRT Jorenby 1999 Unable to obtain full data
2 NRT Joseph 1996 No weight data
2 NRT Kalman 2006 No weight data
2 NRT Killen 1984 No weight data
2 NRT Killen 1990 No weight data
2 NRT Killen 1997 No weight data
2 NRT Killen 1999 Unable to obtain full data
2 NRT Kornitzer 1987 Unable to obtain full data
2 NRT Kornitzer 1995 No weight data
2 NRT Kralikova 2002 No weight data
2 NRT Kralikova 2009 Participants could reduce smoking or quit smoking
2 NRT Leischow 1996 No weight data
2 NRT Leischow 1999 No weight data
2 NRT Leischow 2004 No weight data
2 NRT Lewis 1998 No weight data
2 NRT Llivina 1988 No weight data
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(Continued)
2 NRT Malcolm 1980 No weight data
2 NRT Marshall 1985 No weight data
2 NRT McGovern 1992 No weight data
2 NRT Molyneux 2003 No weight data
2 NRT Moolchan 2005 No weight data
2 NRT Mori 1992 No weight data
2 NRT Muller 1990 No weight data
2 NRT Nakamura 1990 No weight data
2 NRT Nebot 1992 No weight data
2 NRT Niaura 1994 No weight data
2 NRT Niaura 1999 No weight data
2 NRT Ockene 1991 No weight data
2 NRT Oncken 2007 No weight data
2 NRT Otero 2006 No weight data
2 NRT Page 1986 No weight data
2 NRT Paoletti 1996 No weight data
2 NRT Peng 2007 Less than 6 months follow up
2 NRT Perng 1998 No weight data
2 NRT Piper 2007 No weight data
2 NRT Puska 1979 No weight data
2 NRT Richmond 1993 No weight data
2 NRT Rose 1994 No weight data
2 NRT Rose 1998 No weight data
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(Continued)
2 NRT Rose 2006 No weight data
2 NRT Rose 2009 Participants took medication before quit day
2 NRT Roto 1987 Unable to obtain full data
2 NRT Russell 1983 No weight data
2 NRT Schneider ’85A No weight data
2 NRT Schneider ’85B No weight data
2 NRT Schneider 1995 No weight data
2 NRT Schneider 1996 No weight data
2 NRT Schnoll 2010 No weight data
2 NRT Schuurmans 04 No weight data
2 NRT Segnan 1991 No weight data
2 NRT Shiffman 2009 Not abrupt quitting
2 NRT Sonderskov 97 No weight data
2 NRT Stapleton 2011 Less than 6 months follow up
2 NRT Tonnesen 1988 No weight data
2 NRT Tonnesen 2000 No weight data
2 NRT Tonnesen 2006 No weight data
2 NRT Veaugh-Geiss 2010 No weight data
2 NRT Villa 1999 No weight data
2 NRT Westman 1993 No weight data
2 NRT Wisborg 2000 No weight data
2 NRT Wong 1999 No weight data
2 NRT Zelman 1992 No weight data
2 RM STRATUS-EU 2006 Unable to obtain data
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(Continued)
2 RM STRATUS-US 2006 Unable to obtain data
2 RM STRATUS-WW 2005 Unable to obtain data
2 VA Hajek 2011 Participants took medication before quit day
2 VA Tsukahara 2010 No weight data for abstainers
2 VA Williams 2007 No weight data
VA Carson 2010 Less than 6 months follow up
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D A T A A N D A N A L Y S E S
Comparison 1. Pharmacological interventions versus placebo for post cessation weight control: weight change
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean weight change (kg) at end
of treatment
8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Dexfenfluramine versus
placebo
1 33 Mean Difference (IV, Fixed, 95% CI) -2.5 [-2.98, -2.02]
1.2 Phenylpropanolamine
versus Placebo
3 112 Mean Difference (IV, Fixed, 95% CI) -0.50 [-0.80, -0.20]
1.3 Ephedrine + Caffeine
versus Placebo
1 40 Mean Difference (IV, Fixed, 95% CI) -1.30 [-2.87, 0.27]
1.4 Naltrexone versus Placebo 2 179 Mean Difference (IV, Fixed, 95% CI) -0.78 [-1.52, -0.05]
1.5 Chromium versus placebo 1 15 Mean Difference (IV, Fixed, 95% CI) -0.81 [-3.05, 1.43]
2 Mean weight change (kg) at 6
months
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Phenylpropanolamine
versus Placebo
1 38 Mean Difference (IV, Fixed, 95% CI) -2.06 [-5.56, 1.44]
2.2 Ephedrine + caffeine
versus placebo
1 32 Mean Difference (IV, Fixed, 95% CI) -0.70 [-2.72, 1.32]
2.3 Chromium versus placebo 1 9 Mean Difference (IV, Fixed, 95% CI) -3.87 [-12.01, 4.27]
3 Mean weight change (kg) at 12
months
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Phenylpropanolamine
versus placebo
1 38 Mean Difference (IV, Fixed, 95% CI) -1.04 [-5.03, 2.95]
3.2 Ephedrine + Caffeine
versus placebo
1 24 Mean Difference (IV, Fixed, 95% CI) 1.20 [-1.84, 4.24]
Comparison 2. Pharmacological interventions versus placebo for post cessation weight control: smoking cessation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Abstinence at 6 months 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Phenylpropanolamine
gum versus placebo
1 295 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.76, 2.53]
1.2 Ephedrine + Caffeine
versus placebo
1 225 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.53, 2.11]
1.3 Naltrexone versus placebo 2 557 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.72, 1.43]
1.4 Chromium versus placebo 1 143 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.12, 1.84]
2 Abstinence at 12 months 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Phenylpropanolamine
gum versus placebo
1 295 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.80, 2.73]
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2.2 Ephedrine + Caffeine
versus Placebo
1 225 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.60, 3.48]
2.3 Naltrexone versus placebo 1 385 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.67, 2.31]
Comparison 3. Behavioural weight management interventions versus advice or no intervention: weight change
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean weight change (kg) at end
of treatment
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Weight management
education versus no weight
intervention
2 140 Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.57, 0.50]
1.2 Personalised weight
management support versus no
weight intervention
3 121 Mean Difference (IV, Fixed, 95% CI) -1.11 [-1.93, -0.29]
1.3 Personalised weight
management support versus
weight management education
1 47 Mean Difference (IV, Fixed, 95% CI) -1.12 [-2.17, -0.07]
1.4 VLCD + advice versus
advice
1 121 Mean Difference (IV, Fixed, 95% CI) -3.7 [-4.82, -2.58]
1.5 Early versus late
personalised weight
management support
1 41 Mean Difference (IV, Fixed, 95% CI) 1.4 [-1.32, 4.12]
2 Mean weight change (kg) at 6
months
3 118 Mean Difference (IV, Fixed, 95% CI) 1.59 [0.33, 2.86]
2.1 Weight management
education verses no weight
intervention
2 81 Mean Difference (IV, Fixed, 95% CI) 0.89 [-0.78, 2.55]
2.2 Personalised weight
management support versus no
weight intervention
1 15 Mean Difference (IV, Fixed, 95% CI) 0.40 [-2.54, 3.34]
2.3 Early versus late
personalised weight
management support
1 22 Mean Difference (IV, Fixed, 95% CI) 4.2 [1.63, 6.77]
3 Mean weight change (kg) at 12
months
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Weight management
education versus no weight
intervention
2 61 Mean Difference (IV, Fixed, 95% CI) -0.21 [-2.28, 1.86]
3.2 Personalised weight
management support versus no
weight intervention
2 40 Mean Difference (IV, Fixed, 95% CI) -2.58 [-5.11, -0.05]
3.3 Personalised weight
management support versus
weight management education
1 17 Mean Difference (IV, Fixed, 95% CI) -2.49 [-5.51, 0.53]
105Interventions for preventing weight gain after smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3.4 VLCD + advice versus
advice
1 62 Mean Difference (IV, Fixed, 95% CI) -1.30 [-3.49, 0.89]
Comparison 4. Behavioural weight management interventions versus advice or no intervention: smoking cessation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Abstinence at 6 months 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Weight management
education versus no
intervention
3 660 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.80, 1.31]
1.2 Personalised weight
management support versus no
intervention
2 254 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.54, 1.43]
1.3 Personalised weight
management support versus
weight management education
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.40, 1.65]
2 Abstinence at 12 months 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Weight management
education versus no
intervention
2 522 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.48, 0.90]
2.2 Personalised weight
management support versus no
intervention
2 254 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.47, 1.33]
2.3 Personalised weight
management support versus
weight management education
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.46, 2.02]
2.4 VLCD + advice versus
advice
1 287 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [1.10, 2.73]
Comparison 5. CBT to accept moderate weight gain versus no behavioural weight advice: smoking cessation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Abstinence at 6 months 2 496 Odds Ratio (M-H, Fixed, 95% CI) 1.70 [1.13, 2.56]
1.1 No additional
pharmacotherapy treatment
2 301 Odds Ratio (M-H, Fixed, 95% CI) 1.83 [1.07, 3.13]
1.2 With bupropion 1 195 Odds Ratio (M-H, Fixed, 95% CI) 1.53 [0.81, 2.89]
2 Abstinence at 12 months 2 496 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.83, 1.86]
2.1 No additional
pharmacotherapy
2 301 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [0.81, 2.79]
2.2 With bupropion 1 195 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.62, 1.81]
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Comparison 6. CBT to accept moderate weight gain versus no behavioural weight advice: weight change
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean weight change (kg) at end
of treatment
2 164 Mean Difference (IV, Fixed, 95% CI) -0.18 [-0.56, 0.20]
1.1 With no additional
pharmacotherapy
2 105 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.57, 0.55]
1.2 With bupropion 1 59 Mean Difference (IV, Fixed, 95% CI) -0.33 [-0.86, 0.20]
2 Mean weight change (kg) at 6
months
2 101 Mean Difference (IV, Fixed, 95% CI) 0.74 [0.24, 1.24]
2.1 With no additional
pharmacotherapy
2 55 Mean Difference (IV, Fixed, 95% CI) 0.31 [-0.75, 1.37]
2.2 With bupropion 1 46 Mean Difference (IV, Fixed, 95% CI) 0.86 [0.30, 1.42]
3 Mean weight change (kg) at 12
months
2 76 Mean Difference (IV, Fixed, 95% CI) 0.13 [-0.72, 0.98]
3.1 With no additional
pharmacotherapy
2 44 Mean Difference (IV, Fixed, 95% CI) -0.82 [-2.68, 1.04]
3.2 With bupropion 1 32 Mean Difference (IV, Fixed, 95% CI) 0.38 [-0.57, 1.33]
Comparison 7. All types of antidepressant versus placebo for smoking cessation: weight change
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean weight change (kg) at end
of treatment
9 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Bupropion versus placebo 7 869 Mean Difference (IV, Fixed, 95% CI) -1.12 [-1.47, -0.77]
1.2 Fluoxetine versus placebo 2 144 Mean Difference (IV, Fixed, 95% CI) -0.99 [-1.36, -0.61]
2 Mean weight change (kg) at end
of treatment: dose response
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Bupropion: 300mg/day v
150mg/day placebo
1 44 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.89, 0.69]
2.2 Bupropion: 300mg/day v
100mg/day placebo
1 37 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.86, 0.66]
3 Mean weight change (kg) at 6
months
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Bupropion versus placebo 4 218 Mean Difference (IV, Fixed, 95% CI) -0.87 [-2.21, 0.47]
3.2 Fluoxetine versus placebo 2 124 Mean Difference (IV, Fixed, 95% CI) -0.01 [-1.11, 1.10]
4 Mean weight change (kg) at 6
months: dose response
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Bupropion: 300mg/day v
150mg/day
1 40 Mean Difference (IV, Fixed, 95% CI) 0.10 [-2.76, 2.96]
4.2 Bupropion: 300mg/day v
100mg/day
1 29 Mean Difference (IV, Fixed, 95% CI) -2.10 [-6.22, 2.02]
4.3 Fluoxetine: 40mg v 20mg 1 34 Mean Difference (IV, Fixed, 95% CI) 0.47 [-1.82, 2.76]
4.4 Fluoxetine: 60mg v 30mg 1 49 Mean Difference (IV, Fixed, 95% CI) 3.00 [1.67, 4.33]
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5 Mean weight change (kg) at 12
months
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Bupropion versus placebo 4 252 Mean Difference (IV, Fixed, 95% CI) -0.38 [0.00, 1.24]
6 Mean weight change (kg) at 12
months: dose response
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Bupropion: 300mg/day v
150mg/day
1 33 Mean Difference (IV, Fixed, 95% CI) 0.20 [-4.81, 5.21]
6.2 Bupropion: 300mg/day v
100mg/day
1 24 Mean Difference (IV, Fixed, 95% CI) -2.0 [-8.04, 4.04]
Comparison 8. Exercise interventions versus no exercise for smoking cessation: weight change
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean weight change (kg) at end
of treatment
4 404 Mean Difference (IV, Fixed, 95% CI) -0.25 [-0.78, 0.29]
1.1 Exercise + SC versus SC
only
4 404 Mean Difference (IV, Fixed, 95% CI) -0.25 [-0.78, 0.29]
2 Mean weight change (kg) at 12
months
3 182 Mean Difference (IV, Fixed, 95% CI) -2.07 [-3.78, -0.36]
2.1 Exercise + SC versus SC
only
3 182 Mean Difference (IV, Fixed, 95% CI) -2.07 [-3.78, -0.36]
Comparison 9. All types of NRT versus placebo for smoking cessation: weight change
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean weight change (kg) at end
of treatment
19 2600 Mean Difference (IV, Fixed, 95% CI) -0.69 [-0.88, -0.51]
1.1 Gum versus placebo 4 345 Mean Difference (IV, Fixed, 95% CI) -0.58 [-1.02, -0.13]
1.2 Patch versus placebo 10 1619 Mean Difference (IV, Fixed, 95% CI) -0.82 [-1.06, -0.58]
1.3 Inhaler versus placebo 2 111 Mean Difference (IV, Fixed, 95% CI) -0.37 [-1.19, 0.45]
1.4 Sub-lingual tablet versus
placebo
2 478 Mean Difference (IV, Fixed, 95% CI) -0.48 [-0.99, 0.03]
1.5 Intranasal spray versus
placebo
1 47 Mean Difference (IV, Fixed, 95% CI) 0.90 [-1.54, 3.34]
2 Mean weight change (kg) at end
of treatment: patch v spray
1 154 Mean Difference (IV, Fixed, 95% CI) -0.30 [-1.76, 1.16]
3 Mean weight change (Kg) at end
of treatment: lozenge v gum
1 54 Mean Difference (IV, Fixed, 95% CI) -2.45 [-4.43, -0.47]
4 Mean weight change (kg) at end
of treatment: dose response
4 1038 Mean Difference (IV, Fixed, 95% CI) 0.22 [-0.04, 0.48]
4.1 4mg vs 2mg gum 1 161 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.61, 0.41]
4.2 22mg vs 11mg patch 1 15 Mean Difference (IV, Fixed, 95% CI) -0.40 [-2.65, 1.85]
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4.3 44mg vs 22mg patch 1 24 Mean Difference (IV, Fixed, 95% CI) -0.20 [-1.99, 1.59]
4.4 25mg patch vs 15mg
patch- 8 week treatment course
1 497 Mean Difference (IV, Fixed, 95% CI) 0.40 [0.04, 0.76]
4.5 25mg patch vs 15mg
patch- 22 weeks treatment
1 299 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.57, 0.97]
4.6 15x2mg gum vs 7x2mg
gum
1 24 Mean Difference (IV, Fixed, 95% CI) 1.59 [-0.27, 3.45]
4.7 30x2mg gum vs 15x2mg
gum
1 18 Mean Difference (IV, Fixed, 95% CI) -0.27 [-1.83, 1.29]
5 Mean weight change (kg) at 6
months
9 771 Mean Difference (IV, Fixed, 95% CI) -0.37 [-0.88, 0.14]
5.1 Gum versus placebo 2 103 Mean Difference (IV, Fixed, 95% CI) -0.83 [-2.35, 0.69]
5.2 Patch versus placebo 4 282 Mean Difference (IV, Fixed, 95% CI) -0.31 [-1.09, 0.47]
5.3 Inhaler versus placebo 1 57 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.98, 0.78]
5.4 Sub-lingual tablet versus
placebo
2 329 Mean Difference (IV, Fixed, 95% CI) -0.19 [-1.09, 0.72]
6 Mean weight change (kg) at 6
months: patch v spray
1 103 Mean Difference (IV, Fixed, 95% CI) 2.0 [-0.72, 4.72]
7 Mean weight change (kg) at 6
months: lozenge v gum
1 40 Mean Difference (IV, Fixed, 95% CI) -2.35 [-5.34, 0.64]
8 Mean weight change (kg) at 12
months
15 1334 Mean Difference (IV, Fixed, 95% CI) -0.42 [-0.92, 0.08]
8.1 Gum versus placebo 1 49 Mean Difference (IV, Fixed, 95% CI) -0.07 [-3.07, 2.93]
8.2 Patch versus placebo 6 770 Mean Difference (IV, Fixed, 95% CI) -0.23 [-0.90, 0.45]
8.3 Intranasal spray versus
placebo
3 122 Mean Difference (IV, Fixed, 95% CI) -1.55 [-3.09, -0.00]
8.4 Inhaler versus placebo 2 90 Mean Difference (IV, Fixed, 95% CI) -1.03 [-2.23, 0.17]
8.5 Sub-lingual tablet versus
placebo
3 303 Mean Difference (IV, Fixed, 95% CI) 0.27 [-0.99, 1.54]
9 Mean weight change (kg) at 12
months: lozenge v gum
1 33 Mean Difference (IV, Fixed, 95% CI) -3.31 [-9.77, 3.15]
10 Mean weight change (kg) at 12
months: dose response
2 423 Mean Difference (IV, Fixed, 95% CI) 0.24 [-0.49, 0.96]
10.1 22mg patch vs 11mg 1 7 Mean Difference (IV, Fixed, 95% CI) -3.90 [-10.74, 2.94]
10.2 44mg patch vs 11mg 1 12 Mean Difference (IV, Fixed, 95% CI) -2.2 [-10.12, 5.72]
10.3 25mg patch vs 15mg- 8
week treatment course
1 198 Mean Difference (IV, Fixed, 95% CI) 0.60 [-0.43, 1.63]
10.4 25mg patch vs 15mg- 22
weeks treatment course
1 206 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.04, 1.04]
11 Mean weight change (kg) at
12 months: longer course vs.
shorter
1 404 Mean Difference (IV, Fixed, 95% CI) -0.24 [-0.97, 0.48]
11.1 22 weeks vs 8 weeks
25mg patch
1 222 Mean Difference (IV, Fixed, 95% CI) -0.5 [-1.46, 0.46]
11.2 22 weeks vs 8 weeks
15mg patch
1 182 Mean Difference (IV, Fixed, 95% CI) 0.10 [-1.00, 1.20]
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Comparison 10. Varenicline versus placebo for smoking cessation: weight change
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean weight change (kg) at end
of treatment
11 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 1mg versus placebo 3 254 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.68, 0.43]
1.2 2mg versus placebo 11 2008 Mean Difference (IV, Fixed, 95% CI) -0.41 [-0.63, -0.19]
2 Mean weight change (kg) at 6
months
1 105 Mean Difference (IV, Fixed, 95% CI) 0.41 [-0.79, 1.61]
3 Mean weight change (kg) at 12
months
2 151 Mean Difference (IV, Fixed, 95% CI) 1.11 [-0.75, 2.98]
Comparison 11. Varenicline versus bupropion: weight change
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean weight change (kg) at end
of treatment
3 598 Mean Difference (IV, Fixed, 95% CI) 0.51 [0.09, 0.93]
Comparison 12. Varenicline versus NRT: weight change
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean weight change (kg) at end
of treatment
1 319 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.58, 0.48]
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Analysis 1.1. Comparison 1 Pharmacological interventions versus placebo for post cessation weight control:
weight change, Outcome 1 Mean weight change (kg) at end of treatment.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 1 Pharmacological interventions versus placebo for post cessation weight control: weight change
Outcome: 1 Mean weight change (kg) at end of treatment
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Dexfenfluramine versus placebo
1 Spring 1995 18 1 (0.7) 15 3.5 (0.7) 100.0 % -2.50 [ -2.98, -2.02 ]
Subtotal (95% CI) 18 15 100.0 % -2.50 [ -2.98, -2.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.22 (P < 0.00001)
2 Phenylpropanolamine versus Placebo
1 Cooper 2005 16 0.59 (3.04) 22 1.81 (2.18) 3.0 % -1.22 [ -2.97, 0.53 ]
1 Klesges 1990 15 0.04 (1.07) 12 0.72 (1.04) 14.2 % -0.68 [ -1.48, 0.12 ]
1 Klesges 1995 19 0.34 (0.54) 28 0.78 (0.61) 82.8 % -0.44 [ -0.77, -0.11 ]
Subtotal (95% CI) 50 62 100.0 % -0.50 [ -0.80, -0.20 ]
Heterogeneity: Chi?? = 0.97, df = 2 (P = 0.61); I?? =0.0%
Test for overall effect: Z = 3.23 (P = 0.0012)
3 Ephedrine + Caffeine versus Placebo
1 Norregaard 1996 27 0.2 (2.22) 13 1.5 (2.45) 100.0 % -1.30 [ -2.87, 0.27 ]
Subtotal (95% CI) 27 13 100.0 % -1.30 [ -2.87, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
4 Naltrexone versus Placebo
1 Toll 2010 8 3.1 (4.1) 14 4.4 (4.2) 4.2 % -1.30 [ -4.89, 2.29 ]
1 O’Malley 2006 123 1.14 (1.94) 34 1.9 (1.98) 95.8 % -0.76 [ -1.51, -0.01 ]
Subtotal (95% CI) 131 48 100.0 % -0.78 [ -1.52, -0.05 ]
Heterogeneity: Chi?? = 0.08, df = 1 (P = 0.77); I?? =0.0%
Test for overall effect: Z = 2.09 (P = 0.036)
5 Chromium versus placebo
1 Parsons 2009 4 0.98 (1.88) 11 1.79 (2.15) 100.0 % -0.81 [ -3.05, 1.43 ]
Subtotal (95% CI) 4 11 100.0 % -0.81 [ -3.05, 1.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi?? = 48.63, df = 4 (P = 0.00), I?? =92%
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Analysis 1.2. Comparison 1 Pharmacological interventions versus placebo for post cessation weight control:
weight change, Outcome 2 Mean weight change (kg) at 6 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 1 Pharmacological interventions versus placebo for post cessation weight control: weight change
Outcome: 2 Mean weight change (kg) at 6 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Phenylpropanolamine versus Placebo
1 Cooper 2005 16 1.64 (6.36) 22 3.7 (3.8) 100.0 % -2.06 [ -5.56, 1.44 ]
Subtotal (95% CI) 16 22 100.0 % -2.06 [ -5.56, 1.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
2 Ephedrine + caffeine versus placebo
1 Norregaard 1996 22 3.1 (2) 10 3.8 (2.97) 100.0 % -0.70 [ -2.72, 1.32 ]
Subtotal (95% CI) 22 10 100.0 % -0.70 [ -2.72, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 Chromium versus placebo
1 Parsons 2009 3 4.72 (6.59) 6 8.59 (4.09) 100.0 % -3.87 [ -12.01, 4.27 ]
Subtotal (95% CI) 3 6 100.0 % -3.87 [ -12.01, 4.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi?? = 0.88, df = 2 (P = 0.64), I?? =0.0%
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Analysis 1.3. Comparison 1 Pharmacological interventions versus placebo for post cessation weight control:
weight change, Outcome 3 Mean weight change (kg) at 12 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 1 Pharmacological interventions versus placebo for post cessation weight control: weight change
Outcome: 3 Mean weight change (kg) at 12 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Phenylpropanolamine versus placebo
1 Cooper 2005 16 0.82 (7.14) 22 1.86 (4.58) 100.0 % -1.04 [ -5.03, 2.95 ]
Subtotal (95% CI) 16 22 100.0 % -1.04 [ -5.03, 2.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
2 Ephedrine + Caffeine versus placebo
1 Norregaard 1996 18 5.9 (3.56) 6 4.7 (3.19) 100.0 % 1.20 [ -1.84, 4.24 ]
Subtotal (95% CI) 18 6 100.0 % 1.20 [ -1.84, 4.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Chi?? = 0.77, df = 1 (P = 0.38), I?? =0.0%
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Analysis 2.1. Comparison 2 Pharmacological interventions versus placebo for post cessation weight control:
smoking cessation, Outcome 1 Abstinence at 6 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 2 Pharmacological interventions versus placebo for post cessation weight control: smoking cessation
Outcome: 1 Abstinence at 6 months
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Phenylpropanolamine gum versus placebo
1 Cooper 2005 22/147 16/148 100.0 % 1.38 [ 0.76, 2.53 ]
Subtotal (95% CI) 147 148 100.0 % 1.38 [ 0.76, 2.53 ]
Total events: 22 (Treatment), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
2 Ephedrine + Caffeine versus placebo
1 Norregaard 1996 22/152 10/73 100.0 % 1.06 [ 0.53, 2.11 ]
Subtotal (95% CI) 152 73 100.0 % 1.06 [ 0.53, 2.11 ]
Total events: 22 (Treatment), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
3 Naltrexone versus placebo
1 O’Malley 2006 57/292 20/93 61.2 % 0.91 [ 0.58, 1.43 ]
1 Toll 2010 23/87 19/85 38.8 % 1.18 [ 0.70, 2.01 ]
Subtotal (95% CI) 379 178 100.0 % 1.01 [ 0.72, 1.43 ]
Total events: 80 (Treatment), 39 (Control)
Heterogeneity: Chi?? = 0.55, df = 1 (P = 0.46); I?? =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
4 Chromium versus placebo
1 Parsons 2009 3/73 6/70 100.0 % 0.48 [ 0.12, 1.84 ]
Subtotal (95% CI) 73 70 100.0 % 0.48 [ 0.12, 1.84 ]
Total events: 3 (Treatment), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
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Analysis 2.2. Comparison 2 Pharmacological interventions versus placebo for post cessation weight control:
smoking cessation, Outcome 2 Abstinence at 12 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 2 Pharmacological interventions versus placebo for post cessation weight control: smoking cessation
Outcome: 2 Abstinence at 12 months
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Phenylpropanolamine gum versus placebo
1 Cooper 2005 22/147 15/148 100.0 % 1.48 [ 0.80, 2.73 ]
Subtotal (95% CI) 147 148 100.0 % 1.48 [ 0.80, 2.73 ]
Total events: 22 (Treatment), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
2 Ephedrine + Caffeine versus Placebo
1 Norregaard 1996 18/152 6/73 100.0 % 1.44 [ 0.60, 3.48 ]
Subtotal (95% CI) 152 73 100.0 % 1.44 [ 0.60, 3.48 ]
Total events: 18 (Treatment), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
3 Naltrexone versus placebo
1 O’Malley 2006 43/292 11/93 100.0 % 1.25 [ 0.67, 2.31 ]
Subtotal (95% CI) 292 93 100.0 % 1.25 [ 0.67, 2.31 ]
Total events: 43 (Treatment), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 3.1. Comparison 3 Behavioural weight management interventions versus advice or no
intervention: weight change, Outcome 1 Mean weight change (kg) at end of treatment.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 3 Behavioural weight management interventions versus advice or no intervention: weight change
Outcome: 1 Mean weight change (kg) at end of treatment
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Weight management education versus no weight intervention
1 Pirie 1992 39 0.5 (1.85) 49 0.67 (1.83) 47.8 % -0.17 [ -0.94, 0.60 ]
1 Hall 1992 21 1.2 (1.18) 31 1.12 (1.54) 52.2 % 0.08 [ -0.66, 0.82 ]
Subtotal (95% CI) 60 80 100.0 % -0.04 [ -0.57, 0.50 ]
Heterogeneity: Chi?? = 0.21, df = 1 (P = 0.65); I?? =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Personalised weight management support versus no weight intervention
1 Spring 2004 21 2.44 (2.77) 10 3.71 (1.66) 27.3 % -1.27 [ -2.84, 0.30 ]
1 Perkins 2001 17 2.6 (3.4) 16 3.7 (3) 14.1 % -1.10 [ -3.28, 1.08 ]
1 Hall 1992 26 0.08 (2.4) 31 1.12 (1.54) 58.7 % -1.04 [ -2.11, 0.03 ]
Subtotal (95% CI) 64 57 100.0 % -1.11 [ -1.93, -0.29 ]
Heterogeneity: Chi?? = 0.06, df = 2 (P = 0.97); I?? =0.0%
Test for overall effect: Z = 2.66 (P = 0.0079)
3 Personalised weight management support versus weight management education
1 Hall 1992 26 0.08 (2.4) 21 1.2 (1.18) 100.0 % -1.12 [ -2.17, -0.07 ]
Subtotal (95% CI) 26 21 100.0 % -1.12 [ -2.17, -0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
4 VLCD + advice versus advice
1 Danielsson 1999 68 -2.1 (3.37) 53 1.6 (2.9) 100.0 % -3.70 [ -4.82, -2.58 ]
Subtotal (95% CI) 68 53 100.0 % -3.70 [ -4.82, -2.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.48 (P < 0.00001)
5 Early versus late personalised weight management support
1 Spring 2004 21 2.44 (2.77) 20 1.04 (5.58) 100.0 % 1.40 [ -1.32, 4.12 ]
Subtotal (95% CI) 21 20 100.0 % 1.40 [ -1.32, 4.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi?? = 37.00, df = 4 (P = 0.00), I?? =89%
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Analysis 3.2. Comparison 3 Behavioural weight management interventions versus advice or no
intervention: weight change, Outcome 2 Mean weight change (kg) at 6 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 3 Behavioural weight management interventions versus advice or no intervention: weight change
Outcome: 2 Mean weight change (kg) at 6 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Weight management education verses no weight intervention
1 Hankey 2009 23 3.9 (3.1) 18 2.7 (3.7) 35.1 % 1.20 [ -0.93, 3.33 ]
1 Pirie 1992 25 4.09 (4.17) 15 3.7 (4.17) 22.3 % 0.39 [ -2.28, 3.06 ]
Subtotal (95% CI) 48 33 57.5 % 0.89 [ -0.78, 2.55 ]
Heterogeneity: Chi?? = 0.22, df = 1 (P = 0.64); I?? =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
2 Personalised weight management support versus no weight intervention
1 Spring 2004 11 6 (3.3) 4 5.6 (2.24) 18.4 % 0.40 [ -2.54, 3.34 ]
Subtotal (95% CI) 11 4 18.4 % 0.40 [ -2.54, 3.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
3 Early versus late personalised weight management support
1 Spring 2004 11 6 (3.3) 11 1.8 (2.83) 24.1 % 4.20 [ 1.63, 6.77 ]
Subtotal (95% CI) 11 11 24.1 % 4.20 [ 1.63, 6.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.20 (P = 0.0014)
Total (95% CI) 70 48 100.0 % 1.59 [ 0.33, 2.86 ]
Heterogeneity: Chi?? = 5.50, df = 3 (P = 0.14); I?? =45%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Chi?? = 5.28, df = 2 (P = 0.07), I?? =62%
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Analysis 3.3. Comparison 3 Behavioural weight management interventions versus advice or no
intervention: weight change, Outcome 3 Mean weight change (kg) at 12 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 3 Behavioural weight management interventions versus advice or no intervention: weight change
Outcome: 3 Mean weight change (kg) at 12 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Weight management education versus no weight intervention
1 Hall 1992 7 3.35 (2.38) 14 3.61 (3.99) 57.4 % -0.26 [ -2.99, 2.47 ]
1 Pirie 1992 25 4.43 (4.95) 15 4.57 (4.96) 42.6 % -0.14 [ -3.31, 3.03 ]
Subtotal (95% CI) 32 29 100.0 % -0.21 [ -2.28, 1.86 ]
Heterogeneity: Chi?? = 0.00, df = 1 (P = 0.96); I?? =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
2 Personalised weight management support versus no weight intervention
1 Hall 1992 10 0.86 (3.95) 14 3.61 (3.99) 61.8 % -2.75 [ -5.97, 0.47 ]
1 Perkins 2001 9 5.4 (3.3) 7 7.7 (4.7) 38.2 % -2.30 [ -6.40, 1.80 ]
Subtotal (95% CI) 19 21 100.0 % -2.58 [ -5.11, -0.05 ]
Heterogeneity: Chi?? = 0.03, df = 1 (P = 0.87); I?? =0.0%
Test for overall effect: Z = 2.00 (P = 0.046)
3 Personalised weight management support versus weight management education
1 Hall 1992 10 0.86 (3.95) 7 3.35 (2.38) 100.0 % -2.49 [ -5.51, 0.53 ]
Subtotal (95% CI) 10 7 100.0 % -2.49 [ -5.51, 0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
4 VLCD + advice versus advice
1 Danielsson 1999 38 2.5 (5.55) 24 3.8 (3.23) 100.0 % -1.30 [ -3.49, 0.89 ]
Subtotal (95% CI) 38 24 100.0 % -1.30 [ -3.49, 0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
Test for subgroup differences: Chi?? = 2.61, df = 3 (P = 0.46), I?? =0.0%
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Analysis 4.1. Comparison 4 Behavioural weight management interventions versus advice or no
intervention: smoking cessation, Outcome 1 Abstinence at 6 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 4 Behavioural weight management interventions versus advice or no intervention: smoking cessation
Outcome: 1 Abstinence at 6 months
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Weight management education versus no intervention
1 Hall 1992 13/51 19/54 20.4 % 0.72 [ 0.40, 1.31 ]
1 Hankey 2009 23/68 18/70 19.6 % 1.32 [ 0.78, 2.21 ]
1 Pirie 1992 55/206 55/211 60.0 % 1.02 [ 0.74, 1.41 ]
Subtotal (95% CI) 325 335 100.0 % 1.02 [ 0.80, 1.31 ]
Total events: 91 (Experimental), 92 (Control)
Heterogeneity: Chi?? = 2.20, df = 2 (P = 0.33); I?? =9%
Test for overall effect: Z = 0.16 (P = 0.87)
2 Personalised weight management support versus no intervention
1 Hall 1992 11/53 19/54 68.1 % 0.59 [ 0.31, 1.12 ]
1 Perkins 2001 13/72 9/75 31.9 % 1.50 [ 0.69, 3.30 ]
Subtotal (95% CI) 125 129 100.0 % 0.88 [ 0.54, 1.43 ]
Total events: 24 (Experimental), 28 (Control)
Heterogeneity: Chi?? = 3.30, df = 1 (P = 0.07); I?? =70%
Test for overall effect: Z = 0.51 (P = 0.61)
3 Personalised weight management support versus weight management education
1 Hall 1992 11/53 13/51 100.0 % 0.81 [ 0.40, 1.65 ]
Subtotal (95% CI) 53 51 100.0 % 0.81 [ 0.40, 1.65 ]
Total events: 11 (Experimental), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
0.5 0.7 1 1.5 2
Favours control Favours experimental
119Interventions for preventing weight gain after smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.2. Comparison 4 Behavioural weight management interventions versus advice or no
intervention: smoking cessation, Outcome 2 Abstinence at 12 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 4 Behavioural weight management interventions versus advice or no intervention: smoking cessation
Outcome: 2 Abstinence at 12 months
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Weight management education versus no intervention
1 Hall 1992 11/51 19/54 24.0 % 0.61 [ 0.32, 1.16 ]
1 Pirie 1992 39/206 59/211 76.0 % 0.68 [ 0.47, 0.97 ]
Subtotal (95% CI) 257 265 100.0 % 0.66 [ 0.48, 0.90 ]
Total events: 50 (Experimental), 78 (Control)
Heterogeneity: Chi?? = 0.07, df = 1 (P = 0.79); I?? =0.0%
Test for overall effect: Z = 2.61 (P = 0.0092)
2 Personalised weight management support versus no intervention
1 Hall 1992 11/53 19/54 73.3 % 0.59 [ 0.31, 1.12 ]
1 Perkins 2001 9/72 7/75 26.7 % 1.34 [ 0.53, 3.41 ]
Subtotal (95% CI) 125 129 100.0 % 0.79 [ 0.47, 1.33 ]
Total events: 20 (Experimental), 26 (Control)
Heterogeneity: Chi?? = 2.03, df = 1 (P = 0.15); I?? =51%
Test for overall effect: Z = 0.89 (P = 0.37)
3 Personalised weight management support versus weight management education
1 Hall 1992 11/53 11/51 100.0 % 0.96 [ 0.46, 2.02 ]
Subtotal (95% CI) 53 51 100.0 % 0.96 [ 0.46, 2.02 ]
Total events: 11 (Experimental), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
4 VLCD + advice versus advice
1 Danielsson 1999 38/137 24/150 100.0 % 1.73 [ 1.10, 2.73 ]
Subtotal (95% CI) 137 150 100.0 % 1.73 [ 1.10, 2.73 ]
Total events: 38 (Experimental), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
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Analysis 5.1. Comparison 5 CBT to accept moderate weight gain versus no behavioural weight advice:
smoking cessation, Outcome 1 Abstinence at 6 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 5 CBT to accept moderate weight gain versus no behavioural weight advice: smoking cessation
Outcome: 1 Abstinence at 6 months
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No additional pharmacotherapy treatment
1 Levine 2010 11/87 10/67 27.9 % 0.83 [ 0.33, 2.08 ]
1 Perkins 2001 40/72 23/75 28.3 % 2.83 [ 1.44, 5.56 ]
Subtotal (95% CI) 159 142 56.2 % 1.83 [ 1.07, 3.13 ]
Total events: 51 (Treatment), 33 (Control)
Heterogeneity: Chi?? = 4.45, df = 1 (P = 0.03); I?? =78%
Test for overall effect: Z = 2.21 (P = 0.027)
2 With bupropion
1 Levine 2010 34/106 21/89 43.8 % 1.53 [ 0.81, 2.89 ]
Subtotal (95% CI) 106 89 43.8 % 1.53 [ 0.81, 2.89 ]
Total events: 34 (Treatment), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Total (95% CI) 265 231 100.0 % 1.70 [ 1.13, 2.56 ]
Total events: 85 (Treatment), 54 (Control)
Heterogeneity: Chi?? = 4.64, df = 2 (P = 0.10); I?? =57%
Test for overall effect: Z = 2.53 (P = 0.011)
Test for subgroup differences: Chi?? = 0.18, df = 1 (P = 0.67), I?? =0.0%
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Analysis 5.2. Comparison 5 CBT to accept moderate weight gain versus no behavioural weight advice:
smoking cessation, Outcome 2 Abstinence at 12 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 5 CBT to accept moderate weight gain versus no behavioural weight advice: smoking cessation
Outcome: 2 Abstinence at 12 months
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No additional pharmacotherapy
1 Levine 2010 8/87 7/67 22.3 % 0.88 [ 0.34, 2.31 ]
1 Perkins 2001 15/72 7/75 19.4 % 2.23 [ 0.97, 5.15 ]
Subtotal (95% CI) 159 142 41.7 % 1.51 [ 0.81, 2.79 ]
Total events: 23 (Treatment), 14 (Control)
Heterogeneity: Chi?? = 2.04, df = 1 (P = 0.15); I?? =51%
Test for overall effect: Z = 1.31 (P = 0.19)
2 With bupropion
1 Levine 2010 24/106 19/89 58.3 % 1.06 [ 0.62, 1.81 ]
Subtotal (95% CI) 106 89 58.3 % 1.06 [ 0.62, 1.81 ]
Total events: 24 (Treatment), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
Total (95% CI) 265 231 100.0 % 1.25 [ 0.83, 1.86 ]
Total events: 47 (Treatment), 33 (Control)
Heterogeneity: Chi?? = 2.72, df = 2 (P = 0.26); I?? =26%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Chi?? = 0.72, df = 1 (P = 0.40), I?? =0.0%
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Analysis 6.1. Comparison 6 CBT to accept moderate weight gain versus no behavioural weight advice:
weight change, Outcome 1 Mean weight change (kg) at end of treatment.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 6 CBT to accept moderate weight gain versus no behavioural weight advice: weight change
Outcome: 1 Mean weight change (kg) at end of treatment
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 With no additional pharmacotherapy
1 Levine 2010 29 5.49 (1.29) 13 3.77 (1.42) 18.1 % 1.72 [ 0.82, 2.62 ]
1 Perkins 2001 40 1.1 (1.4) 23 2.2 (1.4) 28.6 % -1.10 [ -1.82, -0.38 ]
Subtotal (95% CI) 69 36 46.7 % -0.01 [ -0.57, 0.55 ]
Heterogeneity: Chi?? = 22.94, df = 1 (P<0.00001); I?? =96%
Test for overall effect: Z = 0.03 (P = 0.98)
2 With bupropion
1 Levine 2010 43 4.98 (0.79) 16 5.31 (0.96) 53.3 % -0.33 [ -0.86, 0.20 ]
Subtotal (95% CI) 43 16 53.3 % -0.33 [ -0.86, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 112 52 100.0 % -0.18 [ -0.56, 0.20 ]
Heterogeneity: Chi?? = 23.61, df = 2 (P<0.00001); I?? =92%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi?? = 0.67, df = 1 (P = 0.41), I?? =0.0%
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Analysis 6.2. Comparison 6 CBT to accept moderate weight gain versus no behavioural weight advice:
weight change, Outcome 2 Mean weight change (kg) at 6 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 6 CBT to accept moderate weight gain versus no behavioural weight advice: weight change
Outcome: 2 Mean weight change (kg) at 6 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 With no additional pharmacotherapy
1 Levine 2010 19 3.81 (1.17) 7 2.71 (1.4) 18.3 % 1.10 [ -0.06, 2.26 ]
1 Perkins 2001 20 2.9 (2.6) 9 6.4 (3.5) 3.8 % -3.50 [ -6.05, -0.95 ]
Subtotal (95% CI) 39 16 22.1 % 0.31 [ -0.75, 1.37 ]
Heterogeneity: Chi?? = 10.32, df = 1 (P = 0.001); I?? =90%
Test for overall effect: Z = 0.57 (P = 0.57)
2 With bupropion
1 Levine 2010 36 3.96 (0.62) 10 3.1 (0.85) 77.9 % 0.86 [ 0.30, 1.42 ]
Subtotal (95% CI) 36 10 77.9 % 0.86 [ 0.30, 1.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.99 (P = 0.0028)
Total (95% CI) 75 26 100.0 % 0.74 [ 0.24, 1.24 ]
Heterogeneity: Chi?? = 11.12, df = 2 (P = 0.004); I?? =82%
Test for overall effect: Z = 2.91 (P = 0.0037)
Test for subgroup differences: Chi?? = 0.81, df = 1 (P = 0.37), I?? =0.0%
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Analysis 6.3. Comparison 6 CBT to accept moderate weight gain versus no behavioural weight advice:
weight change, Outcome 3 Mean weight change (kg) at 12 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 6 CBT to accept moderate weight gain versus no behavioural weight advice: weight change
Outcome: 3 Mean weight change (kg) at 12 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 With no additional pharmacotherapy
1 Levine 2010 17 5.38 (1.85) 5 5.05 (2.16) 16.5 % 0.33 [ -1.76, 2.42 ]
1 Perkins 2001 15 2.5 (4.2) 7 7.7 (4.7) 4.3 % -5.20 [ -9.28, -1.12 ]
Subtotal (95% CI) 32 12 20.8 % -0.82 [ -2.68, 1.04 ]
Heterogeneity: Chi?? = 5.59, df = 1 (P = 0.02); I?? =82%
Test for overall effect: Z = 0.86 (P = 0.39)
2 With bupropion
1 Levine 2010 25 4.85 (0.97) 7 4.47 (1.18) 79.2 % 0.38 [ -0.57, 1.33 ]
Subtotal (95% CI) 25 7 79.2 % 0.38 [ -0.57, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
Total (95% CI) 57 19 100.0 % 0.13 [ -0.72, 0.98 ]
Heterogeneity: Chi?? = 6.86, df = 2 (P = 0.03); I?? =71%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi?? = 1.26, df = 1 (P = 0.26), I?? =21%
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Analysis 7.1. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight
change, Outcome 1 Mean weight change (kg) at end of treatment.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 7 All types of antidepressant versus placebo for smoking cessation: weight change
Outcome: 1 Mean weight change (kg) at end of treatment
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Bupropion versus placebo
2 AD Nides 2006 22 1.68 (1.92) 10 4 (2.18) 4.9 % -2.32 [ -3.89, -0.75 ]
2 AD Hurt 1997 38 1.5 (2) 16 2.9 (1.9) 9.6 % -1.40 [ -2.53, -0.27 ]
2 AD Piper 2007 69 1.3 (6.2) 26 2.6 (2.3) 4.2 % -1.30 [ -3.01, 0.41 ]
2 AD Jorenby 2006 102 1.88 (3.4) 60 3.15 (4.1) 8.1 % -1.27 [ -2.50, -0.04 ]
2 AD Rigotti 2006 31 1.2 (3.9) 25 2.4 (3.6) 3.1 % -1.20 [ -3.17, 0.77 ]
2 AD Zellweger 2005 248 1.32 (1.8) 66 2.32 (1.64) 59.0 % -1.00 [ -1.45, -0.55 ]
2 AD Gonzales 2006 95 2.12 (1.8) 61 2.92 (3.94) 11.0 % -0.80 [ -1.85, 0.25 ]
Subtotal (95% CI) 605 264 100.0 % -1.12 [ -1.47, -0.77 ]
Heterogeneity: Chi?? = 3.21, df = 6 (P = 0.78); I?? =0.0%
Test for overall effect: Z = 6.30 (P < 0.00001)
2 Fluoxetine versus placebo
2 AD Niaura 2002 73 1.3 (1.4) 46 2.6 (1.8) 37.2 % -1.30 [ -1.91, -0.69 ]
1 Spring 1995 10 2.7 (0.5) 15 3.5 (0.7) 62.8 % -0.80 [ -1.27, -0.33 ]
Subtotal (95% CI) 83 61 100.0 % -0.99 [ -1.36, -0.61 ]
Heterogeneity: Chi?? = 1.61, df = 1 (P = 0.20); I?? =38%
Test for overall effect: Z = 5.18 (P < 0.00001)
Test for subgroup differences: Chi?? = 0.27, df = 1 (P = 0.60), I?? =0.0%
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Analysis 7.2. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight
change, Outcome 2 Mean weight change (kg) at end of treatment: dose response.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 7 All types of antidepressant versus placebo for smoking cessation: weight change
Outcome: 2 Mean weight change (kg) at end of treatment: dose response
Study or subgroup Higher dose Lower dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Bupropion: 300mg/day v 150mg/day placebo
2 AD Hurt 1997 28 2.3 (2.4) 16 2.9 (1.9) 100.0 % -0.60 [ -1.89, 0.69 ]
Subtotal (95% CI) 28 16 100.0 % -0.60 [ -1.89, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 Bupropion: 300mg/day v 100mg/day placebo
2 AD Hurt 1997 21 2.3 (2) 16 2.9 (1.9) 100.0 % -0.60 [ -1.86, 0.66 ]
Subtotal (95% CI) 21 16 100.0 % -0.60 [ -1.86, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi?? = 0.0, df = 1 (P = 1.00), I?? =0.0%
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Analysis 7.3. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight
change, Outcome 3 Mean weight change (kg) at 6 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 7 All types of antidepressant versus placebo for smoking cessation: weight change
Outcome: 3 Mean weight change (kg) at 6 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Bupropion versus placebo
2 AD Uyar 2007 13 0.9 (3) 5 2.5 (2.2) 28.0 % -1.60 [ -4.13, 0.93 ]
2 AD Simon 2009 6 0.5 (19.71) 13 1.69 (15.23) 0.6 % -1.19 [ -19.00, 16.62 ]
2 AD Hurt 1997 19 4.5 (4.7) 9 5.5 (5.4) 10.5 % -1.00 [ -5.11, 3.11 ]
2 AD Zellweger 2005 117 3.35 (2.82) 36 3.86 (5) 60.9 % -0.51 [ -2.22, 1.20 ]
Subtotal (95% CI) 155 63 100.0 % -0.87 [ -2.21, 0.47 ]
Heterogeneity: Chi?? = 0.50, df = 3 (P = 0.92); I?? =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Fluoxetine versus placebo
2 AD Saules 2004 34 3.09 (3.43) 9 6.16 (4.45) 12.4 % -3.07 [ -6.20, 0.06 ]
2 AD Niaura 2002 49 5.13 (2.8) 32 4.7 (2.54) 87.6 % 0.43 [ -0.75, 1.61 ]
Subtotal (95% CI) 83 41 100.0 % -0.01 [ -1.11, 1.10 ]
Heterogeneity: Chi?? = 4.21, df = 1 (P = 0.04); I?? =76%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi?? = 0.96, df = 1 (P = 0.33), I?? =0.0%
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Analysis 7.4. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight
change, Outcome 4 Mean weight change (kg) at 6 months: dose response.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 7 All types of antidepressant versus placebo for smoking cessation: weight change
Outcome: 4 Mean weight change (kg) at 6 months: dose response
Study or subgroup Higher dose Lower dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Bupropion: 300mg/day v 150mg/day
2 AD Hurt 1997 19 4.5 (4.7) 21 4.4 (4.5) 100.0 % 0.10 [ -2.76, 2.96 ]
Subtotal (95% CI) 19 21 100.0 % 0.10 [ -2.76, 2.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
2 Bupropion: 300mg/day v 100mg/day
2 AD Hurt 1997 19 4.5 (4.7) 10 6.6 (5.7) 100.0 % -2.10 [ -6.22, 2.02 ]
Subtotal (95% CI) 19 10 100.0 % -2.10 [ -6.22, 2.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
3 Fluoxetine: 40mg v 20mg
2 AD Saules 2004 15 3.35 (3) 19 2.88 (3.8) 100.0 % 0.47 [ -1.82, 2.76 ]
Subtotal (95% CI) 15 19 100.0 % 0.47 [ -1.82, 2.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
4 Fluoxetine: 60mg v 30mg
2 AD Niaura 2002 25 6.6 (2.65) 24 3.6 (2.06) 100.0 % 3.00 [ 1.67, 4.33 ]
Subtotal (95% CI) 25 24 100.0 % 3.00 [ 1.67, 4.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.43 (P < 0.00001)
Test for subgroup differences: Chi?? = 9.25, df = 3 (P = 0.03), I?? =68%
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Analysis 7.5. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight
change, Outcome 5 Mean weight change (kg) at 12 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 7 All types of antidepressant versus placebo for smoking cessation: weight change
Outcome: 5 Mean weight change (kg) at 12 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Bupropion versus placebo
2 AD Rigotti 2006 20 5.6 (8.2) 15 6.9 (5.2) 13.2 % -1.30 [ -5.75, 3.15 ]
2 AD Zellweger 2005 117 4.15 (4.18) 36 4.45 (6.12) 57.1 % -0.30 [ -2.44, 1.84 ]
2 AD Simon 2004 17 2.72 (6.7) 23 2.94 (3.86) 20.7 % -0.22 [ -3.77, 3.33 ]
2 AD Hurt 1997 16 6.1 (7.9) 8 6 (5.4) 9.0 % 0.10 [ -5.28, 5.48 ]
Subtotal (95% CI) 170 82 100.0 % -0.38 [ -2.00, 1.24 ]
Heterogeneity: Chi?? = 0.21, df = 3 (P = 0.98); I?? =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
-4 -2 0 2 4
Favours treatment Favours control
130Interventions for preventing weight gain after smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.6. Comparison 7 All types of antidepressant versus placebo for smoking cessation: weight
change, Outcome 6 Mean weight change (kg) at 12 months: dose response.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 7 All types of antidepressant versus placebo for smoking cessation: weight change
Outcome: 6 Mean weight change (kg) at 12 months: dose response
Study or subgroup Higher dose Lower dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Bupropion: 300mg/day v 150mg/day
2 AD Hurt 1997 16 6.1 (7.9) 17 5.9 (6.7) 100.0 % 0.20 [ -4.81, 5.21 ]
Subtotal (95% CI) 16 17 100.0 % 0.20 [ -4.81, 5.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
2 Bupropion: 300mg/day v 100mg/day
2 AD Hurt 1997 16 6.1 (7.9) 8 8.1 (6.7) 100.0 % -2.00 [ -8.04, 4.04 ]
Subtotal (95% CI) 16 8 100.0 % -2.00 [ -8.04, 4.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Chi?? = 0.30, df = 1 (P = 0.58), I?? =0.0%
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Analysis 8.1. Comparison 8 Exercise interventions versus no exercise for smoking cessation: weight change,
Outcome 1 Mean weight change (kg) at end of treatment.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 8 Exercise interventions versus no exercise for smoking cessation: weight change
Outcome: 1 Mean weight change (kg) at end of treatment
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise + SC versus SC only
2 EX Marcus 1999 24 3.03 (3.45) 13 5.36 (6.94) 1.8 % -2.33 [ -6.35, 1.69 ]
2 EX Marcus 2005 12 3.86 (5.66) 16 4.56 (5.05) 1.7 % -0.70 [ -4.75, 3.35 ]
2 EX Bize 2010 107 2.5 (4.14) 115 2.7 (2.14) 36.9 % -0.20 [ -1.08, 0.68 ]
2 EX Ussher 2003 61 1.8 (1.9) 56 2 (1.9) 59.6 % -0.20 [ -0.89, 0.49 ]
Total (95% CI) 204 200 100.0 % -0.25 [ -0.78, 0.29 ]
Heterogeneity: Chi?? = 1.11, df = 3 (P = 0.77); I?? =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Exercise interventions versus no exercise for smoking cessation: weight change,
Outcome 2 Mean weight change (kg) at 12 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 8 Exercise interventions versus no exercise for smoking cessation: weight change
Outcome: 2 Mean weight change (kg) at 12 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise + SC versus SC only
2 EX Bize 2010 59 4.4 (6.91) 70 6.2 (4.18) 71.8 % -1.80 [ -3.82, 0.22 ]
2 EX Marcus 1999 15 8.92 (8.9) 6 5.76 (12.6) 2.4 % 3.16 [ -7.88, 14.20 ]
2 EX Ussher 2003 14 3.9 (5.3) 18 7.2 (4.1) 25.8 % -3.30 [ -6.66, 0.06 ]
Total (95% CI) 88 94 100.0 % -2.07 [ -3.78, -0.36 ]
Heterogeneity: Chi?? = 1.45, df = 2 (P = 0.49); I?? =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change,
Outcome 1 Mean weight change (kg) at end of treatment.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 9 All types of NRT versus placebo for smoking cessation: weight change
Outcome: 1 Mean weight change (kg) at end of treatment
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Gum versus placebo
2 NRT Cooper 2005 24 2.19 (4.14) 22 3.6 (3.82) 0.7 % -1.41 [ -3.71, 0.89 ]
2 NRT Pirie 1992 34 0.49 (1.82) 15 1.1 (1.81) 2.9 % -0.61 [ -1.71, 0.49 ]
2 NRT Garvey 2000 161 0.95 (1.6) 47 1.5 (1.65) 12.5 % -0.55 [ -1.08, -0.02 ]
2 NRT Gross 1995 35 2.07 (2.26) 7 2.49 (1.54) 1.9 % -0.42 [ -1.78, 0.94 ]
Subtotal (95% CI) 254 91 17.9 % -0.58 [ -1.02, -0.13 ]
Heterogeneity: Chi?? = 0.57, df = 3 (P = 0.90); I?? =0.0%
Test for overall effect: Z = 2.55 (P = 0.011)
2 Patch versus placebo
2 NRT Abelin 1989 72 0.1 (1.8) 45 4.4 (2.2) 6.0 % -4.30 [ -5.07, -3.53 ]
2 NRT Ehrsam 1991 22 1.23 (1.7) 11 1.9 (1.5) 2.7 % -0.67 [ -1.81, 0.47 ]
2 NRT TNSG 1991 332 2 (1.9) 68 2.6 (1.5) 20.9 % -0.60 [ -1.01, -0.19 ]
2 NRT Fiore 1994A 26 2.6 (1.8) 17 3.2 (2.6) 1.8 % -0.60 [ -2.02, 0.82 ]
2 NRT Richmond 1994 55 2.62 (2.68) 22 3.15 (3.63) 1.3 % -0.53 [ -2.20, 1.14 ]
2 NRT CEASE 1999 497 1.7 (2.1) 147 2.2 (2.3) 20.5 % -0.50 [ -0.92, -0.08 ]
2 NRT Fiore 1994B 21 2.6 (1.91) 11 2.8 (1.56) 2.3 % -0.20 [ -1.43, 1.03 ]
2 NRT Gourlay 1995 21 1.9 (3.1) 6 1.9 (3.1) 0.4 % 0.0 [ -2.81, 2.81 ]
2 NRT Tonnesen 1991 43 2.6 (2.1) 7 2.5 (1.9) 1.5 % 0.10 [ -1.44, 1.64 ]
2 NRT Stapleton 1995 155 3.1 (2.9) 41 2.8 (2.3) 5.0 % 0.30 [ -0.54, 1.14 ]
Subtotal (95% CI) 1244 375 62.5 % -0.82 [ -1.06, -0.58 ]
Heterogeneity: Chi?? = 92.55, df = 9 (P<0.00001); I?? =90%
Test for overall effect: Z = 6.74 (P < 0.00001)
3 Inhaler versus placebo
2 NRT Tonnesen 1993 36 3.3 (2) 18 3.8 (1.9) 3.0 % -0.50 [ -1.59, 0.59 ]
2 NRT Hjalmarson 1997 35 1.7 (1.6) 22 1.9 (2.7) 2.3 % -0.20 [ -1.45, 1.05 ]
Subtotal (95% CI) 71 40 5.2 % -0.37 [ -1.19, 0.45 ]
Heterogeneity: Chi?? = 0.13, df = 1 (P = 0.72); I?? =0.0%
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(. . . Continued)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 0.88 (P = 0.38)
4 Sub-lingual tablet versus placebo
2 NRT Shiffman 2002B 158 2.74 (2.68) 63 3.59 (2.72) 5.6 % -0.85 [ -1.64, -0.06 ]
2 NRT Shiffman 2002A 158 2.32 (2.57) 99 2.54 (2.68) 8.0 % -0.22 [ -0.88, 0.44 ]
Subtotal (95% CI) 316 162 13.7 % -0.48 [ -0.99, 0.03 ]
Heterogeneity: Chi?? = 1.43, df = 1 (P = 0.23); I?? =30%
Test for overall effect: Z = 1.85 (P = 0.064)
5 Intranasal spray versus placebo
2 NRT Blondal 1999 29 6.5 (5.6) 18 5.6 (2.9) 0.6 % 0.90 [ -1.54, 3.34 ]
Subtotal (95% CI) 29 18 0.6 % 0.90 [ -1.54, 3.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 1914 686 100.0 % -0.69 [ -0.88, -0.51 ]
Heterogeneity: Chi?? = 98.90, df = 18 (P<0.00001); I?? =82%
Test for overall effect: Z = 7.24 (P < 0.00001)
Test for subgroup differences: Chi?? = 4.22, df = 4 (P = 0.38), I?? =5%
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Analysis 9.2. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change,
Outcome 2 Mean weight change (kg) at end of treatment: patch v spray.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 9 All types of NRT versus placebo for smoking cessation: weight change
Outcome: 2 Mean weight change (kg) at end of treatment: patch v spray
Study or subgroup Patch Spray
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 NRT Lerman 2004 82 1.5 (4.4) 72 1.8 (4.8) 100.0 % -0.30 [ -1.76, 1.16 ]
Total (95% CI) 82 72 100.0 % -0.30 [ -1.76, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 9.3. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change,
Outcome 3 Mean weight change (Kg) at end of treatment: lozenge v gum.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 9 All types of NRT versus placebo for smoking cessation: weight change
Outcome: 3 Mean weight change (Kg) at end of treatment: lozenge v gum
Study or subgroup lozenge gum
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 NRT Pack 2008 31 1.36 (2.86) 23 3.81 (4.17) 100.0 % -2.45 [ -4.43, -0.47 ]
Total (95% CI) 31 23 100.0 % -2.45 [ -4.43, -0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 9.4. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change,
Outcome 4 Mean weight change (kg) at end of treatment: dose response.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 9 All types of NRT versus placebo for smoking cessation: weight change
Outcome: 4 Mean weight change (kg) at end of treatment: dose response
Study or subgroup higher dose lower dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 4mg vs 2mg gum
2 NRT Garvey 2000 86 0.9 (1.8) 75 1 (1.47) 27.2 % -0.10 [ -0.61, 0.41 ]
Subtotal (95% CI) 86 75 27.2 % -0.10 [ -0.61, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
2 22mg vs 11mg patch
2 NRT Dale 1995 8 3 (2) 7 3.4 (2.4) 1.4 % -0.40 [ -2.65, 1.85 ]
Subtotal (95% CI) 8 7 1.4 % -0.40 [ -2.65, 1.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
3 44mg vs 22mg patch
2 NRT Dale 1995 16 2.8 (2.3) 8 3 (2) 2.2 % -0.20 [ -1.99, 1.59 ]
Subtotal (95% CI) 16 8 2.2 % -0.20 [ -1.99, 1.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
4 25mg patch vs 15mg patch- 8 week treatment course
2 NRT CEASE 1999 207 1.9 (2) 290 1.5 (2.1) 52.5 % 0.40 [ 0.04, 0.76 ]
Subtotal (95% CI) 207 290 52.5 % 0.40 [ 0.04, 0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.031)
5 25mg patch vs 15mg patch- 22 weeks treatment
2 NRT CEASE 1999 157 3.2 (3.1) 142 3 (3.6) 11.9 % 0.20 [ -0.57, 0.97 ]
Subtotal (95% CI) 157 142 11.9 % 0.20 [ -0.57, 0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
6 15x2mg gum vs 7x2mg gum
2 NRT Gross 1995 12 2.81 (1.91) 12 1.22 (2.68) 2.0 % 1.59 [ -0.27, 3.45 ]
Subtotal (95% CI) 12 12 2.0 % 1.59 [ -0.27, 3.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.094)
7 30x2mg gum vs 15x2mg gum
2 NRT Gross 1995 11 2.22 (1.81) 7 2.49 (1.54) 2.8 % -0.27 [ -1.83, 1.29 ]
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(. . . Continued)
Study or subgroup higher dose lower dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 11 7 2.8 % -0.27 [ -1.83, 1.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
Total (95% CI) 497 541 100.0 % 0.22 [ -0.04, 0.48 ]
Heterogeneity: Chi?? = 5.44, df = 6 (P = 0.49); I?? =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Chi?? = 5.44, df = 6 (P = 0.49), I?? =0.0%
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Analysis 9.5. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change,
Outcome 5 Mean weight change (kg) at 6 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 9 All types of NRT versus placebo for smoking cessation: weight change
Outcome: 5 Mean weight change (kg) at 6 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Gum versus placebo
2 NRT Hjalmarson 1984 36 1.34 (3.6) 18 2.58 (3.2) 7.3 % -1.24 [ -3.13, 0.65 ]
2 NRT Pirie 1992 34 3.61 (4.18) 15 3.7 (4.18) 4.1 % -0.09 [ -2.63, 2.45 ]
Subtotal (95% CI) 70 33 11.4 % -0.83 [ -2.35, 0.69 ]
Heterogeneity: Chi?? = 0.51, df = 1 (P = 0.48); I?? =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
2 Patch versus placebo
2 NRT Sachs 1993 38 4.3 (3.5) 13 5.8 (2.8) 7.4 % -1.50 [ -3.39, 0.39 ]
2 NRT Richmond 1994 45 3.16 (4.84) 19 4.09 (4.87) 3.8 % -0.93 [ -3.54, 1.68 ]
2 NRT Puska 1995 41 3.8 (3.3) 31 4.3 (2.9) 12.7 % -0.50 [ -1.94, 0.94 ]
2 NRT Bohadana 2000 50 3.1 (3.2) 45 2.7 (2.6) 19.2 % 0.40 [ -0.77, 1.57 ]
Subtotal (95% CI) 174 108 43.1 % -0.31 [ -1.09, 0.47 ]
Heterogeneity: Chi?? = 3.23, df = 3 (P = 0.36); I?? =7%
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(. . . Continued)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 0.78 (P = 0.44)
3 Inhaler versus placebo
2 NRT Hjalmarson 1997 35 3.8 (2.4) 22 4.4 (2.7) 13.7 % -0.60 [ -1.98, 0.78 ]
Subtotal (95% CI) 35 22 13.7 % -0.60 [ -1.98, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
4 Sub-lingual tablet versus placebo
2 NRT Shiffman 2002B 106 4.66 (3.78) 46 5 (4.64) 11.3 % -0.34 [ -1.86, 1.18 ]
2 NRT Shiffman 2002A 111 3.24 (3.76) 66 3.34 (3.67) 20.5 % -0.10 [ -1.23, 1.03 ]
Subtotal (95% CI) 217 112 31.8 % -0.19 [ -1.09, 0.72 ]
Heterogeneity: Chi?? = 0.06, df = 1 (P = 0.80); I?? =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 496 275 100.0 % -0.37 [ -0.88, 0.14 ]
Heterogeneity: Chi?? = 4.45, df = 8 (P = 0.81); I?? =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Chi?? = 0.64, df = 3 (P = 0.89), I?? =0.0%
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Analysis 9.6. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change,
Outcome 6 Mean weight change (kg) at 6 months: patch v spray.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 9 All types of NRT versus placebo for smoking cessation: weight change
Outcome: 6 Mean weight change (kg) at 6 months: patch v spray
Study or subgroup Patch Spray
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 NRT Lerman 2004 53 4.8 (6) 50 2.8 (7.9) 100.0 % 2.00 [ -0.72, 4.72 ]
Total (95% CI) 53 50 100.0 % 2.00 [ -0.72, 4.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 9.7. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change,
Outcome 7 Mean weight change (kg) at 6 months: lozenge v gum.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 9 All types of NRT versus placebo for smoking cessation: weight change
Outcome: 7 Mean weight change (kg) at 6 months: lozenge v gum
Study or subgroup lozenge gum
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 NRT Pack 2008 22 3.95 (5.26) 18 6.3 (4.4) 100.0 % -2.35 [ -5.34, 0.64 ]
Total (95% CI) 22 18 100.0 % -2.35 [ -5.34, 0.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 9.8. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change,
Outcome 8 Mean weight change (kg) at 12 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 9 All types of NRT versus placebo for smoking cessation: weight change
Outcome: 8 Mean weight change (kg) at 12 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Gum versus placebo
2 NRT Pirie 1992 34 4.5 (4.95) 15 4.57 (4.94) 2.7 % -0.07 [ -3.07, 2.93 ]
Subtotal (95% CI) 34 15 2.7 % -0.07 [ -3.07, 2.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2 Patch versus placebo
2 NRT Richmond 1994 34 5.25 (5.09) 17 6.04 (4.97) 2.9 % -0.79 [ -3.71, 2.13 ]
2 NRT Puska 1995 36 5.9 (3.9) 26 6.5 (3.3) 7.7 % -0.60 [ -2.40, 1.20 ]
2 NRT Bohadana 2000 39 4.8 (3.7) 28 5.1 (2.7) 10.6 % -0.30 [ -1.83, 1.23 ]
2 NRT CEASE 1999 404 4.9 (3.7) 70 5.06 (3.8) 26.9 % -0.16 [ -1.12, 0.80 ]
2 NRT Stapleton 1995 76 5.4 (4.69) 18 5.51 (4.8) 4.1 % -0.11 [ -2.57, 2.35 ]
2 NRT Tonnesen 1991 18 4.2 (3.9) 4 3 (3) 2.1 % 1.20 [ -2.25, 4.65 ]
Subtotal (95% CI) 607 163 54.2 % -0.23 [ -0.90, 0.45 ]
Heterogeneity: Chi?? = 1.00, df = 5 (P = 0.96); I?? =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
3 Intranasal spray versus placebo
2 NRT Sutherland 1992 13 3 (4) 14 5.8 (2.9) 3.5 % -2.80 [ -5.45, -0.15 ]
2 NRT Blondal 1999 29 6.5 (5.6) 14 8.3 (4.2) 2.8 % -1.80 [ -4.80, 1.20 ]
2 NRT Hjalmarson 1994 34 4.7 (3.9) 18 5 (4.5) 4.1 % -0.30 [ -2.76, 2.16 ]
Subtotal (95% CI) 76 46 10.4 % -1.55 [ -3.09, 0.00 ]
Heterogeneity: Chi?? = 1.87, df = 2 (P = 0.39); I?? =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
4 Inhaler versus placebo
2 NRT Hjalmarson 1997 35 4.5 (2.9) 22 5.6 (2.2) 14.0 % -1.10 [ -2.43, 0.23 ]
2 NRT Tonnesen 1993 24 4.4 (5.3) 9 5.1 (2.8) 3.2 % -0.70 [ -3.50, 2.10 ]
Subtotal (95% CI) 59 31 17.2 % -1.03 [ -2.23, 0.17 ]
Heterogeneity: Chi?? = 0.06, df = 1 (P = 0.80); I?? =0.0%
Test for overall effect: Z = 1.67 (P = 0.094)
5 Sub-lingual tablet versus placebo
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(. . . Continued)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 NRT Wallstrom 2000 45 5.37 (3.5) 37 5.8 (6) 5.2 % -0.43 [ -2.62, 1.76 ]
2 NRT Shiffman 2002B 67 6.61 (5.76) 28 7.01 (7.22) 2.7 % -0.40 [ -3.41, 2.61 ]
2 NRT Shiffman 2002A 82 4.8 (5.52) 44 3.8 (4.62) 7.5 % 1.00 [ -0.81, 2.81 ]
Subtotal (95% CI) 194 109 15.5 % 0.27 [ -0.99, 1.54 ]
Heterogeneity: Chi?? = 1.21, df = 2 (P = 0.55); I?? =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
Total (95% CI) 970 364 100.0 % -0.42 [ -0.92, 0.08 ]
Heterogeneity: Chi?? = 8.68, df = 14 (P = 0.85); I?? =0.0%
Test for overall effect: Z = 1.65 (P = 0.098)
Test for subgroup differences: Chi?? = 4.53, df = 4 (P = 0.34), I?? =12%
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Analysis 9.9. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change,
Outcome 9 Mean weight change (kg) at 12 months: lozenge v gum.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 9 All types of NRT versus placebo for smoking cessation: weight change
Outcome: 9 Mean weight change (kg) at 12 months: lozenge v gum
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 NRT Pack 2008 19 2.86 (12.43) 14 6.17 (6.17) 100.0 % -3.31 [ -9.77, 3.15 ]
Total (95% CI) 19 14 100.0 % -3.31 [ -9.77, 3.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 9.10. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change,
Outcome 10 Mean weight change (kg) at 12 months: dose response.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 9 All types of NRT versus placebo for smoking cessation: weight change
Outcome: 10 Mean weight change (kg) at 12 months: dose response
Study or subgroup High dose patch Low dose patch
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 22mg patch vs 11mg
2 NRT Dale 1995 2 4.6 (0.1) 5 8.5 (7.8) 1.1 % -3.90 [ -10.74, 2.94 ]
Subtotal (95% CI) 2 5 1.1 % -3.90 [ -10.74, 2.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
2 44mg patch vs 11mg
2 NRT Dale 1995 7 6.3 (5.4) 5 8.5 (7.8) 0.8 % -2.20 [ -10.12, 5.72 ]
Subtotal (95% CI) 7 5 0.8 % -2.20 [ -10.12, 5.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
3 25mg patch vs 15mg- 8 week treatment course
2 NRT CEASE 1999 114 5.3 (3.7) 84 4.7 (3.6) 49.8 % 0.60 [ -0.43, 1.63 ]
Subtotal (95% CI) 114 84 49.8 % 0.60 [ -0.43, 1.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
4 25mg patch vs 15mg- 22 weeks treatment course
2 NRT CEASE 1999 108 4.8 (3.6) 98 4.8 (4) 48.2 % 0.0 [ -1.04, 1.04 ]
Subtotal (95% CI) 108 98 48.2 % 0.0 [ -1.04, 1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 231 192 100.0 % 0.24 [ -0.49, 0.96 ]
Heterogeneity: Chi?? = 2.45, df = 3 (P = 0.48); I?? =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi?? = 2.45, df = 3 (P = 0.48), I?? =0.0%
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Analysis 9.11. Comparison 9 All types of NRT versus placebo for smoking cessation: weight change,
Outcome 11 Mean weight change (kg) at 12 months: longer course vs. shorter.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 9 All types of NRT versus placebo for smoking cessation: weight change
Outcome: 11 Mean weight change (kg) at 12 months: longer course vs. shorter
Study or subgroup Long course Short course
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 22 weeks vs 8 weeks 25mg patch
2 NRT CEASE 1999 108 4.8 (3.6) 114 5.3 (3.7) 56.9 % -0.50 [ -1.46, 0.46 ]
Subtotal (95% CI) 108 114 56.9 % -0.50 [ -1.46, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
2 22 weeks vs 8 weeks 15mg patch
2 NRT CEASE 1999 98 4.8 (4) 84 4.7 (3.6) 43.1 % 0.10 [ -1.00, 1.20 ]
Subtotal (95% CI) 98 84 43.1 % 0.10 [ -1.00, 1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Total (95% CI) 206 198 100.0 % -0.24 [ -0.97, 0.48 ]
Heterogeneity: Chi?? = 0.65, df = 1 (P = 0.42); I?? =0.0%
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Chi?? = 0.65, df = 1 (P = 0.42), I?? =0.0%
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Analysis 10.1. Comparison 10 Varenicline versus placebo for smoking cessation: weight change, Outcome 1
Mean weight change (kg) at end of treatment.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 10 Varenicline versus placebo for smoking cessation: weight change
Outcome: 1 Mean weight change (kg) at end of treatment
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1mg versus placebo
2 VA Nakamura 2007 71 1.38 (2.02) 51 1.48 (1.57) 76.1 % -0.10 [ -0.74, 0.54 ]
2 VA Nides 2006 14 2.14 (2.28) 10 4 (2.28) 9.0 % -1.86 [ -3.71, -0.01 ]
2 VA Oncken 2006 94 2.94 (3.65) 14 2.14 (2.36) 14.9 % 0.80 [ -0.64, 2.24 ]
Subtotal (95% CI) 179 75 100.0 % -0.12 [ -0.68, 0.43 ]
Heterogeneity: Chi?? = 4.97, df = 2 (P = 0.08); I?? =60%
Test for overall effect: Z = 0.44 (P = 0.66)
2 2mg versus placebo
2 VA Gonzales 2006 155 2.37 (2.76) 61 2.92 (3.94) 4.3 % -0.55 [ -1.63, 0.53 ]
2 VA Jorenby 2006 151 2.89 (2.94) 60 3.15 (4.11) 3.8 % -0.26 [ -1.40, 0.88 ]
2 VA Nakamura 2007 84 1.37 (1.55) 51 1.48 (1.57) 16.9 % -0.11 [ -0.65, 0.43 ]
2 VA Niaura 2008 32 4 (4.5) 9 3.8 (1.9) 1.3 % 0.20 [ -1.79, 2.19 ]
2 VA Nides 2006 24 1.96 (2.3) 10 4 (2.28) 1.8 % -2.04 [ -3.73, -0.35 ]
2 VA Oncken 2006 50 2.79 (4.03) 14 2.14 (2.36) 1.8 % 0.65 [ -1.02, 2.32 ]
2 VA Rigotti 2010 161 2.2 (2.7) 48 1.7 (2.6) 7.0 % 0.50 [ -0.35, 1.35 ]
2 VA Tashkin 2011 103 2.5 (2.8) 22 3.6 (2.9) 2.8 % -1.10 [ -2.43, 0.23 ]
2 VA Tonstad 2006 425 0.8 (2.13) 301 1.51 (2.31) 45.8 % -0.71 [ -1.04, -0.38 ]
2 VA Tsai 2008 75 1.29 (2.42) 40 1.59 (1.7) 8.6 % -0.30 [ -1.06, 0.46 ]
2 VA Wang 2009 82 1.58 (2.75) 50 1.38 (2.51) 6.0 % 0.20 [ -0.72, 1.12 ]
Subtotal (95% CI) 1342 666 100.0 % -0.41 [ -0.63, -0.19 ]
Heterogeneity: Chi?? = 17.25, df = 10 (P = 0.07); I?? =42%
Test for overall effect: Z = 3.59 (P = 0.00033)
Test for subgroup differences: Chi?? = 0.86, df = 1 (P = 0.35), I?? =0.0%
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Analysis 10.2. Comparison 10 Varenicline versus placebo for smoking cessation: weight change, Outcome 2
Mean weight change (kg) at 6 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 10 Varenicline versus placebo for smoking cessation: weight change
Outcome: 2 Mean weight change (kg) at 6 months
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 VA Wang 2009 63 2.07 (3.49) 42 1.66 (2.77) 100.0 % 0.41 [ -0.79, 1.61 ]
Total (95% CI) 63 42 100.0 % 0.41 [ -0.79, 1.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Varenicline versus placebo for smoking cessation: weight change, Outcome 3
Mean weight change (kg) at 12 months.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 10 Varenicline versus placebo for smoking cessation: weight change
Outcome: 3 Mean weight change (kg) at 12 months
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 VA Rigotti 2010 67 5.2 (4.4) 26 3.9 (4.8) 76.8 % 1.30 [ -0.82, 3.42 ]
2 VA Tashkin 2011 44 5.7 (9.3) 14 5.2 (5.2) 23.2 % 0.50 [ -3.37, 4.37 ]
Total (95% CI) 111 40 100.0 % 1.11 [ -0.75, 2.98 ]
Heterogeneity: Chi?? = 0.13, df = 1 (P = 0.72); I?? =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Varenicline versus bupropion: weight change, Outcome 1 Mean weight
change (kg) at end of treatment.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 11 Varenicline versus bupropion: weight change
Outcome: 1 Mean weight change (kg) at end of treatment
Study or subgroup Varenicline Bupropion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 AD Gonzales 2006 155 2.37 (2.76) 95 2.12 (1.8) 54.4 % 0.25 [ -0.32, 0.82 ]
2 AD Nides 2006 24 1.96 (2.3) 22 1.68 (1.92) 11.7 % 0.28 [ -0.94, 1.50 ]
2 AD Jorenby 2006 151 2.89 (2.94) 151 1.88 (3.4) 33.9 % 1.01 [ 0.29, 1.73 ]
Total (95% CI) 330 268 100.0 % 0.51 [ 0.09, 0.93 ]
Heterogeneity: Chi?? = 2.82, df = 2 (P = 0.24); I?? =29%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Varenicline versus NRT: weight change, Outcome 1 Mean weight change (kg)
at end of treatment.
Review: Interventions for preventing weight gain after smoking cessation
Comparison: 12 Varenicline versus NRT: weight change
Outcome: 1 Mean weight change (kg) at end of treatment
Study or subgroup Varenicline Nicotine patch
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 VA Aubin 2008 188 2.02 (2.5) 131 2.07 (2.3) 100.0 % -0.05 [ -0.58, 0.48 ]
Total (95% CI) 188 131 100.0 % -0.05 [ -0.58, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.85)
Test for subgroup differences: Not applicable
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butions of Authors)
23 November 2011 New search has been performed Twelve additional studies added. Conclusions largely
unchanged
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